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ABSTRACT
Ann Von Holle: Infant growth trajectories and lipid levels in
adolescence
(Under the direction of Kari North)
Developmental Origins of Health and Disease theory posits that elements of early life
affect susceptibility to chronic disease during adulthood. Postnatal growth is one such element
of early life that has been hypothesized as influencing chronic disease such as Atherosclerotic
Cardiovascular Disease (ASCVD), which is responsible for one out of every three deaths in the
United States. Researchers in the field of developmental origins hypothesize that postnatal
growth is an environmental factor that permanently programs lipid metabolism, a known
and well-established risk factor for ASCVD. We investigated the association between early
postnatal anthropometric change and adverse lipid levels in adolescence in a contemporary
Chilean birth cohort. Primary aims included: a) characterize predictors of infant growth,
b) investigate the association between early infant growth trajectories and lipid levels, and
c) evaluate the capacity of postnatal growth trajectories to modify the association between
functional genetic variants and lipid levels in adolescence.
Results from this research demonstrated distinct patterns of growth in which faster
anthropometric growth groups were associated with a more favorable lipid profile. In the
first manuscript, lower socioeconomic position was associated with a lower length velocity
SITAR parameter (-0.22, 95% CI=-0.31,-0.13). In the second manuscript, the length velocity
SITAR parameter was positively associated with HDL-C levels in adolescence (11.5, SE=4.0)
indicating higher HDL-C levels with faster length growth. Second, latent growth mixture
models supported the strongest associations between higher LDL-C and slower WFL growth
iii
although no associations were statistically significant after adjustment for multiple compar-
isons. Lastly, the third manuscript provided little evidence supporting a concept that growth
is an effect modifier when assessing genetic associations with lipids.
Taken together, these results identify faster growth in early infancy as a protective factor.
Mechanisms by which this occurs remain an open question, and postnatal growth remains a
possible environmental cue for lipid metabolism programming. In turn, this information can
support the search for optimal postnatal growth and with it, the potential for modification of
chronic disease risk factor development later in life.
iv
I dedicate this dissertation to my patient, understanding and
supportive family.
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CHAPTER 1: SPECIFIC AIMS
1.1 Specific Aims
Atherosclerotic Cardiovascular Disease (ASCVD) (Bays et al. 2016) is rare in childhood,
but risk factors for ASCVD are not. The prevalence of adverse levels of High Density
Lipoprotein Cholesterol (HDL-C) (<40 mg/dL), Low Density Lipoprotein Cholesterol (LDL-
C) (≥ 130 mg/dL) and triglycerides (TG) (≥ 130 mg/dL) exceeded 5% in United States
(U.S.) children from 2007 to 2010 (Kit et al. 2012; Kit et al. 2015; Magnussen, Smith, and
Juonala 2013). Importantly, such dyslipidemia in childhood tracks into later life (Celermajer
and Ayer 2006; Kallio et al. 1993), predisposing children to a cumulative risk burden and
subsequent ASCVD events in adulthood.
Strong associations exist between infant growth trajectories and the development of
ASCVD in adulthood, supporting the Developmental Origins of Health and Disease concept
(Hanson and Gluckman 2014; Barker and Osmond 1986; Osmond et al. 1993; Barker et al.
1989; Gahagan, Uauy, and Roseboom 2012; Gluckman et al. 2009). Few empirical studies
have captured the relationship between infant growth trajectories and risk factors for ASCVD
such as dyslipidemia, and of seven recent studies on this topic (Corvalan et al. 2009; Ekelund
et al. 2007; Howe et al. 2010; Kajantie et al. 2008; leunissen_timing_2009-1; Oostvogels et al.
2014; Tzoulaki et al. 2010), only one focuses on ancestrally diverse populations (Corvalan et
al. 2009). Furthermore, these characterizations of growth in infancy do not leverage advanced
methodological approaches in assessing growth. The lack of ancestral diversity in samples and
limited characterization of growth trajectories presents a knowledge gap and an important
area for research in the etiologic origins of ASCVD. I propose to address this gap with a
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contemporary infancy cohort of Hispanic/Latino (HL) origin – the Santiago Longitudinal
Study (SLS) (Lozoff et al. 2003; Gahagan et al. 2009). Three specific aims follow:
1.1.1 Aim 1
Characterize individual infant growth trajectories from birth to five months and identify
sociodemographic predictors of such growth in a Chilean infancy cohort.
1.1.1.1 Aim 1.1
Characterize infant growth trajectories with nonlinear mixed effects models (Cole,
Donaldson, and Ben-Shlomo 2010), which measure individual shifts relative to the population
average curve in: (a) size (above or below on the outcome scale), (b) tempo (to the right
or left on the age scale), and (c) velocity (steep or shallow slope). Assess the association
between postnatal growth characteristics and sociodemographic predictors of postnatal growth
including a socioeconomic index and maternal education.
Note: Subsequent references to “growth trajectory” or “postnatal growth” as nested
within the hypotheses refer to change in weight-for-length (g/cm), weight (kg) and length
(cm) as a group.
1.1.1.1.1 Hypothesis 1a
Positive associations will exist between length growth and favorable sociodemographic
position. Inverse associations will exist between weight and weight-for-length growth favorable
sociodemographic position.
2
1.1.1.2 Aim 1.2
Determine presence of child growth trajectory latent classes with latent growth mixture
models (LGMM).
1.1.1.2.1 Hypothesis 1b
Several classes of growth trajectories exist including one with a steeper weight change
than other groups.
1.1.2 Aim 2
Examine the association between infant growth trajectory characteristics and lipid levels
at 17 years of age.
1.1.2.1 Hypothesis 2
Infants with faster growth are at greater risk of adverse lipid levels in adolescence than
children with slower growth.
1.1.3 Aim 3
Assess gene-environment interaction between growth trajectory characteristics and
genetic variants underlying lipid metabolism at 17 years of age.
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1.1.3.1 Hypothesis 3
Infant growth influences the strength of association between selected genetic variants
and adverse lipid levels for children. For example, in the context of extreme and less favorable
growth characteristics, a stronger association will exist between risk alleles and adverse levels
of LDL-C.
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CHAPTER 2: BACKGROUND AND SIGNIFICANCE
2.1 Overview
This chapter contains three distinct sections: 1) a background for the outcome measures,
lipids and dyslipidemia, which are characterized in the context of an age range from birth to
eighteen years; 2) a motivation to examine associations between postnatal growth and chronic
disease risk factors in adolescence; 3) an outline of analytic issues that may be problematic
given the proposed hypotheses including choice of growth model, parameterization of gene-
environment interaction and polygenic risk score calculation.
2.1.1 Dyslipidemia in children
Lipids and lipoproteins are the primary focus and a continuous outcome measure in the
three aims. Characterizing these measures and how they contribute to ASCVD is necessary
prior to defining its relationship as an outcome in a causal framework as follows. Although
lipids constitute a continuous measure in the presented analyses, a review of a binary lipid
indicator, dyslipidemia, is in order as it is another commonly used measure with valuable
descriptive information.
Dyslipidemia definitions vary across many biologic and demographic domains. Childhood
is one example in which the definition of dyslipidemia varies across time periods. Other
domains include gender, racial, and ethnic groups. Furthermore, tracking of lipid levels to
adulthood, primary and secondary causes of dyslipidemia as well as potential environmental
factors are important to consider prior to formulating hypotheses.
5
Polygenic attributes of dyslipidemia will round out this background section characterizing
dyslipidemia in children. In adults, several large genetic consortia (“Global Lipids Genetics
Consortium (GLGC). Kathiresan Lab” 2014) have identified hundreds of loci influencing
plasma lipid levels in humans. In particular, these studies have produced candidate genetic
loci having a plausible function in lipid metabolism (Willer et al. 2013). Although research
is still ongoing, these genetic variants do appear to extend to populations of children (Shen
et al. 2013; Breitling et al. 2015; Tikkanen et al. 2011; Buscot et al. 2016).
2.1.2 Evidence for an association between postnatal growth and dyslipidemia
later in life
The second section motivates the formulation of the hypotheses postulating an association
between postnatal growth and lipids. Postnatal life presents considerable potential for
intervention that can impact the health trajectory extending far past the immediate period.
With this potential, there have been a variety of animal and human studies in the past ten
years investigating the impact of postnatal growth on ASCVD risk factors later in life. These
studies follow the Developmental Origins of Health and Disease (DOHaD) paradigm, and
they offer evidence that abnormal growth early in development can affect cardiovascular risk
factors, including lipid levels, later in the life course.
Following a description of the current literature in both animal models and humans,
hypothesized biological pathways stemming from current research will be reviewed including
areas spanning liver function, gene expression timing and epigenetic mechanisms. Finally, a
discussion of factors that affect postnatal growth form the last part of this section, important
areas to consider as potential confounders when examining the association between postnatal
growth and dyslipidemia in adolescence.
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2.1.3 Analytic Issues
The last section includes a discussion and resolution of several analytic issues that could
be problematic when specifying analyses that address the three hypotheses. Some of those
issues include: 1) generalizability of growth and dyslipidemia across source populations, 2)
choice of statistical methods to characterize growth in children, 3) accurate ways to detect
gene-environment interactions, and finally 4) formulation of a Polygenic Risk Score (PRS). In
addressing these issues certain points emerge including the importance in selecting methods
that best fit the ample data on hand during the postnatal period as well as best matching
the target population of a HL population.
2.1.4 Summary
This chapter includes characterization of 1) the outcome measure, 2) evidence supporting
the role of postnatal growth as an exposure, and 3) analytic issues presenting themselves
given the choice of exposure and outcome. As will be described next, there is ample evidence
motivating investigation of the link between a postnatal exposure and a chronic disease risk
factor such as unfavorable lipid levels in an understudied population. Furthermore, addressing
these three broad areas will provide a basis upon which relevant analyses can be designed
that support further investigation of causal effects in a HL sample.
2.1.5 Directed Acyclic Graph (DAG)
The following figure provides a conceptual diagram of the causal effect present in
the second hypothesis from the second aim of this dissertation proposal. In this diagram
dyslipidemia represents the terminal endpoint and all relevant confounders to consider when
assessing a causal effect. Areas of research represented in the three main sections of the
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Figure 2.1: Directed Acyclic Diagram (DAG) for research topic.
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background and significance that follow will provide support for the relationships in this
directed acyclic diagram (Fig. 2.1).
2.2 Dyslipidemia in children
Children may be free of ASCVD risk factors, but they certainly are not immune to
their development and are prime candidates for a primordial prevention framework. ASCVD
prevention efforts targeting specific risk factors (Foraker, Olivo-Marston, and Allen 2012;
Pearson 2007; Grundy et al. 1998), are featured as a cornerstone of ideal cardiovascular
health as outlined in the 2020 American Heart Association strategic plan (Lloyd-Jones et
al. 2010). Lipid measures are in all the aims, and it is one such modifiable risk factor in a
prevention framework that can accelerate the atherosclerotic process in children (Daniels,
Pratt, and Hayman 2011). ASCVD risk factors in children may be stronger predictors of
atherosclerosis than measurements at time of examination in adulthood (Gidding 2006)
making this a deserving window of time for additional research.
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2.2.1 Stages of development in childhood
To clarify definitions used throughout this section, any following references to “childhood”
is meant as an informal characterization of all ages from birth to age 18 years. Young
adults would be considered ages 18-21 years (“Ages & Stages. HealthyChildren.org” 2017).
Guidelines from Healthy People 2020 initiative define early childhood from birth to eight
years, middle childhood from ages 6 to 12 years and adolescence from ten to nineteen years
(“Early and Middle Childhood Healthy People 2020” 2017). Adolescent stages in general
include early (11-14 years), middle (15-17) and late (18-22) groups (“Stages of Adolescence.
HealthyChildren.org” 2017). No universally accepted definition of childhood growth stages
exists, but these labels will be used to define age groups in the life course.
2.2.2 Lipoproteins
Lipoproteins are spherical shaped particles configured with hydrophilic and hydrophobic
lipids – fats. Adverse levels of lipoproteins function as a primary causal factor in atherogenesis
ending in cardiovascular disease. The primary role of lipoproteins is to transport hydrophilic
triglycerides and cholesterol esters through the blood from the liver or gut to tissues throughout
the body. The five basic classes of lipoproteins are categorized by their size, as can be seen
in figures figure 2.2 and 2.3. These classes include: 1) chylomicrons, 2) very low-density
lipoprotein, 3) intermediate density lipoprotein, LDL-C, and 5) HDL-C (Jameson 2016).
Subsections below will elaborate on two of these lipoprotein classes including LDL-C and
HDL-C as well as TG and a combination of those three, Total Cholesterol (TC).
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Figure 2.2: Lipoprotein classes (Jameson 2016).
Adverse lipid levels characterize dyslipidemia, and they signal higher risk of atherosclerosis
that can be modified with causal factors including lifestyle choices. A conceptual diagram
of the relationships judged relevant to the hypothesized disease process is included in Fig.
2.1. This disease in childhood negatively influences the path of atherosclerosis (Gidding 2006;
Daniels 2015), and it carries the potential for sustained exposure to atherosclerosis making it
an important area for intervention.
Dyslipidemia differs between children and adults as assessed by lipid thresholds. To
assess dyslipidemia, four separate outcomes from a standard lipid profile are commonly used:
TC, TG, LDL-C, and HDL-C. Dyslipidemia occurs when at least one of the “lipid, lipoprotein,
or apolipoprotein levels are abnormal.” (Peter O. Kwiterovich 2008b). A brief description
of each of these lipoproteins follows, and figure 2.3 (Varbo, Benn, and Nordestgaard 2014)
offers a visual description of their role in atherosclerosis in the arterial wall.
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Figure 2.3: Relationship between lipoproteins and the arterial wall (Varbo et al. 2014).
Thresholds for each of these four factors exist, beyond which there is a higher risk of
“initiation and progression of atherosclerotic lesions. . . ” (Expert Panel 2011). The standard
for dyslipidemia in children started with the 1992 National Cholesterol Education Program
report (“National Cholesterol Education Program (NCEP): Highlights of the Report of the
Expert Panel on Blood Cholesterol Levels in Children and Adolescents” 1992) and most
recently ended with the 2011 guidelines from the “Expert Panel on Integrated Guidelines
for Cardiovascular Health and Risk Reduction in Children and Adolescents” (Expert Panel
2011). Values that are considered above or below acceptable thresholds are characterized in
table 2.1, as reproduced from an expert panel in 2011 (Expert Panel 2011). These values
have evolved into a current pattern shaped by the rise in obesity defined by high triglycerides
and LDL-C combined with lower HDL-C (Daniels 2015).
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Table 2.1: Recommended cut points for lipid and lipoprotein levels in young adults (adapted
from table 9-1 in the 2011 NHLBI guidelines for lipid management in children and adolescents)
Category Low, mg/dL Acceptable, mg/dL Borderline-High, mg/dL High, mg/dL
TC <170 170-199 ≥ 200
LDL <110 110-129 ≥ 130
Non-HDL <120 120-144 ≥ 145
Apolipoprotein B <90 90-109 ≥ 110
Triglycerides
0-9 y <75 75-99 ≥ 100
10-19 y <90 90-129 ≥ 130
HDL cholesterol <40 >45 40-45
Apolipoprotein A-1 <115 >120 115-120
Dyslipidemia in children is prevalent and widespread across countries with over 20% of
children ages 6 to 19 in the United States from 2011 to 2014 having at least one abnormal
lipid measure (Nguyen, Kit, and Carroll 2015; Benjamin et al. 2017). The SLS Chilean cohort
of adolescents aged 17 years also supports the evidence that HL groups carry a larger burden
of ASCVD risk. 79% of this group had at least one abnormal measure of cardiometabolic risk
including adverse levels of TG, HDL-C, blood pressure and fasting plasma glucose (Burrows
et al. 2016). In the sections that follow, each measure from a standard lipid profile including
LDL-C, HDL-C, TG, and TG that are commonly used to assess dyslipidemia are discussed
across various racial and ethnic groups.
2.2.2.1 Quality control
It is also notable that these lipid and lipoprotein measures can vary given different
measurement techniques across different countries or regions constituting a quality control
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problem. In turn, these variations, which constitute bias, may be the source of differences in
risk factor means and not any particular country-level difference. A 2004 report from the
general accounting office (GAO) of the United States (Office 1995) indicates that laboratory
cholesterol measurements have “improved from 25 to 6 percent error” in precision following
reference methods developed through the Centers for Disease Control. The same report notes
that interlaboratory precision was 5.5 to 7.2 percent in 1990.
The Centers for Disease Control (CDC) offers a standardization protocol through the
Cholesterol Reference Method Laboratory Network (CRMLN) (“CDC - Laboratory Standards
- LSP” 2017), which provides standards to labs across the world. In the past, this group had
collaborated with the European group responsible for the quality control in the MONICA
study (Project 2002), WHO Regional Lipid Reference Centre (WHO-RLRC), now defunct.
Standardization across different population sources is critical (Tolonen 2004), and it is the
assumption that laboratory quality control measures similar to what is provided by the
CDC are followed in the sections on lipids that follow. Current CDC protocol indicates that
laboratories following their protocol have bias and coefficient of variation for total cholesterol
less than or equal to 3 percent; HDL-C measures require bias ≤ 4 percent and coefficient of
variation ≤ 5 percent; LDL-C measures require bias and coefficient of variation ≤ 4 percent.
Lastly, lack of standardization or not following similar standards may result in biased and/or
less accurate lipid and lipoprotein measures.
Of note, the MONICA study, in their external quality control estimates, examined
total cholesterol in many different countries and continents. Their standardization efforts
were successful in most countries for LDL-C and TC (Tunstall-Pedoe and World Health
Organization 2003), but less so for HDL-C up until the 1990s (Project 2002, Tolonen (2004)).
Total cholesterol measurements can be quite precise, but accuracy is an issue (Cooper et al.
1992) thus requiring standardization.
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2.2.2.2 Triglycerides (TG)
TG provide unique information regarding cardiovascular disease risk, yet the causal
role for TG is still a matter of current research in cardiovascular disease (Miller et al. 2011;
Nordestgaard and Varbo 2014). For children, there is evidence that triglyceride levels are
an independent biomarker for subsequent cardiovascular disease (Morrison et al. 2009).
A triglyceride measure at or above 150 mg/dL is considered abnormally high for children
and corresponds to a percentile from a designated standard. For example, the value for
triglycerides in table 2.1 corresponds to the 90th percentile for people ages 20-24 in the Lipid
Research Clinics Prevalence Study (Heiss et al. 1980).
Typically, TG measures are collected after fasting given their higher postprandial
variability relative to HDL-C, and they are more difficult to collect as well as being less
frequently done (Kit et al. 2015). Interestingly, recent studies show that non-fasting levels
are considered adequate for screening purposes making the fasting efforts less important
(Nordestgaard and Varbo 2014). However, in the United States fasting levels are still
recommended and therefore they are not included in as many analyses as those with TC or
HDL-C, in which fasting is not required.
2.2.2.3 Low density lipoprotein cholesterol (LDL-C)
LDL-C levels are considered one of the strongest predictors of cardiovascular disease
as well as playing a causal role in atherosclerosis fitting into the “cholesterol hypothesis”
(Catapano and Ference 2015; Linton et al. 2000; Domanski et al. 2011). LDL-C values can be
calculated from a common lipid profile with the most frequent method being the Friedewald
equation: [LDL-cholesterol] = [total cholesterol] – [HDL-cholesterol] – [triglycerides/5]. This
indirect measure has not been without controversy (Martin et al. 2013). The Friedewald
equation was developed in a sample less than 500 people more than 40 years ago, and
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assumptions regarding the ratio of TG:very low-density lipoprotein equal to 5 may be
inaccurate with the amount of variability. One alternative, proposed by Martin et al. (Martin
et al. 2013) is to use an adjustable factor for the TG:very low-density lipoprotein ratio.
However, the indirectly calculated values are very close to the directly measured LDL-C
values (Mora et al. 2009; Tanno et al. 2010).
2.2.2.4 High density lipoprotein cholesterol (HDL-C)
HDL-C is an interesting component of dyslipidemia in that it is a well established
biomarker for cardiovascular risk, but its causal role in atherosclerosis is not yet clear (Rader
and Hovingh 2014). The evolution of therapeutic treatment for LDL-C versus HDL-C levels is
one salient example representing the paucity of evidence supporting HDL-C as a causal factor.
No treatment has been found in which raising HDL-C leads to improved cardiovascular disease
outcomes, unlike the case for LDL-C and statin use. In turn, the “cholesterol hypothesis” has
thus far failed to apply to HDL-C. A plausible causal explanation, named the “HDL function”
hypothesis (Rader and Hovingh 2014), has shifted attention from the amount to the function
of HDL-C. Following this hypothesis implies little is to be gained interpreting amounts of
HDL-C in the bloodstream when evaluating HDL-C as a causal factor in atherosclerosis.
Unlike LDL-C, direct measurement of HDL-C is common and occurs via an assay. For
example, NHANES has used the direct immunoassay method since 2003 (Kit et al. 2015).
Low HDL-C is considered a risk factor with a threshold of 40 mg/dL. Contrary to TG and
LDL-C, favorable levels for the U.S. youth population have decreased over time (Kit et al.
2012).
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2.2.2.5 Total cholesterol (TC)
Total cholesterol is a measure from a commonly conducted blood test and includes the
total count of all cholesterol present in the blood sample, a combination of LDL-C, HDL-C
and VLDL-C (Birtcher 2004). Average levels among U.S. children ages 6 to 19 years have
declined, with the average TC (mg/dL) levels (95% CI) moving from 165 (164, 167) in
1988-1994 to 160 (158, 161) in 2007-2010. Consistent with the decline over time reported in
the previous study, the decline continues among children ages 6-19 years in the United States
between 2011-2014 with 7.4% having high TC (Nguyen, Kit, and Carroll 2015).
2.2.2.6 TG/HDL-C ratio
One measure that has been classified as a marker for insulin resistance is the ratio
of HDL-C to TG. This ratio has been shown to be a valid marker in a diverse range of
racial/ethnic groups such as obese American youth from a range of ethnic/racial backgrounds
(Giannini et al. 2011), indigenous Argentinian children (Hirschler et al. 2015), Chinese adults
with newly diagnosed diabetes (Ren et al. 2016), and obese/overweight Italian children (Di
Bonito et al. 2015). Furthermore, in the study of Italian children, an additional positive
association was found between carotid intima-media thickness (cIMT) and concentric left
ventricular hypertrophy (cLVH) and the HDL-C to TG ratio. Despite the replications
across samples, one recent study in another group of obese and overweight children in rural
Appalachia, United States, indicated no advantage of a TG/HDL-C marker to identify insulin
resistance (Bridges et al. 2016). A caveat for this relationship is that this association between
TG/HDL-C ratio and insulin resistance and organ damage has been mostly in subsets of
general populations such as obese youth, whose lipid profile is characterized by high TG/low
HDL-C (Pires, Sena, and Seiça 2016). Further research in other subgroups is needed to
confirm the utility of this marker for insulin resistance normal weight groups.
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2.2.2.7 non-High Density Lipoprotein Cholesterol (non-HDL-C)
Also associated with the TG/HDL-C ratio, non-HDL-C is another measure incorporating
a composite of lipid measures. Calculation of non-HDL-C is simply equal to TC - HDL-C.
Unlike a measure with directly measured TG, non-HDL-C does not require any fasting to
obtain meaningful estimates and is a stronger marker for coronary artery disease than LDL-C
alone (Pires, Sena, and Seiça 2016; McPherson 2013). An advantage of this measures is the
inclusion of “triglyceride-rich lipoproteins whereas LDL cholesterol does not.” (Helgadottir et
al. 2016) This particular measure has been shown in Mendelian randomization studies to
have an additional association beyond that of LDL with coronary artery disease (CAD) risk
whereas there was no effect when examining TG and coronary artery disease (Helgadottir
et al. 2016). Remnant cholesterol, with a strong association with coronary artery disease
(Varbo, Benn, and Nordestgaard 2014; McPherson 2013) may figure more prominently in
non-HDL-C and support the strength of association with coronary artery disease.
2.2.3 Age patterns in lipid level variation
Average lipid levels in U.S. children follow a distinct pattern from age 2 to 18 years.
The National Health and Examination Study (NHANES) is one of the few studies allowing
examination of lipid levels in children across a broad age range. In the United States mean
non-HDL-C levels remain between 100 and 120 mg/dL between 6 and 18 years of age between
2005-2010 for three racial/ethnic groups: Non-Hispanic Whites, Non-Hispanic Blacks and
Mexican-Americans. Within that range the levels rise from age 6 years peaking at age 10
then decline in early teens to rise again (Fig. 2.4) (Dai et al. 2014). In the same NHANES
sample with some overlap in sampling years, this prevalence pattern across age occurs when
examining separate measures of nonfasting LDL-C and TG, TC and HDL-C (Skinner et al.
2012; Jolliffe and Janssen 2006).
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Figure 2.4: Lipid patterns by age and racial/ethnic group in United States sample, 2005-2010
(Dai et al. 2014).
Notably, the pattern described above does not apply to Mexican-American females
showing little change in average levels from 6 to 12 years. In a study of more than 38,000
Brazilian adolescents aged 12-14 and 15-17 years from 2013-2014 (Faria Neto et al. 2016),
evidence of gender differences also occurs. Age was positively associated with LDL-C levels
in males but not in females, which is similar to the NHANES pattern for Mexican-American
females mentioned above. These published studies provide clues for lipid variation across
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different ages in childhood in different HL samples, which may not match the average United
States patterns for children. Given these fluctuations in lipid levels across childhood, universal
lipid level screening is now recommended between ages 9 to 11 given a decline in cholesterol
levels during adolescence (Peter O. Kwiterovich 2008b; Expert Panel 2011). The next age
at which screening is recommended is 17 to 21 years. Despite these recommendations no
more than 11 percent of U.S. children in a sample exceeding 200,000 were screened in 2012
(Zachariah et al. 2015).
2.2.4 Tracking into adulthood
Once a child achieves an adverse lipid level leading to a diagnosis of dyslipidemia, the
chances are high that this child will have dyslipidemia as an adult (Kallio et al. 1993;
Labarthe, Eissa, and Varas 1991). Thus far the four largest cohorts with information to
provide estimates tracking lipids from childhood to adulthood are: 1) the Young Finns study,
2) the American Bogalusa study, 3) the Australian Childhood Determinants of Adult Health
study, and 4) the Muscatine study (Dwyer et al. 2013). These studies have built strong
evidence over time that adverse lipid levels in childhood are associated with various measures
of subclinical atherosclerosis in adulthood such as carotid intima-media thickness (IMT) and
coronary artery calcification (CAC) (Hartiala et al. 2012; Juonala et al. 2008b; Juonala et al.
2008a; Frontini et al. 2008; S. Li et al. 2007; Raitakari et al. 2003; Li et al. 2003; Davis et al.
2001; Mahoney et al. 1996).
One example representative of findings from these four studies is LDL-C levels in Finnish
adolescents predict Coronary Artery Calcification in adults aged 40 to 46 years independent
of LDL-C changes between the two age periods (Hartiala et al. 2012). For a one standard
deviation increase in adolescent LDL-C measure (mg/dL) the odds ratio for Coronary Artery
Calcification was 1.34. Also, high LDL-C levels during childhood were found to track given
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the development of adverse lifestyle changes between adolescence and measures taken during
adulthood (Magnussen et al. 2011). If individuals developed higher adiposity and and
smoking behaviors after the adolescent measures these people were found to maintain adverse
LDL-C levels in adulthood. This evidence signals the importance of intermediary lifestyle
factors related to overweight and obesity along with smoking in maintaining dyslipidemia.
The most recently published study outlining risk of atherosclerosis in adults after exposure
to abnormal lipid levels in childhood is from Finland (Juhola et al. 2011). In this study more
than 2,200 boys and girls followed for more than 27 years have a correlation of 0.43 to 0.56
(p < 0.0001) between childhood and adulthood cholesterol levels. Also, the ages of 12 to 18
years was considered as having the best sensitivity and specificity for abnormal LDL-C and
HDL-C levels during adulthood, ranging from 75% to 95% and 20% to 57%, respectively. The
evidence supports a strong link between exposure to adverse lipid levels during adolescence
and continuing link to this factor as an adult.
Research on tracking of abnormal lipid values is limited in racial diversity with the
majority of study populations being of European descent. In the Bogalusa study in which over
25% of the sample are black, there were racial differences discovered for a linear association
between childhood lipid levels and carotid intima–media thickness (IMT) in adulthood (S.
Li et al. 2007). LDL-C was identified as being linearly associated across the lifecourse in
regression analyses for both black and white females, but restricted to whites for males. Also,
triglycerides appeared to predict IMT for white males only. Given these variability in these
findings it is important to note that associations with lipids found in one population of
children may not extend to other populations, emphasizing the value in studying associations
between life course exposures and lipids in different samples such as the proposed Chilean
study sample identified for this project.
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2.2.5 Gender differences
In terms of lipid metabolism, adult males and females are different given their unique
hormonal characteristics (Varlamov, Bethea, and Roberts 2015). However, observational
data for children does not support this difference, and gender comparisons in nationally
representative studies indicate little difference in prevalence of childhood dyslipidemia. In
the most recent evaluation of NHANES U.S. data from 2011-2012 for children aged 8 to
17 years, the prevalence of dyslipidemia (95% CI) was 21.0% (148.8, 28.5) and 19.3% (16.2,
22.8) for girls and boys, respectively (Kit et al. 2015). Similarly, the values for non-HDL-C,
often considered a good indicator in childhood for later preclinical atherosclerotic change
(Frontini et al. 2008), is similar in U.S. children ages 6 to 19 years across three different
time periods: 1988-1994, 1999-2002, and 2007-2010 (Kit et al. 2012). Similarities during
childhood remain across gender in countries outside of the U.S. In the proposed study sample
of Chilean children the mean HDL-C levels (SD) mg/dL for males and females aged 17 years
was 38.0 (10.1) and 42.5 (10.7), respectively (Burrows et al. 2016). Mean TG (mg/dL) were
88.4 (52.4) and 88.2 (47.6) for males and females, respectively.
Dyslipidemia prevalence estimates are similar in male and female children, but there
appears to be effect modification occurring by gender when examining the association between
dyslipidemia and obesity. With obesity being a strong comorbidity with dyslipidemia outside
of primary genetic causes in children, presence of this effect modification is an important
reason to stratify the analyses by gender. Although little is published on this topic, a recent
study of 161 Portuguese children indicates that males had stronger associations between
adiposity and ASCVD risk factors compared to females (Pires et al. 2016).
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2.2.6 Primary genetic causes of dyslipidemia
2.2.6.1 Monogenic lipid disorders
Monogenic lipid disorders are distinguished by lipid levels that cannot be altered by
lifestyle choices and are caused by highly penetrant mutations in a small number of genes –
as low as one. Familial hypercholesterolemia (FH) is an autosomal dominant lipid disorder
characterized by very high LDL levels. Marked by disruptions in the lipid metabolic pathway,
these primary disorders are also rare. FH occurs in about 1 in 500 children in the United
States population (Peter O. Kwiterovich 2008a; Peterson and McBride 2012) and “50% of
untreated male heterozygotes and 25% of untreated female heterozygotes will develop CAD
by 50 years of age.” (Peter O. Kwiterovich 2008a) Another example of an inherited disorder
is familial combined hyperlipidemia (FCHL), a disorder characterized by overproduction of
very low density lipoproteins (VLDL). FCHL is considered to be the most common genetic
dyslipidemia in people of European ancestry (Brouwers et al. 2012).
Given the rarity of these genetic disorders in the populations we do not expect to find
many, if anyone, with this disease. However, it is worthwhile further investigating any outliers
in the analyses as a rare condition such as this may serve as a confounder for infant growth
and dyslipidemia outcomes (Basso 2006).
2.2.7 Secondary risk factors for dyslipidemia
Several high-level risk factors worth noting in children include severe hypertension
exceeding the 99th percentile, cigarette smoking, oral contraceptive use, type 1 and type 2
diabetes mellitis (DM), and BMI exceeding the 97th percentile (Expert Panel 2011; Peter O.
Kwiterovich 2008b). Type I and 2 DM could be potential confounders if these factors were on
a pathway to dyslipidemia during adolescence. One such pathway could be a genetic variant
22
associated with both T1DM or T2DM and infant growth. However, no such factors have been
identified in the literature. Also, childhood weight following infant growth can be considered
a mediator (Fig. 2.1) and as such should not be considered in the set of adjustment factors.
Although these conditions or risk factors can lead to dyslipidemia in adolescence they are not
considered confounders because of lack of association with prenatal growth, and as a result
will not be considered in the analyses.
Lastly, other secondary special high risk conditions include chronic kidney disease,
children with heart transplants and Kawasaki disease (Expert Panel 2011). The rarity of
these conditions eliminates these factors from further consideration.
2.2.8 Environmental factors for infants
2.2.8.1 Feeding
During the first four to six months of infancy, breastfeeding, formula feeding or some
combination thereof is the primary food source for infants. There is potential for the type
of feeding to be associated with both dyslipidemia in adolescence and weight change, thus
creating a confounding factor between the outcome and exposure of interest in this proposal.
Many studies, exceeding 30 as of 2012 (Kwiterovich 2012, 153; Koletzko 2009, 41; Hayosh
et al. 2015; Wong et al. 2018; Owen et al. 2008; Gishti et al. 2014), present inconclusive
evidence supporting an association between infant feeding and lipid levels once a child achieves
adolescence. Meta-analyses present evidence supporting a small reduction in total and LDL
cholesterol in adulthood, but no biological basis for a programming effect for adult lipid
profiles exists (Demmers 2005).
A recent study examining “lipidomic profiles” indicates there are differences according
to breastfeeding status at 3 months of age, which decline by 12 months of age. These results,
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relying on metabolic phenotyping previously unavailable in research alongside a cohort
starting after 2000, further supports the prior findings of no persistence of breastfeeding
association with lipid profiles later in age (Prentice et al. 2015). Interestingly, there were
specific lipids detected at three months found to predict weight gain at 12 months. Despite
the association between earlier lipid profile and growth, a connection between breastfeeding
as an environmental exposure in childhood and dyslipidemia in adolescence is equivocal,
reducing its potential as a confounder between infant growth and later dyslipidemia.
2.2.9 Racial and ethnic disparities
Racial and ethnic disparities in dyslipidemia exist and research on this topic is growing to
counter a knowledge gap. Relative to the non-Hispanic White population, the HL population
on average has a higher prevalence of dyslipidemia. Addressing these disparities is important
because higher cardiovascular disease burden is tightly linked with a higher prevalence of risk
factors including dyslipidemia.
Authors investigating subtypes of dyslipidemia patterns across major racial/ethnic groups
in the United States (Frank et al. 2014), found that the adult HL population is characterized
by a pattern of raised TG and lower HDL-C, increasing the risk of atherosclerosis. The
raised TG levels in HL groups has been observed elsewhere, including a systematic review
of literature representing North American countries, including Mexico, from 2000 to 2014
(Gasevic, Ross, and Lear 2015). This particular literature review determined no difference
in low HDL levels between the HL and non-Hispanic White groups, but this finding is
contradicted in other studies, including ones using NHANES data.
National Health and Nutrition Examination Survey (NHANES) is one of the most
commonly used data sources to document health disparities on a national level (Pu et al.
2016). In this survey from 1999 to 2006, the levels of hypercholesteremia (total cholesterol
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>= 5.2 mmol/L = 201 mg/dL) for the HL group were lower than the referent non-Hispanic
White group, with adjusted prevalence ratio (95% CI) of 0.99 (0.94, 1.03) (Ford et al. 2010)
and the prevalence (SE) in 2005-2006 ranging from 45.6 (2.5) for African American men
to 58.7 (2.1) for white women. When considering six different HL subgroups within the
Hispanic Community Health Study/Study of Latinos sample from 2008 to 2011 (Daviglus et
al. 2012) that have the potential for considerable heterogeneity, the prevalence (95% CI) of
hypercholesteremia were lowest for South American women at 31 (27, 36) and highest for
Central American men at 55 (51, 59) – all below those noted in the NHANES sample above.
This differential in which the HL group has higher proportion with low HDL-C mirrors
findings for adults. In a sample representative of the United States, 16% of the Hispanic
group aged 8 to 17 years had low HDL-C compared to 14% of NHW group (Kit et al. 2015) in
2011-2012. Also, in the SLS sample, the data source in the proposed analyses, the prevalence
(95% CI) of low HDL-C is 70% (66%, 73%) (Burrows et al. 2016). In this Chilean sample,
the prevalence of low HDL-C is over five times the U.S. representative NHW sample, but
only represents average age 17 years versus the wider age range mentioned above.
Mean triglyceride levels in samples of children also show an atherogenic pattern in which
the HL group is more likely to have adverse levels than the non-Hispanic White group. In
the U.S. a geometric mean of TG in the non-Hispanic White group aged 12-19 years is 79
(73-86) compared to 83 (73-94) for the Mexican American group. In the SLS Chilean sample
of adolescents of a mean age of 17 years, the overall sample mean (SD) was 88.3 mg/dL (50.2)
(Burrows et al. 2016). As discussed previously in the section addressing TG, another sample
of children from Chile exceeded 90 mg/dL (Salesa Barja 2013).
Deviations from this pattern emerge across racial/ethnic groups when examining pro-
portions with hypertriglyceridemia. In the United States, a recent estimate taken from U.S.
NHANES data estimates 12% of children have TG levels > 150 mg/dL from 2001 to 2008
(Christian et al. 2011). A similar study, stratifying estimates by race/ethnicity had similar
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findings with 12.1% (95% CI: 9.5, 15.2) of non-Hispanic White and 9.3% (95% CI: 7.7-11.2)
of the HL group with high TG exceeding 150 mg/dL (“Prevalence of Abnormal Lipid Levels
Among Youths — United States, 1999–2006” 2010). A similar prevalence of triglyceridemia,
9.4%, occurred in a sample of 2,900 Chilean school children with an average age of 11 years
from 2009-2011 (Barja Yáñez 2015). In contrast, a study of a U.S. population with subgroups
including non-Hispanic White and HL (Mexican-Americans) demonstrated the HL group
more likely to ever have high TG (Frank et al. 2014) than the non-Hispanic White group.
In this study comparing non-Hispanic White versus HL groups, the prevalence was 27.6%
versus 45.4% and 42.5% versus 55.9%, for men and women, respectively.
In sum, disparities between HL and non-Hispanic White groups of children appear
to follow those for adults when examining HDL-C but does not track as closely for TG.
Differences in TG tracking in racial ethnic groups across the lifecourse may account for this
difference, emphasizing the importance of examining children separately from adults. Other
explanations for divergence across age groups in racial/ethnic lipid differences may also lie in
cohort differences in HL subtypes present in U.S. populations.
2.2.10 Polygenic factors
Monogenic lipid disorders, which usually point to mutations in one specific gene as the
cause of extreme lipid levels are evident in early life. Genetic causes of dyslipidemia also
include polygenic factors in which many genetic factors contribute to a susceptibility to
dyslipidemia when combined with environmental factors such as body weight, activity and
poor diet (Kuivenhoven and Hegele 2014). Polygenic dyslipidemias are the most common
type, occupying the remainder of dyslipidemias after accounting for monogenic dyslipidemias,
the most prevalent is familial hypercholesterolemia with 1 in 500 people being affected.
Interestingly, distinguishing between the two based on phenotypes alone is not straightforward
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(Medeiros et al. 2014; Stitziel et al. 2015).
Polygenic effects as defined through Genome-Wide Association Studies (GWAS) efforts
occur through common variants with small effects accumulating into larger aggregate effects
that influence lipid levels in the population. These effects act in concert with modifiable
environmental factors and form the hypothesized causal effect for dyslipidemia (Kuivenhoven
and Hegele 2014). In the past 10 years an ascendance of GWAS (Visscher et al. 2012) has
revealed many common genetic variants associated with lipid levels. As of 2013 the largest
GWAS identifies 157 loci associated with lipid levels (Willer et al. 2013) predominantly in
European ancestral groups. Given this large sample size, this particular study was able to
identify 62 new loci with smaller effects than the 95 previously identified loci (Teslovich et al.
2010). The individual loci were often associated with more than one lipid trait. For example,
there are 16 loci that associated with both HDL-C and TG levels. Taking this information
together, the field is rich for further exploration of genetic variants associated with lipid
levels.
Whether these polygenic factors consistently associate with lipids across the life course
remains unclear although there has been recent research on this topic (Buscot et al. 2016).
Reasons behind this sparsity in research includes lack of longitudinal data to assess any
changes in these associations starting in childhood and going to adulthood. Given the difficulty
in collecting information over such a long range of time this sparsity is not surprising. Though
limited in the amount of evidence present on this topic, common genetic factors identified
through the Global Lipid Genetic Consortium clearly associate with lipids throughout the
life course. Genetic factors do not operate independently when examining common chronic
disorders such as dyslipidemia, and thsi fact underlines the importance of early life as a time
for intervention given these factors manifest at young ages.
Polygenic and environmental effects do interact, but these environmental effects are
27
cumulative over time, and they most likely exert less of a causal effect on heterogeneity in
lipid levels earlier in life compared to later life. Children do not manifest chronic disease as
adults do, and they rarely take lipid lowering medicines so any genetic effects would be less
confounded in earlier time periods absent these biasing and/or confounding factors. Also,
there is heterogeneity in lipid levels across continental ancestral groups. Given the prior
assumption regarding environmental effects cumulating over the lifecourse one would imagine
that these ancestral group differences would be more pronounced during childhood. Young
adult samples create a promising area in which to investigate genetic effects on lipid levels –
perhaps better revealing divergence of associations across ancestral groups.
A diverse set of genetic factors also contributes to dyslipidemia in children in addition to
primary, secondary and environmental factors such as obesity. Research has mostly focused
on adults in determining associations between genetic variants and lipids, but with recent
analyses of child cohorts, information on children is growing (White et al. 2015; Juonala,
Viikari, and Raitakari 2013; Moltó-Puigmartí et al. 2013; Shen et al. 2013; Breitling et al.
2015; Punwasi et al. 2015; Tikkanen et al. 2011; Buscot et al. 2016). Variants characterized
as being associated with lipids in adults are also implicated in children. In particular, work
has been done with PRSs showing the same scores associate with lipids for children and
adults (Tikkanen et al. 2011; Buscot et al. 2016). Of note, this work replicating associations
in children pertains to populations of European descent. Analyses with smaller samples have
been conducted for Turkish (White et al. 2015) and Chinese samples (Shen et al. 2013),
but further work is needed in other racial and ethnic groups given differences in haplotypic
structure and allele frequencies.
The GWAS have established a large number of single nucleotide polymorphisms (SNPs)
associated with lipid outcomes. After identifying these lipid outcomes based on studies
with populations of European descent, analyses followed with more studies in more diverse
racial and ethnic groups, functional analyses and with other cardiovascular disease outcomes.
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Results from these studies since 2013 indicate a common theme of genetic loci linked with
dyslipidemia that tend to generalize across all ancestral groups.
2.2.10.1 Generalizability of association between European-specific variants and
lipid traits to populations of HL descent.
Most GWAS studies investigating connections between genetic variants and lipid levels are
from European populations. These GWAS associations predominantly found in populations
of European descent may not exist in other groups. Reasons for lack of consistent associations
across populations include variation across populations in: 1) risk variant occurrence, 2)
allele frequencies, 3) disease prevalence, 4) risk variant effect sizes (Rosenberg et al. 2010).
Similarly, differences in genetic structure between groups can lead to differences in linkage
disequilibrium, which can also lead to a different association between a lead SNP and the
causal variant found in European populations compared to one from HL descent. All of these
factors are important areas to consider before applying results from studies derived from
European populations to analyses including HL populations.
In particular, generalizability of SNPs, or lack thereof due to the reasons mentioned above,
can compromise PRS formation. For example, without similar effect sizes across population
groups, PRSs have limited meaning when crossing over from the European samples to other
ancestral groups, such as the HL group that is the focus of these analyses. Simulations using
information from the 1000 genomes samples (Martin et al. 2017) demonstrate this concept.
The authors apply GWAS-derived information from a European descent population to form
risk scores in other populations, such as HL samples, resulting in compromised accuracy and
resultant bias. Instead, the authors recommend staying within the source population or one
of similar demographic history when computing PRSs.
Unfortunately, when adhering to advice to use source populations in generating PRS,
29
the downside is there are few genetic studies outside of those using individuals of European
ancestry (Bustamante, Burchard, and De la Vega 2011), although they are on the rise. The
smaller sample size in the training data with a matching target population also means a
decrease in prediction accuracy. A recent Bayesian method has been proposed to combine
both European and the target population when creating PRSs in samples such as the
proposed one of a HL group. This approach combines the benefits of large samples present in
European samples and the representative linkage disequilibrium patterns from the smaller
target population (Marquez, Loh, and Price 2017). In the future, once published, this method
could add another means to estimate PRS. Lastly, no matter the method or approach all
authors agree that PRS prediction accuracy have yet to approach clinical utility.
Recent studies underscore the generalizability of lipid-related loci found in European
samples with HL samples when they find similarities in statistical significance and effect size
across different populations. In one 2012 study the majority of SNPs found in established
lipid risk loci from European samples were concordant in direction of effect in a HL sample:
23/28, 16/20, 21/23, and 19/21 of TC, LDL-C, HDL-C and TG, respectively (Elbers et al.
2012). Studies in different ancestral groups following large GWAS in Europeans indicates
large overlap between different ancestral groups for genes implicated in lipid variation (Coram
et al. 2013). Results from a 2013 study with both HL and African American samples indicate
a correlation of 0.69 in allelic effect sizes for the HL and African American samples for SNPS
found in a European descent GWAS sample (Coram et al. 2013).
These recent studies have been followed by another meta-analysis of HL populations in
2016 (Below et al. 2016), which reveals little heterogeneity in effect sizes between European
and HL samples. However, in this study they did find evidence for linkage disequilibrium
differences between the european ancestry sample from Global Lipid Genetic Consortium
and the HL along with evidence for novel loci in the HL sample indicating diversity in
genetic architecture. Those differences indicate a possibility for measurement error when
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using tag SNPs from groups with european ancestry, which will then dilute effect sizes given
the imperfect association between tag SNPs and the functional variant (Carlson et al. 2013).
However, similarities in effect sizes of many loci across populations do demonstrate how
European results for “GWAS-identified SNPs associated with lipid traits” (Below et al. 2016)
can generalize to HL groups.
The assumption that lipid variants found primarily in samples of European descent
generalize to HL samples may not hold for our particular sample from Chile. Studies of HL
populations focused mainly on Mexicans or Mexican-Americans subgroups, and the existence
of considerable heterogeneity in HL subgroups can undermine the validity of this assumption.
However, the finding that lipid variants generalize across disparate populations such as ones
of African descent provides evidence against this sort of assumption violation. Transethnic
transferability of lipid traits are evident for both HL and African American populations
given, “more than half of the additive phenotypic variance explained by the entire genome
can be attributed to the 10% of the genome showing strongest evidence of association in
Europeans.” (Coram et al. 2013). Furthermore, European lipid risk variants share similar
direction and magnitude of effect in HL and African American populations supporting an
evolutionary biology perspective of shared lipid metabolism variants over generations and
across populations.
Although the majority of lipid variants already established in GWAS do display similar
characteristics in HL groups, there are some variants that do not. Some of these discordant
associations may be due to “different haplotypic structures or contributing variants underlying
risk at these regions. . . ” (Below and Parra 2016). It is also worth noting that the lipid-related
risk variants found in large GWAS are considered common variants. Rare risk variants
found in one ancestral group may not appear in another group, also contributing to lack of
generalizability. This issue is not a prominent factor for the proposed set of variants in these
analyses. None of the variants identified in the first set of reported lipid-related variants
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(Appendix D) had a minor allele frequency less than 0.01, considered to be a threshold for
rare variants (Gibson 2012; Schork et al. 2009).
In terms of identifying genetic variants that underpin chronic diseases such as ASCVD,
no one population can adequately identify all variants associated with disease risk. The
composition of genetic variation across ancestral groups requires investigation with many
sources of descent to quantify hypotheses relating to disease risk. Needless to say, adding
information regarding the risk factor of HDL-C in a diverse sample such as SLS, of American
Indian (44-51%), European (45-51%) and African (4-6%) descent, will be integral to the
mapping of determinants of ASCVD for the entire human population (Rosenberg et al. 2010;
Seldin, Pasaniuc, and Price 2011).
2.3 Evidence for an association between postnatal growth and dis-
tal cardiovascular disease risk factors
Prenatal environment also plays a role in the formation of ASCVD outcomes, and the
combination of prenatal and postnatal growth exposures can lead to different combinations
with different effects on downstream lipid levels (Eleftheriades et al. 2014). At the outset
of DOHaD-motivated studies, the most common hypotheses and data supporting these
hypotheses was intrauterine growth restriction and postnatal catch-up growth resulting in
adverse lipid levels and ASCVD outcomes (Osmond et al. 1993; Singhal and Lucas 2004;
Barker et al. 1989; Visentin et al. 2014). The frequency of research meant to support this
paradigm reflected the availability of older European cohorts subject to food shortages. This
scenario also reflects what can currently occur in a large portion of developing countries (Ong
2015), but with the increasing availability of energy dense foods and sedentary behavior in
developed countries there is also a place to study the effects of faster than average growth on
later ASCVD outcomes.
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Studies of postnatal growth and associations with adverse health outcomes extend to
human observational studies. More recent birth cohort studies include accelerated growth
across a broad array of birth weights providing a proxy for varying prenatal growth conditions.
These studies provide evidence of associations between growth patterns during infancy and
altered lipid levels later in life (Kajantie et al. 2008; Cheung et al. 2000; Barker et al. 2009;
Visentin et al. 2014). In turn, these results have converged to a hypothesis that irregularities in
fetal and postnatal growth influence liver growth and subsequent lipid metabolism (Hochberg
et al. 2011; Perälä and Eriksson 2012; Wijnands, Obermann-Borst, and Steegers-Theunissen
2015).
Postnatal growth in the first year may provide a foundation for metabolic programming
that permanently alters lipid metabolism later in life. Cues to alter lipid metabolism could
lie in the size of the liver following abnormal growth patterns. (Barker et al. 2009; Fall et al.
1992; Kajantie et al. 2008). Alternatively, and more likely given current research, it is possible
that irregular infant growth could function as a cue to modify gene expression in tissues
such as the liver (Peng et al. 2014), which in turn alters lipid levels. These explanations of
potential biological mechanisms cover a broader concept of developmental plasticity in which
a variety of phenotypes can arise from a specific genotype upon exposure to environmental
cues (Hochberg et al. 2011).
Although studies with similar designs demonstrate different directions of effect, the
consensus is that abnormal postnatal growth patterns result in adverse levels of risk factors
for ASCVD. Animal models offer the most convincing evidence for postnatal growth as a
causal effect for lipid metabolism disturbance through experimental manipulation of maternal
and postnatal diet with growth change. Measurement of gene expression at the tissue level
across these groups provides evidence that these metabolic disturbances are occurring at the
molecular level.
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2.3.1 Animal models
In the past ten years, evidence has grown linking infant growth trajectories with cardio-
vascular risk factors, including lipid levels, later in life. Animal studies provide one avenue
to explore risk factors such as lipid levels in later life following postnatal interventions not
ethically possible with human beings, including starvation and organ harvesting.
There are many animal models that demonstrate a link between postnatal growth and
lipid outcomes. Slower growth during the postnatal period leads to altered plasma lipid
concentrations. One experimental animal study demonstrated that food restriction during
the postnatal period resulted in lower TC, TG and HDL-C in the offspring levels at the end
of the lactation period (Lucas et al. 1996). In another study, a food restricted prenatal diet
accompanied by a normal maternal diet in rats during lactation resulted in higher plasma
TG levels (Desai et al. 2007). In contrast, another animal study with rats, displayed evidence
that offspring of rats fed a normal diet during gestation but food restricted during lactation
had higher HDL-C, LDL-C, TC but lower TG (Lee et al. 2013) than normal fed control
groups. Conversely, a different study in rats with postnatal food restriction following a
normal prenatal diet presented evidence of a decline in HDL-C levels and TG levels one year
later (Eleftheriades et al. 2014) relative to a normal diet. This model of restricted prenatal
growth followed by normal or catch-up postnatal growth has dominated the literature, and
substantial body of literature has been published on this topic.
Although receiving less attention but arguably more relevant in developed countries with
Western diets and sedentary lifestyle, postnatal overfeeding and the accompanying increased
growth (Fig. 2.5 (A. Habbout et al. 2013)) occupies a deserved space in the DOHaD concept.
Importantly, postnatal growth can also play a role independent of gestational status (Ahmed
Habbout et al. 2013). This particular set of conditions can lead to impaired lipid metabolism.
In particular, postnatal overfeeding has been generally noted in rodent models to lead to
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higher TG, TC and HDL-C levels (Ahmed Habbout et al. 2013). Study-specific results
indicate postnatal overfeeding leads to higher triglyceride levels (Plagemann et al. 1999;
Kappeler et al. 2009; Pentinat et al. 2010; Bei et al. 2015) and higher HDL levels (Kappeler
et al. 2009). Mice that were overfed, and with faster growth, after either a deprived prenatal
environment or control/standard regime had 15% higher levels of plasma TC at age 7 months,
considered adulthood (Ahmed Habbout et al. 2013). Similar to this experimental setup,
another animal study offers evidence of a positive association between a normal prenatal/high
fat postnatal diet, known to cause faster growth than normal (Koletzko 2009), and higher liver
weight and TG concentrations at one year of age in Wistar rats (Eleftheriades et al. 2014).
An earlier study examining both rats and mice (Hahn 1984) provides evidence for higher
cholesterol levels after postnatal overfeeding across species. However, these associations are
not consistently observed in all animal models of postnatal overfeeding (Ahmed Habbout et
al. 2013). Evidence is mixed in these models, but all point towards lipid levels as a function
of differential growth via altered postnatal food intake in offspring.
Figure 2.5: Diagram of postnatal overfeeding (Habbout et al. 2013).
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2.3.2 Human Studies
Observational human studies also demonstrate associations between postnatal growth
and cholesterol levels. Findings from a prospective cohort study (ALSPAC, Avon Longitudinal
Study of Parents and Children) in Britain starting in 1991 indicate positive associations
between ponderal index (kg/m3) change during infancy and LDL-C and TG levels at 15 years
of age (Howe et al. 2010) with a negative association for HDL-C. Another prospective birth
cohort, the Amsterdam Born Children and their Development (ABCD) Study (Oostvogels et
al. 2014) found a negative association for HDL-C and a positive association for TG at 5-6
years when considering weight or weight-for-length change between one and three months as
an exposure.
Unlike the two prior birth cohort studies, the Stockholm Weight and Pregnancy Develop-
ment Study, a contemporary prospective birth cohort, reported a positive association between
infancy weight gain from zero to six months with HDL-C and TG levels of participants at
age 17 years (Ekelund et al. 2007). In the Helsinki Birth Cohort, evidence suggests that a
larger than expected increase in BMI in the first six months of life was associated with higher
HDL-C and lower non-HDL-C and lower TC for those aged 57-70 years in 1999 (Kajantie et
al. 2008). Lastly, the Northern Finland Birth Cohort 1966 Study provides evidence towards
an inverse association between peak weight velocity (kg/year) in the first six months of life
and HDL-C and TG levels for participants with average age of 31 years (Tzoulaki et al. 2010).
Contrary to the prior five observational studies, the Growth And Obesity Cohort reported
no evidence of a statistically significant association between weight change from birth to
six months and plasma lipids at 4 years of age (Corvalan et al. 2009) in a Chilean cohort
study starting in 2006 when the participants were ages 2 to 4 years of age. This study
included less than 400 children and may not have as precise an effect as found in larger study
numbering in excess of 1,000 individuals. Although these studies in humans do not reveal a
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consistent direction of association between postnatal growth and lipid profiles as a person
ages, the majority of these seven observational studies in humans support the hypothesis
that postnatal growth influences lipid metabolism accompanied by different directions of
association, analytic approaches and age ranges. (Table 2.2) It also should be noted that
studies contradicting a positive association between faster than average growth and adverse
lipid profiles may be due to different measures of growth, i.e. peak weight velocity, or random
variation in association measures given smaller sample sizes.
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Table 2.2: Postnatal growth studies and association with later plasma lipid levels.
# First Au-
thor
Year Country Sample size Age at growthmeasurements Growth measurement Outcome measures
Mean age at outcome
measures (years (SD))
1 Ekelund 2007 Sweden 128 6 months, 1year, 2 year
change in weight Z-score
between 0 to 6 months HDL (+), TG (+)
16.8 (0.4) male; 16.7
(0.4) female
2 Kajantie 2008 Finland 1999
0, 3, 6, 9, 12, 15,
18, 21, 24
months
BMI SD scores at 6 months
adj. for birthweight
TC (-), HDL (+),
non-HDL (-), TG (-)
at 6 months
61.5 (3.0) women; 61.5
(sd=2.8)
3 Leunissen 2009 Netherlands 200 0, 3, 6, 9, 12months
SD score of weight gain
(Z-score) per 3 month
period in first year of life.
HDL-C (-), LDL-C,
TG(+), TC (at 0-3
months only)
20.8 (1.67)
4 Corvalan 2009 Chile 323 0, 6, 12, 18, 24and 36 months
WHO Z-scores difference 0
to 6 months
HDL-C (-), LDL-C
(+), TG (+), TC
[exclusive bf]
4
5 Tzoulaki 2010 Finland 3778 not specified:during infancy
peak weight velocity
(kg/year) HDL-C (-), TG (-) 31
6 Howe 2010 Great
Britain
4601 0, 2, 4 months
SD score of ponderal index
(PI), kg/m3. change from 0
to 2 months (boys) and 0 to
4 months (girls)
LDL (+), HDL (-),
TG (+) 15
7 Oostvogels 2014 Netherlands 1459
change in internal SD score
for weight-for-length from 1
to 3 months
HDL-C (-), TG (+) 5-6
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To date very little evidence exists documenting infant growth and its association with
dyslipidemia in samples from HL populations. The two largest and most comprehensive
analyses include samples from european ancestry populations: ALSPAC in the United
Kingdom (Howe et al. 2010) and the Helsinki Birth Cohort in Finland (Kajantie et al. 2008;
Barker et al. 2009). Ancestral groups different from those of European ancestry remain
understudied. Accordingly, further work in this area will fill in gaps in the literature and
better address causes of dyslipidemia in diverse populations.
2.3.3 Biological pathways
Explaining biological pathways that underpin the association between postnatal growth
environment and later life cardiovascular disease phenotypes is a crucial step in determining
the validity of any causal effect. Despite active research in molecular mechanisms underlying
postnatal programming of chronic adult disease, explanations do not yet clearly define these
pathways (Vo and Hardy 2012; Sohi et al. 2011; Rueda-Clausen, Morton, and Davidge 2011).
However, there have been studies in the past 10 years that leverage new molecular techniques
and enable a better understanding of these processes.
One theme into which the hypothesized biological pathways fit is the “predictive adaptive
response” described by Gluckman and colleagues (Gluckman, Hanson, and Spencer 2005). In
this theory, metabolic disturbance in adulthood is the result of varying epigenetic responses
to environmental exposures early in life. The ability of a genotype to produce different
phenotypes given particular environments is termed plasticity (Hanson et al. 2011; Demetriou
et al. 2015). These responses to particular environments can result in permanent change
in genetic expression to adapt the body for anticipated environments later in life. When
these anticipated environments do not occur there is a mismatch and metabolic disturbances
occur, including dyslipidemia. One of the most prominent explanations for altered lipid levels
39
during childhood is the fetal/postnatal dietary mismatch (Gluckman, Hanson, and Beedle
2007; Hochberg et al. 2011).
2.3.3.1 Liver function
During postnatal development, liver development can respond to environmental expo-
sures with varying phenotypic responses (Vo and Hardy 2012). Altered postnatal weight
change and accompanying impaired liver growth during postnatal development, a crucial
developmental windows (Perälä and Eriksson 2012), is hypothesized as contributing to adverse
lipid metabolism. Impaired postnatal liver growth affecting cholesterol metabolism was a
concept first introduced by Barker when discussing the dyslipidemic outcomes of children
and abdominal circumference at birth (Barker et al. 1993) and continues in the literature
(Kajantie et al. 2008; Barker et al. 2009). However, experimental evidence linking liver
growth per se to impaired metabolism is sparse. Emphasis in developmental programming of
lipid metabolism has evolved from this explanation of liver size change altering metabolic
programming to one of epigenetics as a causal factor (Reichetzeder et al. 2016; Demetriou et
al. 2015).
Research on postnatal programming of nonalcoholic fatty liver disease, a liver disorder,
offers clues on changing liver function in the face of infant growth change, within the
context of nutritional manipulation. Non-optimal gestational liver growth was associated
with biomarkers for liver damage (Fraser et al. 2007), Alanine Aminotransferase and
gamma glutamyltransferase. In a similar, corroborative, and more recent study in a Chinese
population, a positive association existed between famine exposure during either gestation
and/or childhood with Alanine Aminotransferase and nonalcoholic fatty liver disease (Wang et
al. 2016). To explain this association between undernutrition exposure and liver impairment
the authors offer a hypothesis that undernutrition affects “hepatic processing power on lipid
metabolism” (Wang et al. 2016). Specifically, the authors mention an experimental study
40
that points towards increased hepatic sirtuin 1 activity reprogramming hepatic nutrient
sensors, which misinterpret postnatal availability and induce hepatic lipid storage (Wolfe et
al. 2012). In these cases nutrient deficiency not only slows overall growth but changes the
composition of the liver, an organ essential for lipid synthesis.
Although undernutrition functions as the exposure in the prior studies, a similar associa-
tion may occur with nutrient excess and above average growth, the focus in my three aims. A
study in Europeans demonstrated that accelerated infant weight-for-length (WFL) gain from
months 0 to 3 led to a higher risk of nonalcoholic fatty liver disease during early adulthood,
independent of birth weight, but no increase in Alanine Aminotransferase at that age (Breij,
Kerkhof, and Hokken-Koelega 2014). Another study in Europeans examined WFL change
from birth to age one year and found no relationship with liver outcomes (Anderson et al.
2014). However, this particular study did find a positive association between BMI change after
year one and blood-based liver outcomes around 18 years, including Alanine Aminotransferase
and gamma glutamyltransferase. All these studies demonstrate the potential for change in
liver function following different growth patterns.
2.3.3.2 Gene expression timing
Gene expression in rat liver tissue (Li et al. 2009) is enriched during the neonatal
period and suppressed during the prenatal period. During the postnatal period a thorough
study of gene expression levels in the rat shows stronger expression of genes linked with lipid
metabolism occurring exclusively during early postnatal life (Li et al. 2009). The timing
of maximum gene expression during neonatal liver development is also confirmed in animal
models for long noncoding ribonucleic acid (Peng et al. 2014), and this increased activity can
relate to the “functional transition during postnatal liver maturation”. One caveat behind
this evidence is human postnatal development is not the same as rodent organ development
with more activity in rodents in the postnatal period than humans (Rueda-Clausen, Morton,
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and Davidge 2011) and as such these results may not generalize across species.
Fitting within this window of time, postnatal growth is also associated with programming
of the liver tissue via gene expression (Keating and El-Osta 2015; Rueda-Clausen, Morton,
and Davidge 2011). Furthermore, changes in gene expression early in life can permanently
affect long term health outcomes (Tollefsbol 2016), fitting within programming hypotheses of
cardiovascular disease. Higher gene expression levels can also serve as a proxy for genotype
x environment (GXE) interactions (Grishkevich and Yanai 2013) lending credence to the
concept of the postnatal time as a window for gene-environment interaction leading to different
permanent lipid metabolism outcomes.
2.3.3.3 Epigenetics as mechanism for disease
As previously discussed, literature supports an epigenetic disease mechanism to explain
the association between abnormal postnatal growth and dyslipidemia in adolescence. This
particular framework follows what has been advocated in a range of mechanisms matching
epigenotype factors with gene and environment factors as seen in figure 2.6 (Ladd-Acosta and
Fallin 2016) – section c. Epigenetic activity influencing the risk factor outcome motivates
the examination of GXE interactions in this project and guides the selection of genotypes.
Conversely, in this concept the existence of a GXE interaction may not imply the existence
of epigenetic activity given the potential for other paths and residual confounding.
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Figure 2.6: Epigenetics as a mechanism for disease (Ladd Acosta and Fallin 2016)
Epigenetic processes have been implicated in the relationship between abnormal post-
natal growth and lipid outcomes at later ages in animal models. Methylation and histone
modification count among the processes through which these epigenetic processes can occur
(Heerwagen et al. 2010; Robertson 2005; Cedar and Bergman 2009; Guéant et al. 2014a;
Rueda-Clausen, Morton, and Davidge 2011). Although concrete explanations are missing for
this biological mechanism through which the environment induces epigenetic changes (Feil
and Fraga 2012; Kanherkar, Bhatia-Dey, and Csoka 2014), active research has uncovered
evidence of methylation and histone modification as it relates to lipid metabolism. One
human study of postnatal epigenetic metabolic programming, measuring DNA methylation
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of two genes, LEP and TNFα, associated with growth and metabolism, found associations
with total cholesterol and HDL-C in early life (17 months) (Wijnands, Obermann-Borst, and
Steegers-Theunissen 2015).
Methylation and subsequent gene transcription alteration is often tissue dependent (The
GTEx Consortium et al. 2015), and animal studies provide findings relating to longitudinal
changes in liver tissue methylation. Different studies in mouse and sheep models (Vo and
Hardy 2012; Sohi et al. 2011; Khanal et al. 2015; Yates et al. 2009; Chechi, McGuire,
and Cheema 2009), mentioned below, support the hypothesis that epigenetic changes follow
randomized maternal and postnatal diet exposures and trigger metabolic dysfunction and
altered cholesterol levels. Although these findings pertain to dietary changes in the mother
and not postnatal growth per se, these results support a link between postnatal exposures
and permanent cholesterol change with epigenetic factors in a mediating role.
Recent studies hypothesize that dietary alterations in pregnant and lactating mice induce
cholesterol metabolism changes in offspring through epigenetic mechanisms, including histone
modifications and methylation (Sohi et al. 2011). An early study in rats with a dietary
restriction in dams suggest gene expression as a mode through which lipid programming occurs
(Lucas et al. 1996). More recent research with similar experimental conditions sheds more
light on potential downstream lipid metabolic effects. One intervention allowing a normal
postnatal diet following prenatal protein restriction resulted in enhanced levels of hepatic liver
X receptor alpha, which prevented hypercholesteremia by three weeks of age. This receptor,
liver X receptor alpha, regulates the enzyme cholesterol 7-hydroxylase (Cyp7a1) helping
convert cholesterol to bile acids. Notably, this receptor is part of cholesterol homeostasis in
liver tissue. This first of its kind experimental work demonstrated maternal nutrition and
infant growth exposure caused long-term cholesterol dysregulation via epigenetic processes.
The results from this study sets the stage for further research to understand transcription
mechanisms in cholesterol and triglyceride homeostasis (Vo and Hardy 2012; Lillycrop and
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Burdge 2012; Zhang 2015).
Unlike the prior studies, there are also studies focusing on the epigenetic consequences of
overnutrition, which are more relevant to developing countries marked by high fat diets and
sedentary lifestyles (Alexander 2009; Guéant et al. 2014b). Results from these studies indicate
a different biological mechanism stemming from overnutrition. One salient study (Chechi,
McGuire, and Cheema 2009) suggests reduction in LDL-C receptors (LDL-r) following a
maternal postweaning high fat diet during lactation triggering subsequent permanent increases
in LDL-C in offspring. It is also worth noting that this occurred independent of maternal
prenatal intake signalling the postweaning period as a relevant exposure window. Another
animal study (Yu et al. 2015) provides evidence that a high energy and high lipid maternal
diet during gestation and lactation increases deoxyribonucleic acid methylation profiles
of offspring. In particular, peroxisome proliferator-activated receptor gamma and liver X
receptor alpha genes were hypermethylated resulting in lower levels of protein content and
messenger ribonucleic acid. Both of these studies do not note the growth rate of the pups
across treatment groups, and on this point may not directly relate to the postnatal focus in
this project as they may differ across the prenatal and postnatal periods (Wahlig et al. 2012).
The next two animal studies address epigenetic programming of lipids, but in the context
of postnatal overfeeding, which, unlike the two prior studies, is directly linked to faster
postnatal growth. One study (Bei et al. 2015) found increased messenger ribonucleic acid
levels in postnatal overfed rats compared to normal fed controls. Although the messenger
ribonucleic acid related to expression in epididymal fat in male rats, this evidence does
support epigenetic activity being prompted by postnatal overfeeding coinciding with higher
TG levels in the postnatal overfeeding group. Similarly, another rodent model (Conceição
et al. 2015) suggests that postnatal overfeeding results in higher expression of peroxisome
proliferator-activated receptor gamma in liver tissue, a factor associated with lipid metabolism
compared to a group with normal feeding patterns. Taken together, these studies provide solid
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evidence of epigenetic activity relating to lipids and co-occurring with faster than average
growth.
Findings from a sheep study include a high fat postnatal diet in lambs following normal
gestation with the resulting faster growth leads to higher TG and TC levels (Khanal et al.
2015) in lambs at an age equivalent to puberty (6 months). This particular study did not
test for the biological mechanism affecting the postnatal overfeeding, but mentioned that
epigenetic effects may be at play given prior evidence of a) the role of LDLR gene expression
influenced by maternal undernutrition with a postnatal diet rich in cholesterol (Yates et al.
2009) and b) higher cholesterol levels after protein restriction during lactation in rats due to
post-translational histone modification at the promoter of a gene related to the catabolism of
cholesterol into bile acids (Sohi et al. 2011).
Another hypothesis regarding high fat diets implies that a high fat diet would “initiate
epigenetic changes by regulating genes that encode histone modifying enzymes.” (Keating
and El-Osta 2015). These hypotheses at this point are conjecture and the jump from one
exposure, high fat diet in this case, to the outcome, lipid metabolism, has no evidence to
support what could be a very complex biological pathway. The change in organ structure
following the altered diet could also be a causal factor.
All of these animal models lend credibility to the notion that different levels of growth will
produce different levels of liver tissue transcription, which can permanently affect cholesterol
homeostasis. Activity on a molecular level follows exposure to different postnatal regimes.
Given this understanding that there are demonstrated biological outcomes that coincide
with certain growth patterns stemming from dietary regimes, including overfeeding after
normal birth weight, helps provide a foundation upon which to better understand the role of
epigenetics following postnatal growth and influencing cholesterol patterns.
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2.3.4 Factors affecting postnatal growth
Factors affecting postnatal growth may function as confounders if they serve as a common
cause of dyslipidemia in later ages. However, any such factors remain unidentified at this
point (Fig. 2.1). This lack of relevant confounders rules out use of confounders related to
prenatal status in subsequent models aimed at investigating the association between prenatal
growth and lipid outcomes.
2.3.4.1 Environmental factors
Size at birth is a common measure in studies and associated with growth during the
postnatal period and adverse cardiovascular outcome, but if included as part of a postnatal
growth trajectory then this analytic framework would not be subject to confounding bias.
Other factors determine postnatal growth, including gestational age at delivery, gestational
weight gain, parental anthropometrics, socioeconomic status and breastfeeding (Jameson
2016; Pizzi et al. 2014; Fuemmeler et al. 2016). With the exception of socioeconomic status,
commonly associated with adverse health outcomes across the lifespan, these factors are
not implicated in lipid levels later in the lifespan and as such do not represent potential
confounders when assessing the relationship between postnatal growth and dyslipidemia in
adolescence.
2.3.4.2 Genetics
Postnatal growth varies across populations, and these differences have roots in both
genetic and environmental causes (Towne, Demerath, and Czerwinski 2012). From GWAS a
total of 15 variants were found that relate to childhood body mass index between ages 2 and 10
years explaining 2% of the variance (Felix et al. 2016), and it is safe to assume more variants
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will be discovered in the future. These 15 variants (rs13130484, rs11676272, rs4854349,
rs543874, rs713208, rs1421085, rs12429545, rs987237, rs12041852, rs6567160, rs13253111,
rs8092503, rs3829849, rs13387838, rs7550711), are near or in the following genes that are
related to adult BMI: ADCY3, GNPDA2, TMEM18, SEC16B, FAIM2, FTO, TFAP2B,
TNNI3K, MC4R, GPR61, LMX1B and OLFM4. Higher childhood body mass index is linked
to faster postnatal weight gain so it could be considered as a crude proxy for postnatal weight
gain and as such an indicator for genetic determinants. However, variants associated with
infant growth thus far do not exist given the difficulty in collecting this phenotype on a
large enough scale to justify GWAS. These variants, and their potential relationships with
these listed genes, have not shown any functionality related to lipids, discounting any case
for confounding. However, childhood BMI variants are noted as being associated with TG
variants and we cannot rule out any residual confounding (Hormozdiari et al. 2016).
Functioning as an upstream link to postnatal growth, a birthweight phenotype can provide
clues to the genetics of postnatal growth. A large GWAS exceeding 69,000 participants has
revealed seven distinct loci that are associated with birthweight (Horikoshi et al. 2013), and
in this comprehensive study there is no evidence that these loci are associated with lipid
metabolism. However, a subsequent larger study with the number of participants exceeding
150,000 (Horikoshi et al. 2016) identified genetic variants associated with birthweight at
TRIB1 and MAFB loci and lipids as a cardiometabolic measure later in life. When assessing
the relationship between postnatal growth and dyslipidemia these pleiotropic variants may
serve as confounders (Figure 2.1).
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2.4 Analytic Issues
2.4.1 Current analytic approaches for growth
Sparse anthropometric measures early in life have limited the ability to fully capture
postnatal growth as an underlying environmental exposure. Alternative methodological
approaches with repeated infant anthropometric measures in early infancy can provide
evidence to motivate prevention work such as the development of targets for intervention or
therapy (Kathiresan and Srivastava 2012). There are methods from evolving research that
can summarize different components of infant growth such as velocity (slope) and size (birth
weight), which are not necessarily independent of each other. Furthermore, intervention
targets are not definitive as it relates to growth. The application of current methods paired
with more abundant measures for growth can help fill research gaps by providing evidence of
relations between more detailed estimates of infant growth and ASCVD risk factors.
The proposed analytic approach will employ methods determined to be among the best
at estimating growth (Warrington et al. 2013). These sort of analyses may not be possible
in studies constrained by few repeated measures early in life, common when investigating
infant growth associations with cardiovascular disease outcomes. However, the large number
of observations in the first year of life in the SLS sample allows more flexibility in modeling.
Better characterizing growth will allow the ability to detect patterns in growth that may
have been lost with fewer observations. In our case we propose using the SuperImposition by
Translation and Rotation (SITAR) method (Cole, Donaldson, and Ben-Shlomo 2010) to find
characteristics of individual growth including, size, tempo and velocity differences relative to
the group average (Fig. 3.2).
We will also include analyses that can detect patterns in growth, Latent Growth Mixture
Models, to provide alternatives to the SITAR summaries which provide observed measures of
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the growth curve. These latent (unobserved) patterns will then be used to predict lipid levels
in adolescence, considered a distal outcome in the context of the Latent Growth Mixture
Model (Fig. 3.3). Latent class models produce patterns, or classes, of growth that are data
driven, potentially arbitrary, and entirely dependent on the sample itself. Validation of these
patterns in another sample is advantageous to confirm scientifically meaningful subgroups
(Wang and Bodner 2007). Some specific criticisms of this method include subjective decisions
by the investigator to choose the number and definition of latent groups, large variation
within the selected groups representing the patterns, and “unsatisfying generalizability” (Wen
et al. 2012) with different groups occurring with different samples.
2.4.2 Detecting gene-environment interactions
The term “interaction” will be used interchangeably with “effect modification”. The
latter term is preferred in epidemiology given its broader scope indicating a concept of scale-
dependent differences in measure across strata (VanderWeele 2012) instead of a statistical
product term in an analysis. However, the term GXE interaction is frequently used in genetics
and will occupy a place in this dissertation to be consistent with the previous literature. In
the Latent Growth Mixture Model analyses, the interaction will be evaluated as a product
term between genotype and a continuous outcome, lipid measures.
GXE interactions may encapsulate epigenetic modifications following abnormal liver
growth during the postnatal period, as described previously in section 2.3.3.3. These epigenetic
processes have been identified as causal factors mediating the path between postnatal growth
and lipid metabolism later in life. Animal models have provided evidence for epigenetic
changes in early life, but this work is less feasible in human studies, including tissue-specific
methylation measures early in life. GXE interactions possess a strong association with
epigenetic mediating factors (Grishkevich and Yanai 2013; Ong, Lin, and Holbrook 2015; L.
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Liu, Li, and Tollefsbol 2008a; Walker and Ho 2012). Also, the existence of gene expression
has been noted as a potential proxy for GXE interactions (Grishkevich and Yanai 2013), and
this relationship may explain a hypothesized causal relationship.
In light of this rationale motivating a gene-environment assessment, we will conceptualize
the GXE interaction as an environmental effect, growth trajectories, modifying the relationship
between genetic variants and dyslipidemia in adolescence (Fig. 2.7). Choosing which variable
serves as the effect modifier of the other one does not make a difference in how the effects
are modeled, but does lead to an assumption of larger effect sizes compared to a genetic
effect modifier of relationships between the environment and dyslipidemia (Dick et al. 2015).
Genetic variants as selected in GWAS typically have small main effect sizes.
Figure 2.7: Directed Acyclic Diagram (DAG) for aim 3.
lipid risk
allele
dyslipidemia
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The sample size for the proposed research is approximately 500 people. With the
relatively small sample size, a careful choice of candidate SNPs to test a gene-environment
interaction in this scenario is necessary. Candidate gene x environment interactions are not
without their flaws (Dick et al. 2015) and choosing single candidate genetic variants requires
careful consideration. To evaluate a GXE interaction both single variants and a PRS will be
evaluated.
In the scenario in which an individual SNPs are used, pitfalls include: 1) low power
to detect effects, 2) choice of variants not having undergone rigorous testing in GWAS first
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(i.e. low prior probabilities), and 3) failure to correct for multiple testing. To counter these
three problems, the selected single variants will be selected from replicated GWAS as well as
have sufficient power to detect marginal differences in the sample.
Unlike the use of PRSs in GXE analyses, the role for single genetic variants provides more
insight into the source of effects. Although a significant GXE term for a PRS can provide
evidence of an underlying common genetic role of expression, that particular term does not
provide an answer to the question regarding the functional genetic source in an underlying
biological mechanism provided in Fig. 2.7. A single genetic variant better fits within the
hypothesized biological pathway outlined in Fig. 2.7 as well as provides information on which
variants may be loading most in the PRS. Single variant selection provides a more targeted
hypothesis underlying the biological mechanism and an explanation of functional status. In
turn, this approach may better explain the mode through which the exposure in aim 3, infant
growth, modifies the association between lipid variants and dyslipidemia.
The proposed work that examines the modification of the association between these
genetic variants and the dyslipidemia outcomes across different levels of postnatal growth is
presently absent from current literature. Tests of modification of the relationship between
specific variants and a range of infant growth trajectories could provide evidence supporting
the importance of GXE interaction in the pathogenesis of ASCVD, and in particular relating to
dyslipidemia. In turn, any associations arising from these tests would support the hypothesis
that early postnatal growth permanently affects lipid metabolism (Hanson and Gluckman
2014; L. Liu, Li, and Tollefsbol 2008b; Lee et al. 2013).
2.4.2.1 Model choice
A typical interpretation of a GXE interaction involves a cross-product term between
an environmental and genetic factor. Simply including a cross-product term between the
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environmental variable and the genotype coded as three categories (0, 1, or 2 alleles) may not
suffice when detecting an GXE interaction and further sensitivity tests with additional model
terms may be warranted to determine if better fitting models exist (Dick et al. 2015). For
example, different alleles may have differently shaped associations between the environment
and phenotype and relaxing the assumption of similar distributions across alleles may be
necessary to capture the observed associations (Aliev et al. 2014).
Some experts (Aliev et al. 2014) suggest that a single cross product term in a traditional
regression model should never be used when testing GXE interactions. One recent proposed
solution is a “six parameter model” accounting for a G2 term, G representing the coded
genotype of 0, 1 and 2 risk alleles (Aliev et al. 2014; Dick et al. 2015). This type of model
will relax the assumptions that a) the slope differences between the associations representing
the environment and exposure association remain the same across 0 versus 1 and 1 versus 2
alleles, and b) the lines representing the associations for each genotypic groups all cross at
the same point. This specification for interaction allows use of a continuous covariate with
a trichotomous variable, the genotype with up to three copies of the risk allele, and it is a
model for gene-environment interactions in this dissertation. In turn, this model specification
avoids bias as well as types I and II errors.
The six parameter model for a phenotype P , three-level genotype G, and continuous E,
and would be as follows:
P = γ0 + γ1G+ γ2E + γ3G× E + γ4G2 + γ5G2 × E (2.1)
To test existence of a gene-environment interaction the following contrasts would hold:
γ3 + γ5 = 0 (2.2)
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γ3 + 3γ5 = 0 (2.3)
2γ3 + 4γ5 = 0 (2.4)
Testing significance from equations 2.2-2.4 is similar to an omnibus test. To determine
significance the lowest p-value from all three simultaneous contrasts would hold thus limiting
multiple testing problems.
Another alternative includes a meta-analysis approach to “simultaneously estimate global
fixed effects for multiple parameters and test whether they are identically null.” This method
specifies, “. . .models with separate genetic effect parameters for each exposure stratum.”
(Aschard et al. 2010). This method also requires a categorical environmental exposure,
and this aspect of the analysis makes it less viable compared to the prior approach. Also
the former models allow for a wider range of software platforms unlike the meta-analysis
approach, which is commonly done in specialty software used for GWAS types of analyses.
2.4.3 Polygenic Risk Score
Common chronic diseases such as dyslipidemia do not associate with a small number of
genetic variants. Instead, the most likely scenario is a large number of variants, in excess of
150 at this point (Willer et al. 2013), associated with the disease outcome. Incorporating
all of those variants at once is useful, and PRSs are useful in accomplishing that goal. A
polygenic risk score involves a linear combination of number of risk alleles or genetic markers
(Chatterjee, Shi, and García-Closas 2016). We will use an unweighted version, which sums
all trait-increasing alleles across an array of SNPs.
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2.4.3.1 Advantages
Capturing the nature of common diseases, polygenic scores are a simple and useful way
to characterize the underlying genetic risk from many SNPs contributing small yet meaningful
effects upon aggregation. Calculation of PRSs is straightforward and commonly used in
research to encapsulate a broad array of genetic effects.
2.4.3.2 Disadvantages
Although PRSs can provide information from many different loci at once, lack of
generalizability across different ancestral populations has been noted as a major limitation.
Different ancestral populations present with different allele frequencies, haplotypic structures
and perhaps different causal variants. Often weights used in weighted PRSs are derived from
European populations. Transferability of these weights to other populations such as the HL
sample used in this project will not work.
One reason PRSs fail to generalize is the different haplotypic structure causing a
marker allele that may be strongly associated with a trait such as dyslipidemia in European
populations, the default population in which studies are commonly done (Bustamante,
Burchard, and De la Vega 2011), and not associated at all in another population such as
the HL population. This lack of signal concordance can be due to linkage disequilibrium
differences between the populations causing the marker to be more associated in the European
groups compared to others, noted frequently as being the case (Carlson et al. 2013). The
other reason a PRS may fail to generalize is the causal variant in one population is different
than one in the other (Below and Parra 2016). As mentioned in the polygenic risk section
above, applying summary statistics from one population, like those of European descent,
to another population, such as a HL population, renders inaccurate PRSs precisely due to
genetic architecture differences across populations (Martin et al. 2017).
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To counter the transferability problems mentioned above both individual variant and
PRS analyses will be selected from fine mapping projects including samples from samples of
HL populations (Graff M, personal communication) (Ko et al. 2014; Weissglas-Volkov et al.
2013; Below et al. 2016; Elbers et al. 2012; Zubair et al. 2016; Graff et al. 2017) (Appendix
D). The most recent of these studies (Zubair et al. 2016) was a fine mapping genetic study of
variants found on the MEGA array in HL, African and Asian populations, which includes
41 additional variants listed in (Appendix D). Combined, these results variants found in
samples from HL populations and will be considered for analyses in both the PRS and single
variant analyses. Power calculations in the statistical analysis section below will be used to
determine which of the single variants allow enough a priori power to detect an association
in the SLS sample of approximately 500 genotyped individuals.
2.5 Summary
After considering several background areas supporting the aims in this dissertation –
lipid levels in adolescence, evidence for an association between infant growth and dyslipidemia
later in life, and potential analytic issues that may block understanding of the relationship
– a picture emerges of the potential to measure the influence of an early life event on a
well-established risk factor for ASCVD. Dyslipidemia is widely prevalent in children; nearly 1
in 5 children in the United States have dyslipidemia, and this estimate may be even greater
in the SLS sample. Besides the high prevalence, the great potential for dyslipidemia status
to follow a child as they age into adulthood creates a strong reason to address childhood
dyslipidemia. Both animal models and observational evidence from human studies indicate
an association does exist between early life growth and dyslipidemia later in life. Lastly, the
analytic approaches outlined to identify both growth patterns and GXE interactions provide
an avenue to adequately test the third aim in this dissertation.
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These hypotheses specify an association between particular postnatal growth patterns
and dyslipidemia and that these growth patterns may also function as an effect modifier of
the already clearly identified genetic role in dyslipidemia. Evidence from these hypotheses
may inform the mechanism by which these effects are occurring and subsequently inform
future interventions, including altering unfavorable child growth patterns linked with chronic
disease risk factors such as dyslipidemia.
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CHAPTER 3: RESEARCH PLAN
3.1 Outcome Assessment
3.1.1 Anthropometric Measures
Lipid measures have been assessed in the SLS from stored blood samples using Enzymatic
Colorimetric methods. When the participants were 17 years of age, they had their blood
drawn (venipuncture) the morning following an overnight fasting period. Second, infant
anthropometric measures are the main outcome in analyses for aim 1. During the study
recruiting periods from 1991 to 1996, study nurses for the SLS weighed the participating
infant once at monthly clinic visits throughout the first year on electronic scales to the nearest
0.01 kg. Length was measured on a recumbent board to the nearest 0.1 cm. The primary
measure for postnatal growth trajectories will be weight-for-length (weight (g) divided by
length (cm)) because this better represents adiposity than weight alone (Oostvogels et al.
2014; Benn 1971; Taveras et al. 2009). Also, weight and length as separate outcome measures
will be included in separate models as these are frequently included in many studies of infant
growth to date and will facilitate comparisons with prior studies.
3.1.2 Exposure Assessment
Analysis of genetic information will be based on a small number of candidate genes
drawn after careful consideration of replicated associations in very large samples, including
those from the Global Lipids Genetics Consortium with a sample size exceeding 180,000
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individuals (“Global Lipids Genetics Consortium (GLGC). Kathiresan Lab” 2014, Willer et
al. (2013)). This targeted, a priori planned research study of underlying genetic variation in
adverse lipid levels will conserve power in testing (Wright and Christiani 2010) and follows
suggested protocol for gene-environment interaction analyses (Dick et al. 2015) – issues that
figure prominently in analyses involving genetic variation.
Blood samples from participants currently participating in the 21-year follow-up time
have been microarray genotyped for all the candidate genes associated with lipid levels
using the Illumina MEGA array, an enhanced genotyping array optimized for multi-ethnic
populations. With funds from UNC and AHA (15GRNT25880008; PI North), genotyping
using DNA from SLS blood samples is complete for the 679 adults. MEGA was designed
with a 1.25M genome-wide association (GWA) scaffold optimized for imputation accuracy in
African-American, HL, Amerindian, Asian, and European populations. MEGA incorporates
400K low frequency and rare disruptive and non-synonymous variants, derived from a pan-
ethnic panel of 40K whole-exome sequenced individuals. This includes >100K rare disruptive
variants on American Indian backgrounds and a heavily curated catalog of over 40K variants
from clinical and biomedical databases, which is by far the largest set of functional variants
currently available on a commercial chip. With this array we will subset the genotypes with
SNPs that have been replicated in prior studies and present in the general population at a
frequency common enough to detect in our sample.
3.2 Data Source: Santiago Longitudinal Cohort Study (SLCS)
This study of the association between infant growth trajectories and adverse lipid levels
at 17 years of age builds on an ongoing cohort that started with 1,657 infant participants
from Chile (Lozoff et al. 2003) (Fig. 3.1). Participants were recruited during infancy and
have been followed through childhood and adolescence into early adulthood (Lozoff and
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Gahagan, Multiple PI, R01 HD033487; Gahagan, PI, R01 HL088530). Santiago, Chile is the
geographic region of origin for SLS participants. The population of Chile exceeds 14 million
residents and as a country has undergone a “nutrition transition” in which malnutrition
declined during the 1980s and levels of obesity rose (Albala et al. 2002). Obesity levels in
pregnant women rose from 12.9% to 32.7% from 1987 to 2000 (Albala et al. 2001). Chile
has had a universal public health network in place since the 1950s and the infant mortality
rate is comparable to the U.S. (7 and 6 deaths per 1,000 live births in 2010-2014 (“Mortality
Rate, Infant (Per 1,000 Live Births) Data Table” 2014), respectively). By 1998, 87 percent of
infants were still breastfeed at six months of age (Jimenez and Romero 2007).
Figure 3.1: Flow chart of sample size for Santiago Longitudinal Cohort Study.
Originally established as part of a randomized iron deficiency preventive trial (Lozoff et
al. 2003; Lozoff 2012), SLS is still active. The study team in Chile maintains frequent contact
with the study participants and has an established protocol to track participants including
annual postal contact. Recruitment occurred from 1991 to 1996 in low- to middle- income
groups. Full-term infants with birth weight ≥ 3 kg with no iron-deficiency anemia or other
major health problems were eligible to participate. There was a total of 1,657 infants who
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completed the study at 12 months of age by 1996. Following the infant study, 679 children
(Fig. 3.1) from this cohort are participating in additional extensive cardiovascular testing at
17 and 21 years of age. This combination of factors allows for a detailed characterization of
infant weight trajectories paired with high quality cardiovascular measures in adolescence.
As the source study originated to determine effects of iron sufficiency, the treatment
in the randomized trials is one cause of concern as a confounding factor when developing
a causal framework linking infant growth and dyslipidemia in adolescence. First, we will
exclude infants diagnosed with iron deficiency anemia who were part of the neuromaturation
study (n=153). Second, if iron status is identified as being associated with infant growth
in this sample then it could operate as a confounder that should be controlled. Although
iron supplementation has been identified as being associated with growth in certain samples
of children, no association exists in the SLS sample (Gahagan et al. 2009). Furthermore, a
later study of the SLS sample examining infant growth trajectories initially included iron
supplementation status and iron deficiency anemia status as covariates but then dropped
these variables from the analysis because they were not significant in the model (Kang Sim
et al. 2012). Considering the absence of an association between iron supplementation or iron
deficiency and infant growth, this factor is not likely to be a confounder, but randomization
status will be added as a confounder in analyses.
After the first year of life, there were no noted differences between study completers
and non-completers with respect to sex, growth, household size, parental education or group
assignment (Lozoff et al. 2003). At five years of age, results from an internal attrition
analysis of the SLS revealed no statistically significant differences for many socio-demographic
characteristics including gestational age, birth weight, parental education, and maternal age
for participants compared to the non-participants. Non-participating children had significantly
lower SES (0.20 SD, p<0.01). We looked at these same characteristics in the sample that
remained at 17 years, and did not find any significant differences between completers and
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non-completers (data not shown). In sum, this extensive collection of information over a time
spanning the childhood years in this sample is unique, and these data provide a foundation
for testing hypotheses relating infant growth to adverse lipid levels at an average of 17 years
of age.
3.3 Statistical Analyses
The three specific aims of this research project are to 1) characterize sociodemographic
predictors of postnatal growth curves, 2) determine the association between infant growth
trajectories and adverse lipid levels, and lastly, 3) assess the influence of certain growth curve
characteristics on the relationship between genetic variants and adverse lipid levels at 17
years of age.
Prior to analyses listed below for Aims 1 to 3, descriptive statistics for all proposed
confounders, exposure, and outcome variables will be conducted including tables listing
distributional characteristics such as median, mean, standard deviation, interquartile range by
sex of child. In addition to descriptive tables visual interpretation of distributional summaries
such as violin plots of continuous outcomes by gender of child will occur. Any outliers – as
already mentioned for lipid values – will be examined for biological plausibility and if none
exists then there will be a discussion regarding their removal from the analyses. If biologically
plausible then these values will remain in the data set and perhaps subject to transformation.
One example of this phenomenon is TG, which typically do not follow a normal distribution
in samples and are subject to transformation.
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3.3.1 Aim 1.1 – Characterize growth trajectories with SITAR method
To determine characteristics of size, tempo, and velocity of infant growth trajectories
(Fig. 3.2) we will use the approach as outlined by Cole and colleagues (Cole, Donaldson, and
Ben-Shlomo 2010; Warrington et al. 2013). This method uses a shape invariant model (SIM)
for growth originally proposed by Beath (Beath 2007) and extracts three random effects from
this model to characterize the growth curve for each individual. A sample model for a WFL
outcome is:
yit = αi + h
(
t− βi
exp(−γi)
)
(3.1)
where yit is the observed outcome (weight-for-length) for the ith person at the tth time point.
h(t) is a natural cubic spline function of the outcome versus age, t, in this case. The three
random effects in this model, αi, βi, γi, are the random intercept for the outcome, the random
intercept for age, and a random scaling factor for age, respectively. As random effects,
these three variables by definition will have a mean of zero and represent deviations about a
population mean (Fig. 3.2). For example, a positive value for αi represents a shift of the
growth curve upwards. A positive value for βi represents a shift of the growth curve to the
right and a growth curve starting later than the average. Lastly, a positive value for γi leads
to shortening of the age scale and a steeper growth curve and change in outcome over a
one-unit change in time.
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Figure 3.2: Type of change in random effects (α, β, γ) relative to the sample mean trajectory
in weight growth curve trajectories following a shape invariant model (SIM).
The second part of aim 1 is the identification of predictors of growth curves. Each of
the three components of the growth curve will be regressed separately onto the selected
predictors, which include maternal age, maternal education, and socioeconomic position. For
example, to obtain the relationship between maternal pre-pregnancy BMI, xi, and infant
velocity, γi , a simple linear regression model (Pizzi et al. 2014) would be γi = α + β1xi + i.
We used simulations to calculate 90% power to detect a coefficient of 0.1 (sd=0.03) for a one
unit change in maternal age assuming a mean (sd) maternal age of 27 (7) years – estimates
derived from a similar study (Pizzi et al. 2014) .
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3.3.2 Aim 1.2 – Characterize growth trajectories with latent class growth mix-
ture method
Another part of the first aim includes identification of latent growth trajectory patterns.
At its simplest level, data in a latent class growth mixture model (LGMM) approach include
a longitudinal series of measurements for an individual. An example of a series is monthly
weight-for-length values in the first year of life. With these weight-for-length values, a latent
class growth trajectory model (Muthén et al. 2002; Wang and Bodner 2007; Bauer and Reyes
2010) would estimate a discrete number of groups of infant growth trajectories in which the
group members would have as similar growth characteristics as other members in their group
but as different as possible from members in other groups. This approach has been applied
to child growth curves, but relating the latent classes from growth curves to lipid levels as a
distal outcome (response value) remains unexplored (Li et al. 2007).
The LGMM for infant growth adapted from an approach previously done in an asthma
research study (Rzehak et al. 2013) is as follows:
yi = η0i + η1iaget + η2iage2t + η3age3t (3.2)
where yit is the observed weight-for-length for person at time = 0, 1, 2, 3, 4, 5, and 6 months.
Class membership is estimated from the characteristics of the growth model as specified
above using an expectation-maximization (EM) algorithm (Muthén et al. 2002). The last
component in this analysis, also the analysis for the second aim below, involves characterizing
the association between latent groups of infant growth and lipid levels at age 17 years as a
distal outcome (Fig. 3.3). This specified model uses “full-information maximum likelihood”
(FIML) (Collins, Schafer, and Kam 2001) in Mplus (Muthen and Muthen 1998; Jung and
Wickrama 2008) to handle missing data, which is valid in cases of missing at random (MAR)
data – an assumption we make with these data.
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Figure 3.3: Diagram of latent growth mixture model (LGMM) of infant growth. Circles
represent latent variables, rectangles represent observed variables. Note: WFL is weight-for-
length.
3.3.3 Aim 2 – Determine association between growth trajectories and adverse
lipid levels.
3.3.3.1 SITAR
In a second stage of regression models, we use the random effects generated from the
SITAR method mentioned above. In our case, this second stage would be one in which a
lipid level, as a continuous variable, is regressed onto each of the three random effects from
the growth curve in separate models. Some examples of this approach (Jones-Smith et al.
2013; Johnson et al. 2014) include using growth parameters as predictors of obesity later in
life (Jones-Smith et al. 2013) and predicting aspects of growth using infant feeding practices
as a predictor (Johnson et al. 2014). The simple linear regression model we would use for
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this aim would be considered in equation 3.3:
Yi = g0 + g1αi + i (3.3)
in which the ith person has an observed lipid outcome of yi. In this model, g0 is the intercept,
g1 is the coefficient for the growth parameter indicating a change in a numeric lipid outcome
for a one-unit change in the respective growth parameter, and i is the term for random error
for the ith person.
Monte Carlo simulations with 1,000 replications in R software were used to estimate
power for aim 2 (R Core Team 2015), scripts available in online repository available upon
request. The SITAR model in the simulation is the same model as specified above in equation
3.1. The SITAR data were randomly simulated using α ∼ N(2, 0.5), β ∼ N(0, 0.5) and
γ ∼ N(0, 0.5). Size, tempo and velocity person-level random effects were then pulled from the
randomly generated data and used as covariates in a model with lipid levels as the outcome as
specified in equation 3.3. Power was determined as the probability to detect a true effect from
the 1,000 replications. Power to detect a change in a lipid level, in mg/dL, was determined
using a sample size of 500, an α = 0.05, mean lipid level of 40, and sd=0.25 for the parameter
estimates. Power exceeds 94%, 86% and 27% to detect a change in lipid levels for a one-unit
change in the size, tempo, and velocity random effects, respectively.
3.3.4 Aim 3 – Determine change in association between SNPs and adverse lipid
levels across characteristics of infant growth
To assess the presence of a GXE interaction effect we will first evaluate the association
between genetic variants and lipid levels at 17 years of age (Ritchie 2015) in model 3.4:
Y = Z0β0 + x1a1 +  (3.4)
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For model 2, Y is the vector of observed lipid levels; Z0 is the vector of the intercept and
relevant covariates outside of genetic factors that could be confounders, such as ancestry, age
and sex of participant; a1 is the coefficient for the additive effects of the ith SNP (Cordell
2002); Gi noted below represents the number of reference alleles and ranges from 0 to a total
of 2 at the bi-allelic SNP. The additive effect is one in which each additional allele present
in the genotype results in one additional unit in the covariate. To evaluate the interaction
between the growth terms and the selected genetic variants we would expand upon the main
effects model (Equation 3.4), and include interaction terms between the growth parameters
as determined and analyzed from aims 1 and 2 in equation 2.1. This model will follow the
format in the section reviewing specification of interaction with a trichotomous genotype,
equation 2.1.
Lastly, we will combine all identified genetic variants from Appendix D into a PRS by
summing the number of unweighted risk alleles (Krarup et al. 2015; Rader 2015, Isaacs et al.
(2013)) and use this as a covariate in a linear regression analysis with main effects,
Yi = µ+ c1 ·GRS + g1 · γ + i (3.5)
and interaction terms
Yi = µ+ c1 ·GRS + g1 · γ + iGRS×g1 ·GRS · g1 + i (3.6)
to test an interaction between the risk score, GRS, and the growth exposures, γ, via F-tests.
Aim 3 posits growth trajectory characteristics modify the association between certain
SNPs and lipid levels. To estimate power, we considered interaction effects as mentioned in
equation 2.1 above to measure the association between nonlinear growth trajectory random
effects and a continuous lipid outcome. One important piece of information that can affect
power is the minor allele frequency of the SNPs of interest. To compute power, we selected a
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minor allele frequency of 0.19 – the lowest frequency of the suggested candidate SNPs – to
determine the most conservative estimates with genotype frequencies assumed to follow Hardy-
Weinberg equilibrium (0.04/0.31/0.65). Other fixed parameters included in power simulations
included a sample size of 500 people (allowing for around 25% dropout or missing data),
an average outcome of 40 mg/dL (standard deviation=10), an additive genetic coefficient
(a1) of 1, and interaction effects (ias, iat, iav) of 0.25. The R scripts for power available in
github repository upon request. In general, estimates for power given these assumptions as
applied to simulations of equation 2.1 indicate power exceeding 0.80 for all estimates with
the exception of velocity effects.
3.3.4.1 Individual variants – main effects
The genetic variants determined to have a strong likelihood of association with lipids
in source HL populations (Appendix D) cannot all be used for single variant association
tests, as specified in equation 2.1. A prominent factor limiting the selection of variants is
power to detect an effect with a sample size of 500. We determined which variants would
have an a priori power of 0.80 (appendix F) given a) the minor allele frequency from the
source population (Ad Mixed American), b) a sample size of 500 (approximately equal to
the genotyped sample), and c) the effect size of the single variant tests as determined from
the source (Appendix D). Based on these parameters we determined a list of variants (MS3:
Table 2), which were appropriate for single variant testing. More details regarding the power
calculations can be found in appendix F.
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CHAPTER 4: MANUSCRIPT 1 — SOCIODEMOGRAPHIC
PREDICTORS OF EARLY POSTNATAL GROWTH
4.1 Overview
Background
Infant growth varies across socioeconomic factors including maternal education and
income, serving as an indicator of environmental influence in early life with long term health
consequences. Previous research has identified sociodemographic gradients in growth with a
focus on the first year and beyond, but estimates are sparse for growth before 6 months.
Methods
Participants (n=1,412) were from a randomized iron deficiency anemia prevention trial
in healthy infants from low- to middle-income neighborhoods in Santiago, Chile (1991-1996).
Anthropometric measures included monthly weight (kg), length (cm) and weight-for-length
(WFL) values from 0 to 5 months. For each measure, we estimated 3 individual-level growth
parameters (size, timing and velocity) as outcomes from SuperImposition by Translation and
Rotation (SITAR) models. Subsequently, we used lasso regression with post-selection inference
methods to estimate the linear association between each of the growth parameter outcomes
and covariates including gestational age, maternal age, education, and socioeconomic position
(SEP). We used a false discovery rate=0.05 to correct for multiple comparisons.
Results
Lower SEP was associated with lower length velocity growth parameters in the pooled
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sample (-0.22, 95% CI=-0.13,-0.31) – outcome units are percent increase in velocity above the
average growth curve. Lower SEP was also associated with slower growth timing for females
(0.25, 95% CI=0.05,0.42) – outcome units are shifts in days from the average growth curve.
Conclusion
Previous research on growth in older infants and children shows positive associations be-
tween income and/or maternal education with length velocity. We found evidence supporting
an this direction of association at an earlier age, which may inform age-specific prevention
efforts aimed at infant growth.
4.2 Introduction
Focus on early life infant growth has grown as evidence accumulates of an association
between this putative exposure and the development of adult disease, sometimes decades later.
Some chronic disease outcomes associated with infant growth characteristics include obesity,
insulin resistance, nonalcoholic fatty liver disease, endothelial dysfunction, and metabolic
syndrome (Gillman 2008; Baird et al. 2005; Larnkjaer et al. 2010; Breij, Kerkhof, and Hokken-
Koelega 2014; Leunissen 2009; Touwslager et al. 2015). Explanations for these associations
include early infancy as a critical window of time for susceptibility to environmental exposures
for chronic disease risk factors (Plagemann et al. 2012; Johnson, Kuh, and Hardy 2015).
The role of infant growth as an exposure affecting health in the life course (Power, Kuh,
and Morton 2013) motivates identification of infant growth predictors that may lead to further
research on modifiable factors and interventions. Growth for a variety of anthropometric
measures can be a marker for both genetic and environmental factors (Gillman et al. 2013;
Dubois et al. 2012), and it can serve as an indicator of poor environment in early life.
Socioeconomic position (SEP) is one example of an environmental factor in which different
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levels appear to be associated with particular growth patterns. In particular, socioeconomic
differentials exist in child growth for length (McCrory et al. 2017; Murasko 2014; Howe et
al. 2012; Patel et al. 2014; Queiroz et al. 2012; Matijasevich et al. 2012; Herngreen et al.
1994; Silva et al. 2012) and weight (Pizzi et al. 2014; Hui et al. 2010; Fuemmeler et al. 2016;
Wijlaars et al. 2011) – the direction of association depending on the type of growth measure.
Generally, for weight, lower SEP is associated with faster growth and the inverse holds true
for length during childhood. Furthermore, there is evidence that socioeconomic gradients in
growth emerge in early life (Howe et al. 2012) and persist (McCrory et al. 2017).
A reasonable assumption would be that these associations between SEP and growth
hold at earlier ages, but evidence is scarce to confirm this association. In fact, among the
few studies looking at an association between infant length (linear) growth and SEP, two
studies reported a positive association at 0-3 months (Patel et al. 2014; Matijasevich et al.
2012); another study reported an inverse association between these two factors during the
same age range (Silva et al. 2012); and one more reports no association (Howe et al. 2012).
This inconclusive evidence supports further investigation to better clarify these associations.
Of studies examining sociodemographic predictors of growth during infancy and child-
hood, evidence gaps remain, which include an absence of detailed characterization in the
earliest period of infant growth. Usually there are few observations in studies before six
months leading to linear specifications between the weight or height and time instead of
curvilinear models of growth, which offer a better fit. Growth during the first six months in
the human lifespan is characterized by accelerated growth at the outset and leveling off of
at six months (Falkner and Tanner 1978; Lejarraga 2012; Hauspie, Cameron, and Molinari
2004). Given these unique features, early infant growth may yield unique associations with
predictors than for later periods. Few studies restricted the time span to early infancy –
before six months of age. Identifying similar associations between sociodemographic factors
and growth in this earlier time period can shift the focus for potential effects and interventions
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even earlier.
In addition to the search for similarities with studies spanning times after early infancy,
the identification of novel associations in this age range can better pinpoint the timing and
influence of sociodemographic factors. Given the sparsity of information in the literature
focusing on this time period, our aim in this paper is to examine sociodemographic predictors
of infant weight, length and weight-for-length (WFL) growth from zero to five months in an
infancy cohort from Chile. We expect that SEP will be inversely associated with weight gain
and positively associated with length growth.
4.3 Methods
4.3.1 Study sample
The data in this study are drawn from the Santiago Longitudinal Study (SLS), a
longitudinal cohort study from Santiago, Chile. Infants were recruited, from 1991 – 1996,
for an infancy iron deficiency anemia preventive trial or neuromaturation study for those
with anemia and the next nonanemic control (Lozoff et al. 2003; Lozoff 2012; Gahagan et
al. 2009). We characterized the growth period prior to treatment randomization, which
occurred at six months, partly to reduce confounding from randomization status and to
include as early a time period as possible with as many repeated observations as possible
to adequately characterize the nonlinear growth curve. Inclusion criteria for the preventive
trial included full-term infants with birthweight ≥ 3.0 kg, vaginal birth, no major health
problems for the infant, and no iron deficiency anemia present at 5 to 6 months. The sample
size in infancy included 1,645 infants who completed the preventive trial and 153 in the
neuromaturation study. The participants included in this analysis numbered 1,412 individuals
with anthropometric measures for at least two time points.
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4.3.2 Outcome and sociodemographic measures
Three anthropometric measurements including weight (kg), length (cm), and weight-
for-length (WFL) (g/cm) were assessed. Weight was measured to the nearest 0.01 kg on an
electronic scale at local public health clinics. Length was measured on a recumbent board to
the nearest 0.1 cm. Gestational age (GA) was among the set of variables included in models
as a covariate.
Sociodemographic measures were self-reported by the mother, and they include: maternal
age (years), total years of education, and the modified Graffar index (Graffar 1956), an index
of socioeconomic position (SEP) within lower-income countries (Alvarez, Muzzo, and Ivanović
1985). The modified Graffar index represents a sum of 10 measures including education,
expenditures, and housing characteristics, which are summed to create a scale with higher
values indicating lower social class (Appendix Table A1).
4.3.3 Statistical analyses
Summary statistics included median and interquartile range for continuous variables and
percents with counts for categorical variables. All summary statistics were stratified by sex
of child.
The outcomes, infant weight, length and weight-for-length (WFL) growth from birth
to five months were assessed using the SITAR approach (Cole, Donaldson, and Ben-Shlomo
2010). In this approach, a nonlinear mixed effects model was fit (Beath 2007) using the R
nlme package (Pinheiro et al. 2017). The nonlinear mixed model can produce up to three
different measures of growth for each individual, which have been named “size”, “tempo” and
“velocity” (Cole, Donaldson, and Ben-Shlomo 2010). The “size” SITAR growth parameter
indicates a shift of the growth curve up and down for an individual relative to the average
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growth curve. The “tempo” SITAR growth parameter indicates a shift of the growth curve
to the left and right on the age scale for an individual relative to the average growth curve.
Lastly, the “velocity” SITAR growth parameter indicates a transformation of the age scale in
the nonlinear model, shrinking or enlarging the age scale for an individual relative to the
average growth curve. These three parameters are noted as having biologically meaningful
interpretations, which are difficult to obtain with complex growth models (Beath 2007) and
are a primary reason for our use of this method. Unless otherwise noted, any references to
“size”, “tempo”, and “velocity” herein refer to these parameters from the SITAR construct
applied to early infant growth.
Prior to any subsequent model fitting with the predictors we assessed best model fit for
each of the anthropometric measures via the lowest Bayesian Information Criterion (BIC)
for growth independently of any covariates. After evaluating all possible combinations of
SITAR models from one to three parameters for each of the three anthropometric measures,
best fit (Appendix Table B1) entailed: 1) all three growth parameters for weight (BIC=-
22941), 2) sex-specific growth trajectories with tempo and velocity parameters for length
(BIC=-38001), and 3) sex-specific growth trajectories with size and tempo parameters for
WFL (BIC=-22809).
After selecting relevant growth parameters for each of the three anthropometric measures,
we used the relevant growth parameters as outcome measures in separate linear regression
models. A sample interpretation of the model with the weight size growth parameter is
percentage change in log(kg) for a one unit change in the predictor (Cole and Altman 2017;
Cole 2000). Similarly, a one unit change in the predictor corresponds to a shift in the time
scale in days for the tempo growth parameter and percentage change in the velocity growth
parameter.
To examine the association between predictors and infant growth parameters, we ran
simple linear regression models. In the first set of models, we ran each of the variables
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separately. The second set, identified as the “adjusted model”, started with all four covariates:
gestational age, maternal age, maternal total years of education, Graffar index (Graffar 1956).
We removed covariates from the model based on a least absolute shrinkage and selection
operator (lasso) approach (Tibshirani 2011; Walter and Tiemeier 2009; Walter and Tiemeier
2009; Franklin et al. 2015; Pavlou et al. 2016). This approach has been shown to have
better performance than conventional model selection methods with a univariate approach
(Greenland 2007) such as stepwise methods (Harrell 2015; Ratner 2010). The lasso approach is
helpful in selecting out predictors with the strongest effects (Hastie, Tibshirani, and Friedman
2017) while balancing bias and variation in the model. We used the glmnet (Friedman,
Hastie, and Tibshirani 2010) package in R to estimate shrunken parameter estimates, and
the selectiveInference package (Tibshirani et al. 2017) to provide inference via statistical
tests and confidence intervals. Each set of comparisons by outcome, i.e. weight, length or
weight-for-length were considered separately when controlling multiple comparisons with a
Bonferroni correction at an alpha level of 0.05.
We used a complete case data set, i.e. all participants with non-missing covariates, as
the number of missing was less than one percent for all variables with the exception of the
Graffar index with less than three percent missing. In the sample, the median number of
non-missing outcome (anthropometric) values was six out of six monthly measures (birth to
five months). The percent of missing outcome values at each time point ranged from 9% at
months 1 and 2 to 0.2% at birth.
4.4 Results
Slightly more males (53%) than females (47%) were recruited for this study (n=1,412)
related to the requirement that birthweights were 3 kg or greater. Median gestational age (Q1,
Q3) was 40 weeks (39, 40) as preterm infants were excluded. Mothers were a median (Q1, Q3)
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of 26 (22, 31) years of age and had a median (Q1, Q3) of 10 (8,12) years of education at the
time of their infant’s birth (Table 1). For the six monthly anthropometric measurements, no
time point had more than 12% missing observations: each infant had at least two observations,
and 72% of the participants had measures at all six time points.
The following three sections address results from the growth trajectory analyses for the
three separate anthropometric outcomes: weight (kg), length (cm) and weight-for-length
(WFL) (g/cm). All results below correspond to those found statistically significant after
adjustment for multiple comparisons unless otherwise indicated.
4.4.1 Weight trajectories: size, tempo and velocity
Sex-stratified analyses were used for all three anthropometric outcomes as estimated
associations between the SITAR growth parameters and SEP indicators differed by sex of
child.
All three SITAR parameters, i.e. “size, ‘tempo” and “velocity”, best satisfy model fit
diagnostic tests for weight trajectories (Appendix Table B1). Maternal age was positively
associated with the weight size parameter for females (0.21, 95% CI = 0.07, 0.34) in the
unadjusted model (Table 2) indicating 0.21% increase in log(weight (kg)) from the average
growth curve for each year increase in maternal age. Also, maternal age was inversely
associated with weight velocity parameter in the female subgroup (-0.41, 95% CI = -0.71,
-0.12) in the unadjusted model indicating higher maternal age is associated with slower
weight growth. Gestational age in the pooled sample was significantly associated with the
weight tempo parameter (-2.01, 95% CI = -2.98, -1.70) in the adjusted model, indicating a
leftward shift of about 2 days for an additional week in gestational age. This indicates earlier
timing of weight gain in infants who achieved longer gestational age (Table 2). There was no
substantive difference in this association in the sex-stratified analyses.
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4.4.2 Length trajectories: tempo and velocity
For length (linear) growth, the “tempo” and “velocity” SITAR growth parameters best
satisfy model fit diagnostic tests (Appendix Table B1). In the pooled group, the coefficient
of association between the Graffar index and the velocity parameter (-0.22, 95% CI = -0.13,
-0.31) (Table 3) indicated that for each unit increase in the Graffar index, there was a -0.22%
decrease from the average length velocity, showing a positive relationship between the length
velocity parameter and SEP. This positive association was not substantively different in
the sex-stratified analyses, all indicating faster linear (length) growth with higher SEP. In
contrast to the female and male samples, all covariates remain in the pooled adjusted model
with less than 6% decline from the unadjusted SEP coefficient (-0.23, 95% CI = -0.31, -0.15).
Gestational age was inversely associated with the length tempo parameter in the pooled
sample (-2.94, 95% CI = -3.51, -2.41), indicating a leftward shift of about 3 days of the
trajectory on the time scale, and a faster start to length growth, for each one week increase in
gestational age (Table 3). Gestational age was associated with the length velocity parameter
for the pooled sample (0.61, 95% CI =0.06, 1.15).
4.4.3 Weight-for-length trajectories: size and tempo
For WFL growth, inclusion of the “size” and “tempo” SITAR parameters best satisfy
model fit diagnostic tests (Appendix Table B1). Lower SEP was positively associated with the
WFL tempo parameter for the female subgroup (0.25, 95% CI = 0.05, 0.42) in the adjusted
model. This estimate approximates a rightward shift in time (days) relative to the average
growth curve indicating later growth timing with lower SEP.
Similar to weight and length trajectories, GA was inversely associated with the WFL
tempo parameter in the pooled sample (-1.99, 95% CI = -2.83, -1.49) (Table 4) indicating
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a two day shift to the left on the time scale from the average growth curve for every one
week increase in gestational age. Similar values were found in the sex-stratified analyses, all
indicating earlier timing of WFL growth with higher gestational age.
4.5 Discussion
In this research, we found associations between SEP, measured by the Graffar index,
and length growth characteristics. Lower SEP was associated with slower length growth
and a later timing of WFL growth as reflected by the inverse association with the length
velocity parameter in the pooled sample and lower SEP and the positive association with the
WFL tempo parameter in the female subgroup. Higher tempo values translate to a rightward
shift in growth relative to the average growth curve as well as a later age at peak velocity
(Cole et al. 2016). In our analyses we leveraged monthly measures of weight (kg), length
(cm), and WFL (g/cm) from birth to the five months combined with nonlinear mixed effects
growth model approaches to obtain more detailed characteristics of growth patterns and their
associations with sociodemographic characteristics, which include maternal age, maternal
education, and a socio-economic index. This comprehensive analysis was accompanied by a
thorough evaluation of model fit for each outcome and elimination of covariates via shrinkage
procedures to optimize mean squared error of the models.
Of three studies investigating associations between sociodemographic predictors and
infant growth before six months, two found a positive association between length growth
and maternal education (Patel et al. 2014; Matijasevich et al. 2012), used as a proxy for
SEP. Only one study found an inverse association with length growth (Silva et al. 2012).
For the studies including age ranges exceeding six months of age up to five years of age, all
demonstrated a positive association between maternal education and length growth (Patel et
al. 2014; Howe et al. 2012; Silva et al. 2012; Matijasevich et al. 2012). The majority of these
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studies support the unfavorable association between lower SEP and slower length (linear)
growth.
Prior studies representing European high-income countries have noted that their findings
of either an inverse (Silva et al. 2012) or no relationship (Howe et al. 2012) between SEP
and length (linear) growth may not generalize to low to middle-income countries. Nutritional
deviations from the Western diet and lifestyle were one of the reasons given for lack of
generalization across studies. Chile, the region from which the data were collected, offers an
interesting context for an assessment of generalization because it was transitioning from a
low- to high-income country during the recruitment period for this study. By 1990 40% of
the population in Chile was below the poverty line (Jimenez and Romero 2007) and by 2012
Chile was classified by WHO as an upper middle-income country (Gitlin and Fuentes 2012).
Accompanying this rising income at the country-level, there were nutrition and epidemiologic
transitions occurring during the recruitment period (Albala et al. 2001; Albala et al. 2002).
These transitions began in the 1970s and were still occuring during the 1990s in which
consumption of high calorie food accompanied with a sedentary lifestyle resulted in rising
obesity prevalence across all socioeconomic levels. In the context of a Western diet and lifestyle
prevalent across all SEP stratum, we found a positive association between SEP and length
(linear) growth. Also, studies from low- and middle-income countries in Brazil (Matijasevich
et al. 2012) and Belarus (Patel et al. 2014) support a positive association between length
velocity and SEP. The two latter studies are associations during early infancy and the two
former studies are not, which may indicate a conflating of environment with age range.
Furthermore, all of these prior studies use maternal education, a variable that did not have a
significant association with length growth in our results, although the direction of association
was consistent with analyses examining early growth prior to 6 months (Matijasevich et al.
2012; Patel et al. 2014). Altogether, these findings underscore the multifactorial and complex
relationship between SEP and early growth making it difficult to assess generalizability.
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Maternal age is the only sociodemographic factor associated with the SITAR weight size
growth parameter. Maternal age can be a proxy for parity, a measure not available in these
data that is also positively associated with size at birth. The positive association between the
weight size growth parameter and maternal age is similar to one that appeared in a cohort
from the same geographic area of Santiago, Chile, the Growth and Obesity Cohort Study
(GOCS) study (Pizzi et al. 2014). This similarity in association across two geographically
similar cohorts from different decades supports a lack of cohort effect in this measure. Also,
although not significant after correction for multiple comparisons, the inverse association
between weight velocity and maternal age is consistent with the GOCS study results. GOCS
started 10 years later than SLS, including growth spanning 2 years from birth. Furthermore,
the time period spanned in these analyses, 0-5 months, is much earlier and much shorter
than the other study, which spans 0-2 years, indicating this association appears earlier in the
postnatal period than previously assessed.
In similar analyses with a United States sample GA is also inversely associated with
growth timing (Fuemmeler et al. 2016). Gestational age, considered a confounder, remained
in almost all of our models, and similar to the prior study was consistently associated with
earlier timing of growth across all three growth types. This association translates to an earlier
start to growth and a leftward shift of the growth curve with increasing GA. Its consistent and
strong effect sizes across all models underlines its role as a traditional confounder although
GA ranged from 37 to 42 weeks by design.
Biological mechanisms linked to plausible modifiable factors in early infancy can support
the relationship between length growth and lower SEP in first five months of age. Education
may be linked with the ability to use information to improve the health of their infant
(Matijasevich et al. 2012; Patel et al. 2014). Breastfeeding and maternal smoking are two
commonly proposed mechanisms, but there is no strong uniform evidence pointing to any
particular factor. For example, feeding practices are known to be associated with growth
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patterns in early infancy. Bottle feeding is associated with faster growth (Rzehak et al. 2017;
Goncalves et al. 2012; Karaolis-Danckert et al. 2007). However, evidence is mixed regarding
breastfeeding accounting for the link between SEP and infant growth. Some studies provide
evidence that breastfeeding accounts for the association between SEP and infant growth
(Wijlaars et al. 2011; Silva et al. 2012) and one did not (Matijasevich et al. 2012). In
this sample prevalence in breastfeeding was homogenous (Kang Sim et al. 2012; Khuc et
al. 2012) and not associated with infant weight change in the first year. We did a post-hoc
analysis examining the association between duration of breastfeeding and the continuous
SEP measure used in these analyses, i.e. the Graffar index, and we did not find a substantive
or significant association (data not shown). Maternal smoking status, either prenatal or
postnatal is another suggested mechanism on the pathway between SEP and early infant
growth. No evidence exists that this factor substantially alters the association between SEP
and growth (Svensson et al. 2014; Herngreen et al. 1994; Wijlaars et al. 2011; Silva et al.
2012).
Other potential mechanisms operating through SEP could include gestational weight
gain and maternal nutrient status. Size at birth, considered a proxy for these two factors
and represented in these analyses by the size SITAR parameter, does not display any
significant or meaningful association with any of the sociodemographic measures for any
of the anthropometric measures. These findings do not offer strong support for those
biological mechanisms, but it can be argued that size at birth is a crude proxy for these two
proposed mechanisms and better measures may confirm a role as a mediator through which
SEP gradients influence length growth. Altogether, these findings suggest weak evidence
supporting the aforementioned mechanisms as mediators. Further research will be useful in
clarifying the biological mechanisms behind the association between SEP and early infant
growth.
The lasso approach is a unique aspect of these analyses, and the resulting covariate
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removal indicates interesting patterns for the weight and length outcomes. Maternal education
was frequently dropped from the analysis, which is not surprising given the lack of variation
in the measure. When it did remain, as in the weight models, it has a similar direction of
association with velocity models as found in previous studies (Hui et al. 2010; Pizzi et al.
2014). However, as noted before, another measure of SEP was retained in all models as well
as being significant after correction. This finding continues to support evidence of SEP as an
important predictor of growth factors even in subsets of populations that are homogenous in
terms of income. Furthermore, using education as a proxy for SEP in circumstances such as
these may not be warranted.
Strengths of this study include an assessment of growth that captures the nonlinear
shape in the first five months of life. In the SITAR method the three growth measures are not
independent of each other, and each one should be evaluated in the context of the other growth
measures. For example, the height velocity measure demonstrates a positive association with
the Graffar index, a measure of SEP. For the case of length (linear) trajectories, combinations
of either tempo and velocity or size and velocity SITAR parameters have a correlation of 0.33
in the pooled sample (Appendix Table B2). When characterizing length trajectories and their
association with SEP, the tempo coefficient was positive, although not statistically significant,
indicating a rightward shift in the growth curve – slower start to growth – coupled with a
lower velocity parameter estimate. Similarly, higher length size estimates would accompany
higher length velocity. This suggests lower SEP coincides with both a slower start to growth
and slower growth. This combination of factors may signal a sub-group with a particular
growth pattern having negative health outcomes and of interest for future research. Further
examination of this subgroup as it relates to adverse health outcomes later in life is of interest
and a current area of our research.
Some limitations of this study included a smaller sample size than similar studies that
number in the thousands or tens of thousands (McCrory et al. 2017; Pizzi et al. 2014; Hui
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et al. 2010), and we may lack power to detect effects compared to these studies. Also, the
Graffar index is a measure that does not translate to other higher income groups and as a
result these associations with infant growth will not generalize to other groups. Residual
confounding is another limitation that may bias the results. Lastly, the degree to which
growth trajectory parameters changed relative to a change in the sociodemographic predictors
may not be meaningful despite findings of significance. However, not enough is known in this
area of research to make definitive conclusions regarding substantive meaning – for example,
small perturbations in early infancy growth could cause even larger health effects in late
adulthood when chronic disease is prevalent.
This investigation examined various growth characteristics from birth to 5 months and
their association with sociodemographic factors in a Chilean infancy cohort. We found a
positive association between SEP and faster length (linear) growth, which matches previous
findings that span periods of time great than the first six months. The association between
maternal age and weight size were also corroborated in prior studies with a larger time span
of growth. Overall, these results continue to support the idea that early infant growth is
not independent of sociodemographic factors even in the first five months of growth and in
population with a relatively homogenous income levels. Further research into this critical
period offering great potential for intervention is needed.
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4.6 Tables
Table 4.1: (MS1: Table 1) Descriptive statistics
Characteristic Male Female Total
n 747 665 1412
Gestational age
(weeks)
40.0 [39.0, 40.0] 40.0 [39.0, 40.0] 40.0 [39.0, 40.0]
Graffar Index 27.0 [23.0, 33.0] 27.0 [23.0, 33.0] 27.0 [23.0, 33.0]
Maternal age
(years)
26.0 [21.8, 30.9] 25.5 [21.7, 30.3] 25.8 [21.8, 30.8]
Maternal
Education (years)
10.0 [8.0, 12.0] 10.0 [8.0, 12.0] 10.0 [8.0, 12.0]
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Table 4.2: (MS1: Table 2) Sociodemographic predictors and association with weight SITAR growth parametersa,b, stratified by
sex of child in the Santiago Longitudinal Study, 1991-1996
Males Females Total
Unadjusted Adjustedc Unadjusted Adjustedc Unadjusted Adjustedc
CharacteristicSize Tempo Velocity Size Tempo Velocity Size Tempo Velocity Size Tempo Velocity Size Tempo Velocity Size Tempo Velocity
Gest age 0.59
(-0.12,
1.31)
-2.28
(-3.15,
-1.41)
-0.81
(-2.28,
0.66)
NA -1.96
(-3.15,
-1.40)
NA 0.76
(-0.02,
1.54)
-2.38
(-3.32,
-1.45)
-2.14
(-3.87,
-0.42)
0.45
(-0.32,
9.88)
-2.23
(-3.35,
-1.47)
-1.58
(-3.85,
0.08)
0.64
(0.10,
1.18)
-2.35
(-2.98,
-1.71)
-1.53
(-2.70,
-0.37)
0.53
(-0.05,
1.15)
-2.01
(-2.98,
-1.70)
-1.06
(-2.67,
0.01)
Maternal
age
0.11
(-0.00,
0.23)
-0.06
(-0.20,
0.09)
-0.07
(-0.31,
0.17)
0.07
(-0.11,
0.21)
-0.06
(-0.21,
0.26)
-0.06
(-0.33,
0.82)
0.21
(0.07,
0.34)
-0.02
(-0.18,
0.15)
-0.41
(-0.71,
-0.12)
0.19
(-6.13,
0.22)
0.01
(-2.29,
0.13)
-0.36
(-0.67,
-0.04)
0.16
(0.07,
0.25)
-0.03
(-0.14,
0.07)
-0.20
(-0.39,
-0.00)
0.15
(-0.78,
0.22)
-0.01
(-0.16,
0.83)
-0.18
(-0.56,
0.22)
Maternal
education
-0.03
(-0.32,
0.26)
0.14
(-0.21,
0.49)
-0.04
(-0.62,
0.55)
NA NA NA -0.01
(-0.31,
0.29)
0.06
(-0.30,
0.43)
-0.03
(-0.69,
0.64)
0.00
(-Inf,
-0.41)
0.12
(-0.95,
0.52)
NA -0.03
(-0.24,
0.19)
0.10
(-0.15,
0.36)
-0.04
(-0.50,
0.41)
0.00
(-10.67,
0.04)
0.04
(-1.59,
1.58)
-0.05
(-0.75,
4.42)
Graffar
Indexd
-0.12
(-0.23,
-0.01)
-0.13
(-0.27,
0.01)
-0.15
(-0.39,
0.08)
-0.08
(-0.22,
0.07)
-0.13
(-0.28,
0.03)
-0.13
(-0.41,
0.28)
-0.07
(-0.19,
0.06)
0.12
(-0.03,
0.28)
0.28
(0.00,
0.57)
-0.03
(-5.15,
0.23)
0.13
(-0.24,
0.29)
0.23
(-0.16,
0.52)
-0.09
(-0.18,
-0.00)
-0.01
(-0.11,
0.09)
0.06
(-0.12,
0.25)
-0.06
(-0.83,
0.04)
-0.00
(-0.06,
3.49)
0.02
(-1.66,
0.32)
a Size units are percentage change in log(weight) from average, tempo units are time (days), velocity units in percent change from average.
b Bold values indicate significance with Bonferroni correction at alpha level of 0.05
c Adjusted linear regression models only include non-zero coefficients from lasso regression models that include all covariates in full model.
d Higher Graffar index values indicate lower socioeconomic status.86
Table 4.3: (MS1: Table 3) Sociodemographic predictors and association with length SITAR growth parametersa,b, stratified by
sex of child in the Santiago Longitudinal Study, 1991-1996
Males Females Both
Unadjusted Adjustedc Unadjusted Adjustedc Unadjusted Adjustedc
Characteristic Tempo Velocity Tempo Velocity Tempo Velocity Tempo Velocity Tempo Velocity Tempo Velocity
Gest age -3.33
(-4.09,
-2.56)
0.99
(0.29,
1.68)
-3.05
(-4.10,
-2.55)
NA -2.57
(-3.36,
-1.79)
0.25
(-0.52,
1.02)
-2.53
(-3.33,
-1.77)
NA -2.97
(-3.52,
-2.42)
0.64
(0.12,
1.15)
-2.94
(-3.51,
-2.41)
0.61
(0.06,
1.15)
Maternal age -0.04
(-0.18,
0.09)
0.09
(-0.03,
0.20)
-0.01
(-0.10,
1.64)
NA -0.17
(-0.30,
-0.03)
0.01
(-0.13,
0.14)
-0.15
(-0.29,
0.01)
NA -0.10
(-0.19,
-0.00)
0.05
(-0.04,
0.14)
-0.07
(-0.17,
0.06)
0.02
(-0.35,
0.10)
Maternal
education
0.06
(-0.26,
0.38)
0.12
(-0.16,
0.40)
NA NA -0.18
(-0.49,
0.13)
0.28
(-0.01,
0.58)
-0.14
(-0.45,
0.52)
0.16
(-0.35,
0.52)
-0.05
(-0.28,
0.17)
0.20
(-0.00,
0.40)
-0.06
(-0.27,
0.73)
0.13
(-0.21,
0.34)
Graffar Indexd 0.06
(-0.06,
0.19)
-0.26
(-0.37,
-0.15)
0.05
(-0.25,
0.36)
-0.21
(-0.37,
-0.14)
0.16
(0.03,
0.29)
-0.19
(-0.32,
-0.07)
0.13
(-0.03,
0.26)
-0.17
(-0.31,
-0.05)
0.11
(0.02,
0.20)
-0.23
(-0.31,
-0.15)
0.09
(-0.02,
0.18)
-0.22
(-0.31,
-0.13)
a Size units are percentage change in log(length) from average, tempo units are time (days), velocity units in percent change from average.
b Bold values indicate significance with Bonferroni correction at alpha level of 0.05
c Adjusted linear regression models only include non-zero coefficients from lasso regression models that include all covariates in full model.
d Higher Graffar index values indicate lower socioeconomic status.
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Table 4.4: (MS1 Table 4) Sociodemographic predictors and association with weight-for-length (WFL) SITAR growth
parametersa,b, stratified by sex of child in the Santiago Longitudinal Study, 1991-1996
Males Females Both
Unadjusted Adjustedc Unadjusted Adjustedc Unadjusted Adjustedc
Characteristic Size Tempo Size Tempo Size Tempo Size Tempo Size Tempo Size Tempo
Gest age 0.09
(-0.55,
0.73)
-2.03
(-2.91,
-1.15)
NA -1.58
(-2.90,
-1.11)
0.05
(-0.58,
0.69)
-2.34
(-3.35,
-1.32)
NA -2.32
(-3.35,
-1.33)
0.07
(-0.38,
0.52)
-2.17
(-2.84,
-1.51)
NA -1.99
(-2.83,
-1.49)
Maternal age 0.07
(-0.03,
0.18)
-0.09
(-0.23,
0.06)
0.04
(-0.23,
0.16)
-0.08
(-0.24,
0.17)
0.02
(-0.09,
0.13)
-0.18
(-0.36,
-0.00)
NA -0.13
(-0.36,
0.14)
0.05
(-0.03,
0.12)
-0.13
(-0.24,
-0.02)
0.03
(-0.16,
0.12)
-0.11
(-0.22,
0.03)
Maternal
education
-0.09
(-0.35,
0.16)
0.08
(-0.27,
0.44)
NA NA -0.10
(-0.35,
0.14)
0.00
(-0.40,
0.40)
NA 0.07
(-2.11,
0.42)
-0.10
(-0.28,
0.08)
0.04
(-0.22,
0.31)
NA NA
Graffar Indexd -0.08
(-0.18,
0.02)
-0.07
(-0.21,
0.07)
-0.05
(-0.17,
0.15)
-0.08
(-0.24,
0.17)
0.08
(-0.02,
0.19)
0.26
(0.10,
0.43)
0.04
(-0.21,
0.18)
0.25
(0.05,
0.42)
-0.01
(-0.08,
0.07)
0.08
(-0.03,
0.19)
NA 0.06
(-0.14,
0.17)
a Size units are percentage change in log(WFL) from average, tempo units are time (days), velocity units in percent change from average.
b Bold values indicate significance with Bonferroni correction at alpha level of 0.05
c Adjusted linear regression models only include non-zero coefficients from lasso regression models that include all covariates in full model.
d Higher Graffar index values indicate lower socioeconomic status.
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CHAPTER 5: MANUSCRIPT 2 — INFANT GROWTH TRAJECTORIES
AND LIPID LEVELS IN ADOLESCENCE: EVIDENCE FROM A
CHILEAN INFANCY COHORT
5.1 Overview
Introduction
Growth in early infancy is hypothesized to affect chronic disease risk factors later in life.
To date, most reports draw on European ancestry cohorts with few repeated observations in
early infancy. We investigated the association between infant growth from birth to 5 months
and lipid levels in adolescents in a Hispanic/Latino cohort to determine if previous findings
generalize to diverse study populations and to obtain more detailed growth estimates.
Methods
We characterized infant growth with monthly measures from birth to five months in
males (n=311) and females (n=285) from the Santiago Longitudinal Study (SLS) using three
metrics: weight (kg), length (cm) and weight-for-length (g/cm). Nonlinear mixed effects
(SITAR) and latent growth mixture models (LGMM) were two approaches to estimate infant
growth characteristics. Growth was the exposure and lipid levels at 17 years were the outcome,
including HDL-C, LDL-C, TG, and a TG:HDL-C ratio.
Results
SITAR analyses demonstrated a positive relationship between the length velocity scaling
factor before six months of age and HDL-C levels in adolescence (12.1, SE=4.2) indicating
higher HDL-C levels with faster length growth. The strongest associations from the LGMM
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models were between higher LDL-C and slower WFL growth. However, no associations
from the LGMM models met the adjusted significance levels. With the exception of WFL
trajectories for males, two-class trajectory models offered the best fit. All three types of
trajectories were characterized according to their slopes: “slower” and “faster” for the two
class models and “slower”, “faster” and “fastest” for the three class models. When assessing
average lipid values across these latent class groups, most associations pointed towards the
faster growth groups having favorable lipid profiles.
Summary
This study provides evidence of associations between infant growth from birth to five
months and blood lipid profiles during adolescence. The two different analytic approaches
offered complementary findings supplying evidence towards a protective effect of faster
growing infants: adolescent HDL-C is positively associated with the length velocity SITAR
parameter; lower LDL-C demonstrates the strongest association with faster WFL growth.
In each case, slower growth is associated with adverse lipid profiles – not faster growth as
originally hypothesized. Further research with larger samples in this window of time can
better distinguish the role of growth in early versus later infancy and childhood as an exposure
affecting CVD risk in adulthood.
5.2 Introduction
Children may be free of cardiovascular disease risk factors, but they certainly are
not immune to their development and are prime candidates for a primordial prevention
framework. Cardiovascular disease prevention efforts targeting specific risk factors (Foraker,
Olivo-Marston, and Allen 2012; Pearson 2007; Grundy et al. 1998) are featured as a
cornerstone of ideal cardiovascular health as outlined in the 2020 American Heart Association
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strategic plan (Lloyd-Jones et al. 2010). Adverse lipid levels are a modifiable risk factor in a
prevention framework that can accelerate the atherosclerotic process in children (Daniels,
Pratt, and Hayman 2011). Also, this window of time deserves more research and scrutiny given
evidence that cardiovascular risk factors in children are stronger predictors of atherosclerosis
than measurements at time of examination in adulthood (Gidding 2006).
Postnatal life presents considerable potential for intervention that can impact the health
trajectory extending far past the immediate period. With this potential in the early life period,
there have been a variety of animal and human studies in the past ten years investigating the
impact of early postnatal growth on cardiovascular disease risk factors later in life. Following
a developmental origins of health and disease concept, these studies offer evidence that
abnormal growth early in development can affect cardiovascular risk factors, including lipid
levels, later in the life course.
Once a child achieves an adverse lipid level leading to a diagnosis of dyslipidemia, the
chances are high that this child will have dyslipidemia as an adult (Kallio et al. 1993;
Labarthe, Eissa, and Varas 1991; Juhola et al. 2011). Building evidence (Hartiala et al.
2012; Juonala et al. 2008b; Juonala et al. 2008a; Frontini et al. 2008; S. Li et al. 2007;
Raitakari et al. 2003; Li et al. 2003; Davis et al. 2001; Mahoney et al. 1996) established
that adverse lipid levels in childhood are associated with various measures of subclinical
atherosclerosis in adulthood such as carotid intima-media thickness and coronary artery
calcification. Furthermore, 12 to 18 years is a window of time considered having the best
sensitivity and specificity for predicting abnormal LDL-C and HDL-C levels during adulthood,
ranging from 75% to 95% and 20% to 57%, respectively (Juhola et al. 2011). Evidence
supports a strong link between adverse lipid levels during adolescence and adulthood.
In the past ten years, evidence has grown linking infant growth trajectories with cardio-
vascular risk factors, including lipid levels, later in life. There are a variety of animal models
demonstrating a link between postnatal growth prior to weaning and plasma lipid outcomes,
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including ones with slower growth. Slower growth during the postnatal period leads to altered
plasma lipid concentrations – not all with a consistent direction of association. For example,
some rodent studies link restricted postnatal growth with lower TC, TG, and/or HDL-C
in offspring towards the end of the lactation period (Lucas et al. 1996; Eleftheriades et al.
2014), and others demonstrate lower TG and higher HDL-C, LDL-C, and TC (Lee et al.
2013) than normal fed control groups.
Historically, there has been a focus on restricted postnatal growth when studying the
impact of postnatal growth on cardiometabolic outcomes. Although receiving less attention
but arguably more relevant in developed countries with Western diets, postnatal overfeeding
and the accompanying increased growth is relevant to the investigation of early life growth
influences. Importantly, postnatal growth can also play a role independent of gestational
status (Ahmed Habbout et al. 2013) that influences impaired lipid metabolism. In particular,
some postnatal overfeeding models have been generally noted in rodent models to lead to
higher TG, TC and HDL-C levels (Ahmed Habbout et al. 2013; Eleftheriades et al. 2014;
Hahn 1984). As with other animal models, these associations are not consistent (Ahmed
Habbout et al. 2013). Despite mixed evidence, studies suggest altered lipid levels following
differential growth via altered postnatal food intake in offspring.
Observational human studies also demonstrate associations between postnatal weight or
weight and length change and cholesterol levels. Findings from prospective cohort studies
mostly indicate a larger change in weight or length in the first one or two years are associated
with an adverse lipid profile, including HDL-C, LDL-C and TG levels ranging from 4 years
(Oostvogels et al. 2014; Corvalan et al. 2009) to adolescence (Howe et al. 2010; Ekelund et al.
2007). Also, for Corvalan et al. (2009), it is worth noting that this association is conditional
on exclusive or predominant breastfeeding at the 5-year end point. Tzoulaki et al. (2010) is
the exception to these studies in that peak weight velocity in the first two years is associated
with a favorable lipid profile, i.e. higher HDL-C and lower TG. Of these studies, it alone
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measures velocity while the other studies measure differences between two time points. The
paucity of evidence involving detailed growth characterization, especially in early infancy,
motivates further study to better understand the role this early developmental period may
play in lipid metabolism.
Given the sparsity of observational studies containing detailed growth estimates in
early infancy and its possible role in altering lipid metabolism, our aim in this study is to
characterize growth in this early developmental and to measure its association with lipid levels
in later life. In addition to limited data on growth during this developmental period, there
is a lack of ancestral diversity and information from lower income countries in the existing
characterizations. We propose to evaluate these associations in a low- to middle-income
infancy cohort from Santiago, Chile. In line with most prior evidence from observational
studies, our hypothesis is that faster growth is associated with an unfavorable lipid profile.
Results from this study can better define how growth in early infancy may lead to lipid
disturbances, which can inform potential interventions.
5.3 Methods
5.3.1 Sample
The Santiago Longitudinal Study (SLS) is a cohort study with origins as an infancy iron
deficiency anemia preventive trial from 1991-1996 (Lozoff et al. 2003; Lozoff, Kaciroti, and
Walter 2006; Gahagan et al. 2009). Recruitment inclusion criteria for the preventive trial
included full-term infants with birthweight ≥ 3.0 kg and no major health problems (1,645
completers at 12 months). Any infant with iron deficiency anemia at six months was part
of the neuromaturation study and not included in this study (n=153). In this particular
analysis, SLS lipid measures collected at 17 years of age are the outcomes of interest (n=596).
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We omitted individuals with lipid values exceeding 5 standard deviations (n=6).
5.3.2 Anthropometric, lipid, and covariate measures
Three body size measures including weight (kg), length (cm), and weight-for-length
(WFL) (g/cm) are used to characterize growth trajectories. Weight was measured to the
nearest 0.01 kg on an electronic scale at well-baby visits in local public health clinics (Gahagan
et al. 2009). Length was measured on a recumbent board to the nearest 0.1 cm.
Cholesterol values, high density lipoprotein cholesterol (HDL-C) and triglycerides (TG),
were obtained with venipuncture from participants at an average age of 17 years following
a 12 hour overnight fast. The lipid panel was measured with a dry analytical method in
the Vitros system (Vitros®; Ortho Clinical Diagnostics Inc., Raritan, NJ, USA) (Burrows et
al. 2016). Low density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald
equation (Friedewald, Levy, and Fredrickson 1972): total cholesterol - HDL-C - TG/5. The
TG:HDL ratio was another cardiometabolic outcome.
After careful consideration of confounders, adjusted analyses included sex of child and
socioeconomic status as measured by a modified Graffar index (Graffar 1956). This index
represents socioeconomic position (SEP) within lower-income countries (Alvarez, Muzzo, and
Ivanović 1985), and it includes 12 measures including education, expenditures, and housing
characteristics, which are summed to create a scale with higher values indicating lower social
class. We also included randomization of treatment at six months.
5.3.3 Statistical Analysis
Summary statistics included median and interquartile range for the continuous variables
and percents with counts for categorical variables. All summary statistics were stratified by
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sex of child.
To estimate the association between early infant growth and lipid measures, we used two
different approaches: 1) nonlinear mixed effects with a SITAR approach (Cole, Donaldson,
and Ben-Shlomo 2010) and 2) latent growth mixed effects models (LGMM) (Muthén and
Shedden 1999; Muthén et al. 2002). For each of these modeling approaches an extensive
evaluation of model fit was conducted for the growth curve modeling (Appendices B and C)
prior to estimating the association of growth characteristics and the outcome, lipid levels.
We selected number of classes in LGMM models for weight, length and weight-for-length
after evaluating the adjusted Bayesian Information Criterion (aBIC) and the Bootstrap
Likelihood Ratio Test (BLRT) across quadratic and cubic models (Nylund, Asparouhov, and
Muthén 2007; Schoot et al. 2016). Any classes with fewer than 30 people were not considered.
Finally, substantive meaning of the growth classes was considered before making the final
selection. Considering all four lipid distal outcomes, sex-stratified and pooled analyses, and
three different types of trajectories with and without adjustment resulted in 64 different
models. We used a Bonferroni correction at an alpha level of 0.05 to adjust for multiple
comparisons per family of tests.
The SITAR approach (Cole, Donaldson, and Ben-Shlomo 2010) can extract up to three
random effects from a nonlinear model as outlined by Beath (2007) that indicate individual
changes from the average growth curve for: a) size (shifts up and down from the average
growth curve in units used for log transformed weight (kg), height (cm), and WFL (g/cm)),
b) tempo (shifts left and right from the average growth curve relating to timing of growth
in month units) and c) velocity, a scaling factor that shrinks or enlarges the time scale
from the average growth curve – larger values as parameterized according to the model by
Cole, Donaldson, and Ben-Shlomo (2010) indicate faster velocity. Fit was evaluated for all
combinations of the three growth factors, i.e. size, tempo and velocity (Appendix table B).
In turn, the random effects served as exposure variables in simple linear regression models
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with lipids outcomes. Each of these growth factors are considered as covariates in models to
estimate the association with the three lipid outcomes. All nonlinear models were fit in R (R
Core Team 2015) using the nlme package in R (Pinheiro et al. 2017). To handle missing
data in the SITAR models we used the multivariate imputation by chained equations (mice)
method with the mice R package (Buuren and Groothuis-Oudshoorn 2011).
The final LGMM model included a cubic polynomial model for the six time points from
birth to month 5. Intercept and slope growth factors were specified as random effects. We
also included an autocorrelation structure in random effects as this model feature improves
fit (Gilthorpe et al. 2014). We reduced number of classes via evaluation of adjusted Bayesian
Information Criterion (aBIC), bootstrap likelihood ratio tests (BLRT) and substantive
meaning of trajectories upon visual examination (Schoot et al. 2016) (Appendix table
A3). For the sample pooling across sex of child, the 2-class model was the best fit for all
three trajectories, including height, weight, and WFL trajectories (Appendix table A3).
For sex-stratified analyses the fit results were similar with the exception of the male WFL
3-class solution. To evaluate associations between growth classes and distal outcomes, we
used separate models for each of the lipid distal outcomes: HDL-C, LDL-C and TG. We
compared mean lipid values across the latent classes using the manual 3-step BCH procedure
(Asparouhov and Muthén 2014), which allows for unequal variances of distal outcomes across
different groups and is robust to outliers. All LGMM were fit in Mplus version 8.0 (Muthen
and Muthen 1998) and data handling in R with the MplusAutomation package (Hallquist
and Wiley 2017). The specified models use a full information maximum likelihood (FIML)
(Collins, Schafer, and Kam 2001) in Mplus (Muthen and Muthen 1998; Jung and Wickrama
2008) to handle missing data, which is valid in cases of missing at random (MAR) data – an
assumption we make with these data.
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5.4 Results
Of the 596 participants, the median (25th, 75th percentile) TG, LDL-C, and HDL-C
(mg/dL) at an average age of 17 years was 73.7 (56.9, 100.7), 91.7 (77.6, 106.9), and 39.5
(33.0, 46.4), respectively (Table 1). Around half (52%, n=311) of the participants were male.
Body size trajectories spanned six time points at monthly intervals with no more than seven
percent of observations missing at each month and no missing for measures at birth. All
participants had at least two anthropometric observations for this time range, and an average
of six observations per individual.
5.4.1 SITAR
After visually examining all parameter estimates with 95% confidence intervals and
determining little heterogeneity by sex of child, we decided to include analyses pooling males
and females together and to adjust for sex of child. Subsequent results reflect associations for
the total sample including sex of child as a covariate along with randomization status and SES
as confounders. For length trajectories, there exists a positive adjusted association between
velocity and HDL-C (mg/dL) (11.5, SE=4.1) (Table 2) indicating a 11.5 unit increase in
HDL-C (mg/dL) for a one unit change in the SITAR height velocity scaling factor. Faster
length growth, i.e. the velocity component, is associated with more favorable, i.e. higher,
HDL-C levels. Although not reaching significance, it bears noting that tempo, i.e. the timing
of growth, for this lipid outcome is inversely associated with HDL-C (-1.5, SE=1.2) indicating
a one month shift to later timing of growth (shift growth curve to left), relative to the average,
is associated with lower HDL-C. The length tempo parameter is positively associated with
LDL-C (6.90, SE=2.6) indicating a one month shift in later growth timing is associated with
more than 6 units greater LDL-C.
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5.4.2 LGMM
5.4.2.1 Trajectory descriptions
The best fitting cubic polynomial model for WFL trajectories in the group pooling across
sex of child (pooled group) includes two groups that will be identified as “slower” and “faster”
velocity groups (Figure 1). The “slower velocity” trajectory is distinguished by the lowest
WFL at birth (69.7 g/cm), lowest slope (11.8), and least deceleration (-0.43). The “faster
velocity” trajectory has the highest WFL at birth (70.7 g/cm), highest slope (21.0) and
highest deceleration (-2.6) (Table 3). Upon visual inspection, weight trajectories display less
heterogeneity in the groups (Figure 1), but they are similar to the pooled WFL trajectories
in that there are two distinct latent growth classes. In contrast, the length growth classes
offer the least heterogeneity during this time period from zero to five months, especially for
the female group.
When fitting the WFL trajectories to the female group, only two trajectories remain,
which satisfy the fit criteria that best correspond to “slower velocity” (intercept=69.3,
slope=10.0, and quadratic term=0.12) and “faster velocity” (intercept=69.4, slope=18.8,
and quadratic term=-2.3) groups (Table 3). In contrast to the female group with two WFL
trajectories, the male group had three WFL trajectories – again with the lower velocity group
having higher LDL-C. The three groups included: 1) a “slower velocity” group (intercept =
68.7, slope = 8.8, and quadratic term = 0.86), 2) a “faster velocity” group (intercept = 70.3,
slope = 17.3, and quadratic term = -1.9), and 3) a “fastest velocity” group (intercept = 71.0,
slope = 25.5, and quadratic term = -3.8) (Table 3). Conditions similar to those of the pooled
group above apply to the weight and length trajectories for the sex-stratified groups.
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5.4.2.2 Weight trajectories
For the pooled sample, the association between weight trajectory latent class groups and
LDL-C represented the largest mean differences for all combinations of exposure and outcome
groups, with the “slower” velocity group exceeding the “faster” velocity group by 5 mg/dL
for both the unadjusted (6.5, 95% CI = 1.1, 11.9, p-value=0.02) and adjusted (5.3, 95% CI =
-0.4, 11.0, p-value=0.07) (Table 4). However, none of these values are statistically significant
following adjustment for multiple comparisons. These values change little after adjustment
for potential confounders, unlike the LDL-C distal outcome for length trajectories.
Of the other lipid measures considered, including HDL-C, TG, and the TG:HDL-C ratio,
the HDL-C differences coincided with the LDL-C findings in that unfavorable levels were
associated with slower growth groups relative to faster growth groups. For example, the
female, male and pooled weight trajectories indicated that the “slower velocity” groups had
adjusted HDL-C that were 3.1 mg/dL (95% CI = -6.6, 0.4), 2.0 mg/dL (95% CI = -5.0, 1.1),
and 1.9 mg/dL (95% CI = -4.5, 0.7) lower than the “faster velocity” group, respectively
(Table 4). The differences in log(TG) between growth classes were consistently close to null
as were the TG:HDL ratios.
5.4.2.3 Weight-for-length (WFL) trajectories
.In the sex-stratified analyses the WFL trajectories demonstrate the largest differences
in LDL-C. Similar to the weight trajectory analyses, a similar pattern exists with the “slower”
velocity group having the higher mean LDL-C. The female “slower velocity” group had a
average LDL-C of 97.4 mg/dL (95% CI = 93.5, 101.2), and had 5.0 mg/dL higher LDL-C
(95% CI = -2.1, 12.0; p-value=0.17) (Table 4) compared to the “faster velocity” group. After
adjusting for confounders, the difference changes little at 5.4 mg/dL (95% CI = -2.4, 13.2;
p-value=0.17).
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LDL-C remained the highest in the male “slower velocity” group (101.3, 95% CI = 93.7,
109.0) (Table 5), and is 11.6 mg/dL (95% CI = 2.2, 20.9) higher than the “faster velocity”
group and 13.9 mg/dL (95% CI = 3.4, 24.5) higher (Table 4) than the “fastest velocity”
group (Wald Chi-square = 8.14, 2 df, p-value=0.017). Adjusting for confounders did not
substantively change the difference for the “slower” versus “faster” velocity group at 12.0
mg/dL (95% CI = 2.8, 21.1). The difference for the “slower” versus “fastest” group of 7.8
mg/dL (95% CI = -3.5, 19.0) diminishes after adjustment for confounders.
5.4.2.4 Length trajectories
Unlike the SITAR results, no significant associations were found between latent class
infant length growth trajectory groups and lipid outcomes in adolescence. This outcome is in
part due to low entropy, ~0.3, in the length trajectory models, meaning more measurement
error of latent class identification and a lower ability to identify distinct height latent growth
classes. Similarly, upon visual inspection of the length trajectories, it is clear that there is
also little substantive differences in the trajectories.
5.5 Discussion
In these analyses we estimated associations between growth in early infancy and lipid
levels in adolescence from two different methods in a Chilean infancy cohort. We found
a positive association between the length velocity SITAR parameter and HDL-C levels
in adolescence. Following adjustment for multiple comparisons, there were no significant
associations between latent class growth trajectories, considered the exposure, and lipid levels
during adolescence, considered the outcome. Examining the size of mean lipid differences
across each type of trajectory, the LDL-C distal outcomes had the strongest signals for weight
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and WFL trajectories in which the lower velocity group had the highest LDL-C levels relative
to the high velocity group. Neither of these findings support the original hypothesis of faster,
more extreme, growth and an association with adverse lipid levels.
In terms of early infant length trajectories, faster linear (length) growth has been linked
to unfavorable lipid levels. In contrast to these prior findings, the velocity parameter from
the SITAR model in these analyses, indicating how fast an infant grows, has a positive
association with HDL-C levels, considered a protective cardiovascular disease risk factor.
Most studies of growth during infancy focus on weight or some combination of weight and
length including weight-for-length, body mass index (kg/m2) or the ponderal index (kg/m3).
Studies with length change measures over childhood (Corvalan et al. 2009; Tzoulaki et al.
2010) indicate no association with lipids. The first study (Corvalan et al. 2009) measures
lipid levels in children of an average age of four years and the second study uses peak height
velocity (Tzoulaki et al. 2010) as a measure spanning an age range of the first two years of life.
Both of these differences in age at outcome measure and type of measure across studies may
contribute to the differences in the literature. Nonetheless, these results do not support the
hypothesis that faster growth contributes to an adverse lipid profile. The finding of a positive
association between HDL-C and length velocity is unique in that it provides a meaningful
measure of the rate of length change spanning the early infancy period connected with an
endpoint more than a decade later.
Unlike the SITAR results, the results from LGMM do not provide evidence supporting
an association between growth patterns and HDL-C. It is also worth noting that there is
very little variation in growth patterns when examining length trajectories in this sample for
the first five months (Figure 1). No latent growth pattern is associated with HDL-C, but
when examining growth characteristics as a homogenous group, i.e. the SITAR model, one
observes an association. In this respect, it is useful to have two complementary analyses in
cases where one type of model, the LGMM, does not provide enough information, as occurs
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for length measures.
Despite the lack of heterogeneity of length growth classes as mentioned before, the
LGMM does have its uses, however, and results from this method informs our hypothesis
despite null findings following adjustments for multiple comparisons. When examining the
effect sizes across the four different lipid distal outcome measures, the LDL-C lipid distal
outcome appears to have the strongest association with different WFL latent growth classes
in analyses for samples that are stratified by sex of child. The male WFL trajectories also
have three distinct growth classes compared to the weight and length trajectories (Figure 1),
contributing to better differentiation of growth and potential for differences in lipid outcomes.
There is a consistent inverse gradient in LDL-C across growth classes, an association robust
to adjustment for confounders. In all three different groups the fastest growth group does
not have unfavorable lipid levels, i.e. the highest mean LDL-C. Instead, the “low velocity”
group has the highest LDL-C.
This finding of the slower growing group carrying higher risk of unfavorable lipid levels
is in contrast to previous studies, which have shown a positive association with rate of
growth during infancy and adverse lipid levels later in life. Another study contradicting
the association between faster early anthropometric growth and unfavorable lipid profiles
examined the association between peak height and weight velocity and cardiometabolic
outcomes around age 30. Evidence exists showing a positive association between peak height
velocity and HDL-C (Tzoulaki et al. 2010), but only after adjusting for a mediating factor,
BMI during adulthood. This positive association between faster growth and a favorable lipid
profile coincides with the results from these analyses despite differences across population
types, cohort timing and type of measure: this study was a European cohort with data
collected around three decades prior to SLS, and it included peak weight velocity, a different
measure from the average velocity measure in this study. However, similar to the approach
in this paper, this study used a parametric form of growth accompanied by multiple early
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measures of weight and length.
Most studies examined the role of early infant growth and cardiometabolic profiles
by assessing differences in weight or length across two time points. In addition to the
simpler assessment of body size change over time, design differences between this study and
previous studies make it difficult to explain the disparities in the direction of association when
examining WFL growth trajectories. These disparities can be attributed to many factors
including secular time effects, varying endpoint ages, different populations, different methods,
or varying combinations of all four. For example, another Chilean study less than a decade
after SLS (Corvalan et al. 2009) indicates weight change having a positive association with
adverse lipid levels for those with exclusive or predominant breastfeeding. The end-point age,
5 years, was more than ten years lower than the one in these analyses and growth change
only included two observations. Another more recent study in Canadian children (Van Hulst
et al. 2017) indicated a positive association between growth in the first two years of life
with unfavorable HDL-C levels. There were three or more observations in the infant growth
period, and this period spanned the first two years – a wider age span than what we used to
measure trajectories. This difference alone could account for the difference, not considering
the differences in populations (White versus Hispanic/Latino), endpoint age (10-12 years vs
17 years), and a method including a longitudinal analysis of WFL Z-scores. These differences
underscore the need to separate out time periods when assessing associations between infant
growth and cardiometabolic outcomes, the first six months in particular. Furthermore, these
differences may have consequences in intervention design to lower cardiometabolic risk factors.
Some limitations of this study include sample size issues and factors relating to causal
effect estimation. This sample size of less than 600 individuals is small for LGMM (Kim
2014), and it can preclude detection of smaller, but important, growth patterns perhaps at
greater risk for unfavorable lipid levels. In addition to sample size, the conceptual issue of
using growth as an exposure limits inference regarding any underlying biological mechanism.
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Growth, considered the exposure in this study, can be a marker for different biological
mechanisms, including types of feeding such as a higher fat diet or lower amounts of food
such as those used in experimental animal studies to alter early postnatal growth. Assessing
growth limits an explanation of the biological mechanism by which the association may occur.
However, the marker itself may have much less measurement error in these aforementioned
observational studies than the contributing factors to growth. Another limitation is the often
cited residual confounding, which may also explain the associations between growth and lipid
levels.
Lastly, a limitation is the lack of assessment of direct and indirect effects by which infant
growth is associated with lipid levels in adolescence. In assessing indirect effects, relations
between infant growth and BMI change later in childhood and adolescence would be of great
interest as this connection has strong evidence in the existing literature, and it would offer an
explanation of altered lipid levels through infant growth. However, a higher TG:HDL ratio
is commonly found in obese groups (Pires, Sena, and Seiça 2016), and this outcome is not
substantively associated with any of the lipid levels for any of the trajectory types. This lack
of association hints that later BMI change associated with early infant growth may not be a
pathway by which early infant growth is influencing lipid levels.
Some strengths of this study included the specification of a comprehensive array of
many anthropometric observations (weight, length and WFL), many lipid measures (HDL-C,
LDL-C, TG and HDL-C:TG ratio), and two distinct analytic approaches in often understudied
populations in this line of research: low- to middle-income Hispanic/Latino groups. The
combination of exposures and outcomes allowed comparisons as to which distal lipid outcome
had the strongest effect within particular types of trajectories. In this particular research the
LDL-C outcome within the weight and WFL trajectories demonstrated the strongest effects.
In designing future analyses, it may be worth designating LDL-C as the primary outcome to
maximize power in these sorts of studies, which are difficult to replicate given the difficulty in
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collecting this sort of high quality longitudinal data. Another advantage was the side-by-side
use of two distinct analytic techniques of SITAR and LGMM, which allowed comparisons of
best ways to assess associations between growth and the designated cardiometabolic outcome,
lipids in this case. SITAR lent itself best to the height trajectories in this early period of life
before six months of age given the lack of heterogeneity of growth patterns, and LGMM was
better suited at distinguishing differences in lipid outcomes across heterogeneous WFL and
weight growth patterns.
This assessment of a wide array of exposure and outcome measures representing a com-
prehensive analysis of growth patterns in this particular age period has not been summarized
in the literature to our knowledge. Singling out this window of time has been fruitful in that
the association between faster growth and adverse cardiometabolic factors may not apply,
and as a consequence interventions may be different dependent on the time at which the
infant growth is occurring. Although few if any associations were statistically significant,
the association between slower growth and unfavorable lipids levels present in this research
supports some previous research. Most importantly, the collection of repeated anthropometric
measures during this time period in early infancy would be most helpful in confirming this
association, which is important as it may have great potential for intervention.
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5.6 Tables
Table 5.1: (MS2: Table 1) Descriptive statistics, median [IQR]
Characteristic Male Female Total
n 311 285 596
No added iron, n (%) 158 (50.8) 125 (43.9) 283 (47.5)
Triglycerides (mg/dL) 71.4 [55.6, 100.1] 76.0 [58.4, 101.6] 73.7 [56.9, 100.7]
Total cholesterol (mg/dL) 143.0 [130.4, 158.2] 154.0 [137.5, 169.8] 146.9 [133.0, 165.1]
LDL-C (mg/dL) 89.2 [75.7, 104.3] 94.5 [80.7, 109.5] 91.7 [77.6, 106.9]
HDL-C (mg/dL) 37.0 [31.3, 42.8] 42.2 [35.6, 50.3] 39.5 [33.0, 46.4]
Still breastfeeding at 6 months, n (%) 193 (63.1) 186 (67.1) 379 (65.0)
Graffar Index 32.6 (7.0) 32.3 (6.7) 32.5 (6.9)
Maternal age (years) 26.5 (6.4) 26.4 (6.4) 26.5 (6.4)
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Table 5.2: (MS2: Table 2) Coefficients for association between SITAR growth parameter (se) and lipid outcome by sex of child,
type of trajectory, and adjustment status
Unadjusted Adjusteda
Sex Trajectory type Lipid Size Tempo Velocity Size Tempo Velocity
All Length HDL-C – -1.89 (1.11) 13.09 (3.99) – -1.51 (1.15) 11.54 (4.05)
All Length LDL-C – 6.75 (2.50) -21.28 (9.06) – 6.90 (2.60) -19.92 (9.23)
All Length log(TG) – -0.01 (0.05) -0.09 (0.16) – -0.00 (0.05) -0.08 (0.17)
All Weight HDL-C -1.41 (4.25) -1.21 (1.03) 2.08 (1.82) -2.80 (4.25) -1.16 (1.05) 1.96 (1.82)
All Weight LDL-C -10.27 (9.60) 0.96 (2.34) -4.16 (4.12) -8.99 (9.63) 0.98 (2.39) -3.15 (4.13)
All Weight log(TG) 0.19 (0.17) -0.01 (0.04) -0.02 (0.07) 0.20 (0.17) -0.00 (0.04) -0.01 (0.07)
All WFL HDL-C 0.31 (4.53) -0.43 (0.94) – -0.92 (4.56) -0.40 (0.94) –
All WFL LDL-C -14.90 (10.24) -1.54 (2.12) – -11.81 (10.32) -1.19 (2.14) –
All WFL log(TG) 0.21 (0.18) 0.00 (0.04) – 0.23 (0.19) 0.01 (0.04) –
Female Length HDL-C – -1.51 (1.49) 11.85 (5.43) – -1.65 (1.58) 12.37 (5.64)
Female Length LDL-C – 6.87 (3.42) -33.65 (12.52) – 6.82 (3.62) -32.20 (12.96)
Female Length log(TG) – 0.02 (0.06) -0.11 (0.24) – 0.04 (0.07) -0.10 (0.25)
Female Weight HDL-C 3.98 (5.91) -0.56 (1.40) -0.52 (2.57) 3.76 (5.99) -0.55 (1.44) -0.86 (2.63)
Female Weight LDL-C -24.11 (13.62) -0.41 (3.24) -3.12 (5.95) -22.81 (13.72) -1.00 (3.32) -0.71 (6.04)
Female Weight log(TG) 0.13 (0.25) -0.04 (0.06) -0.07 (0.11) 0.13 (0.26) -0.03 (0.06) -0.07 (0.11)
Female WFL HDL-C -0.14 (5.94) -0.72 (1.30) – -1.08 (6.11) -0.85 (1.32) –
Female WFL LDL-C -19.11 (13.71) -1.71 (3.02) – -13.73 (14.04) -1.23 (3.04) –
Female WFL log(TG) 0.05 (0.26) -0.05 (0.06) – 0.06 (0.26) -0.04 (0.06) –
Male Length HDL-C – -2.35 (1.67) 14.51 (5.88) – -1.58 (1.71) 12.11 (5.88)
Male Length LDL-C – 6.61 (3.67) -7.20 (13.11) – 6.84 (3.81) -5.93 (13.29)
Male Length log(TG) – -0.05 (0.06) -0.06 (0.23) – -0.04 (0.07) -0.07 (0.23)
Male Weight HDL-C -6.99 (6.10) -1.98 (1.53) 4.61 (2.57) -8.86 (6.03) -1.72 (1.56) 5.38 (2.55)
Male Weight LDL-C 4.03 (13.50) 2.55 (3.39) -5.17 (5.69) 5.22 (13.57) 3.16 (3.50) -4.81 (5.74)
Male Weight log(TG) 0.25 (0.23) 0.03 (0.06) 0.03 (0.10) 0.26 (0.24) 0.04 (0.06) 0.04 (0.10)
Male WFL HDL-C 0.92 (7.00) -0.12 (1.35) – 1.50 (6.97) 0.40 (1.36) –
Male WFL LDL-C -9.24 (15.46) -1.36 (2.97) – -7.58 (15.59) -1.00 (3.05) –
Male WFL log(TG) 0.42 (0.27) 0.06 (0.05) – 0.45 (0.27) 0.07 (0.05) –
Note:
Bold values indicate statistical significance at FDR=0.05
a Adjusted for randomization status, gestational age, Graffar index, and breastfeeding status
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Table 5.3: (MS2: Table 3) Parameters for the growth classes
Categories Intercept Slope Quadratic
Sex of child Trajectory type Class Order Not adjusted Adjusteda Not adjusted Adjusteda Not adjusted Adjusteda
Slower 50.372 50.274 2.637 2.702 0.225 0.216
Length Faster 51.232 50.933 3.701 3.265 -0.138 0.004
Slower 3.511 3.499 0.817 0.826 0.026 0.027
Weight Faster 3.679 3.683 1.354 1.283 -0.084 -0.075
Slower 69.712 69.573 11.803 11.808 -0.426 -0.351
Both
WFL Faster 70.772 70.806 21.032 19.754 -2.602 -2.381
Slower 50.199 50.291 2.849 2.675 0.107 0.117
Length Faster 50.819 50.607 3.623 3.762 -0.192 -0.179
Slower 3.519 3.514 0.627 0.612 0.081 0.082
Weight Faster 3.486 3.492 1.163 1.123 -0.080 -0.063
Slower 69.328 69.357 9.989 10.074 0.123 0.078
Female
WFL Faster 69.379 69.320 18.736 18.781 -2.271 -2.200
Slower 50.748 50.735 2.056 2.024 0.495 0.504
Length Faster 51.246 51.246 3.844 3.829 -0.146 -0.140
Slower 3.501 3.515 0.838 0.799 0.041 0.051
Weight Faster 3.674 3.641 1.399 1.362 -0.104 -0.093
Slower 68.690 69.454 8.827 8.346 0.860 1.101
Faster 70.331 69.915 17.248 16.658 -1.896 -1.750
Male
WFL
Fastest 70.994 70.964 25.486 24.372 -3.765 -3.505
a Adjusted for sex of child in pooled sample, randomization status, breastfeeding at six months, and socioeconomic status.
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Table 5.4: (MS2: Table 4) Pairwise growth class differences in lipid distal outcome.
Categories Slower vs Faster Slower vs Fastest Faster vs Fastest Overall test: p-value, (Chi-sq, df)
Sex Outcome Lipid Not adjusted Adjusteda Not adjusted Adjusteda Not adjusted Adjusteda Not adjusted Adjusteda
Both Length HDL-C -2.13 (-5.13, 0.87) -2.48 (-5.14, 0.18) – – – – 0.164, (1.94,1) 0.067, (3.35,1)
Both Length LDL-C 5.79 (-0.92, 12.50) 1.43 (-4.83, 7.68) – – – – 0.091, (2.86,1) 0.655, (0.20,1)
Both Length log(TG) 0.01 (-0.11, 0.14) -0.05 (-0.16, 0.05) – – – – 0.825, (0.05,1) 0.318, (0.99,1)
Both Length TG:HDL
ratio
– -0.02 (-0.06, 0.02) – – – – – 0.304, (1.06,1)
Both Weight HDL-C 0.89 (-1.54, 3.33) -1.92 (-4.51, 0.66) – – – – 0.472, (0.52,1) 0.144, (2.13,1)
Both Weight LDL-C 6.47 (1.05, 11.88) 5.29 (-0.39, 10.97) – – – – 0.019, (5.48,1) 0.068, (3.34,1)
Both Weight log(TG) 0.02 (-0.08, 0.12) 0.03 (-0.08, 0.14) – – – – 0.695, (0.15,1) 0.603, (0.27,1)
Both Weight TG:HDL
ratio
0.02 (-0.01, 0.06) 0.00 (-0.03, 0.03) – – – – 0.169, (1.89,1) 0.980, (0.00,1)
Both WFL HDL-C 0.80 (-1.68, 3.29) -1.24 (-3.94, 1.46) – – – – 0.526, (0.40,1) 0.368, (0.81,1)
Both WFL LDL-C 5.05 (-0.36, 10.45) 5.41 (-0.39, 11.22) – – – – 0.067, (3.35,1) 0.068, (3.34,1)
Both WFL log(TG) -0.00 (-0.11, 0.10) 0.00 (-0.11, 0.11) – – – – 0.916, (0.01,1) 0.969, (0.00,1)
Both WFL TG:HDL
ratio
-0.01 (-0.05, 0.02) 0.01 (-0.02, 0.04) – – – – 0.462, (0.54,1) 0.682, (0.17,1)
Female Length HDL-C 0.93 (-2.67, 4.54) 1.62 (-1.74, 4.98) – – – – 0.612, (0.26,1) 0.344, (0.90,1)
Female Length LDL-C 3.44 (-4.68, 11.55) -4.23 (-11.73, 3.26) – – – – 0.407, (0.69,1) 0.268, (1.23,1)
Female Length log(TG) 0.01 (-0.13, 0.15) 0.10 (-0.03, 0.23) – – – – 0.919, (0.01,1) 0.126, (2.34,1)
Female Length TG:HDL
ratio
0.08 (-0.08, 0.24) -0.00 (-0.05, 0.04) – – – – 0.317, (1.00,1) 0.869, (0.03,1)
Female Weight HDL-C -4.76 (-8.07, -1.46) -3.11 (-6.58, 0.36) – – – – 0.005, (8.00,1) 0.079, (3.09,1)
Female Weight LDL-C 3.50 (-3.68, 10.68) 1.88 (-5.85, 9.60) – – – – 0.340, (0.91,1) 0.634, (0.23,1)
Female Weight log(TG) 0.00 (-0.12, 0.13) -0.01 (-0.15, 0.13) – – – – 0.950, (0.00,1) 0.883, (0.02,1)
Female Weight TG:HDL
ratio
0.01 (-0.03, 0.05) 0.03 (-0.01, 0.07) – – – – 0.644, (0.21,1) 0.124, (2.36,1)
Female WFL HDL-C -1.27 (-4.83, 2.30) -1.99 (-5.74, 1.76) – – – – 0.486, (0.49,1) 0.298, (1.08,1)
Female WFL LDL-C 4.96 (-2.06, 11.97) 5.41 (-2.36, 13.18) – – – – 0.166, (1.92,1) 0.172, (1.86,1)
Female WFL log(TG) -0.04 (-0.17, 0.10) -0.04 (-0.18, 0.10) – – – – 0.602, (0.27,1) 0.558, (0.34,1)
Female WFL TG:HDL
ratio
-0.01 (-0.06, 0.04) 0.00 (-0.04, 0.04) – – – – 0.673, (0.18,1) 0.960, (0.00,1)
Male Length HDL-C -1.25 (-5.01, 2.51) -2.45 (-6.10, 1.20) – – – – 0.515, (0.42,1) 0.188, (1.73,1)
Male Length LDL-C 3.02 (-5.51, 11.55) 1.48 (-6.99, 9.95) – – – – 0.488, (0.48,1) 0.732, (0.12,1)
Male Length log(TG) -0.03 (-0.19, 0.13) 0.02 (-0.13, 0.18) – – – – 0.724, (0.12,1) 0.753, (0.10,1)
Male Length TG:HDL
ratio
0.03 (-0.02, 0.08) 0.01 (-0.04, 0.06) – – – – 0.253, (1.31,1) 0.827, (0.05,1)
Male Weight HDL-C -1.54 (-4.49, 1.40) -1.96 (-4.98, 1.07) – – – – 0.304, (1.05,1) 0.204, (1.61,1)
Male Weight LDL-C 0.74 (-6.10, 7.58) 1.70 (-5.41, 8.81) – – – – 0.832, (0.04,1) 0.639, (0.22,1)
Male Weight log(TG) 0.02 (-0.11, 0.15) 0.01 (-0.12, 0.15) – – – – 0.778, (0.08,1) 0.826, (0.05,1)
Male Weight TG:HDL
ratio
-0.02 (-0.06, 0.02) -0.01 (-0.06, 0.03) – – – – 0.379, (0.77,1) 0.466, (0.53,1)
Male WFL HDL-C -0.12 (-4.23, 3.99) -1.60 (-6.10, 2.91) -1.23 (-6.12, 3.66) -0.68 (-6.00, 4.64) -1.11 (-5.54, 3.32) 0.92 (-3.64, 5.48) 0.861, (0.30,2) 0.772, (0.52,2)
Male WFL LDL-C 11.59 (2.24, 20.93) 11.96 (2.78, 21.14) 13.95 (3.40, 24.49) 7.75 (-3.48, 18.99) 2.36 (-7.10, 11.81) -4.20 (-14.73, 6.33) 0.017, (8.14,2) 0.038, (6.54,2)
Male WFL log(TG) 0.05 (-0.11, 0.21) -0.04 (-0.19, 0.12) 0.02 (-0.16, 0.21) -0.02 (-0.22, 0.17) -0.03 (-0.20, 0.15) 0.01 (-0.18, 0.20) 0.836, (0.36,2) 0.893, (0.23,2)
a Adjusted for sex of child in pooled sample, randomization status, breastfeeding at 6 months, and socioeconomic status.
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Table 5.5: (MS2: Table 5): Mean distal lipid value by growth class and type of growth measure
Latent Class Groups
Categories Slower Faster Fastest
Sex Outcome Lipid Not adjusted Adjusteda Not adjusted Adjusteda Not adjusted Adjusteda
Both Length HDL-C 39.50 (37.89, 41.10) 38.66 (36.60, 40.73) 41.63 (39.78, 43.48) 41.15 (40.01, 42.28) – –
Both Length LDL-C 96.17 (92.70, 99.64) 94.62 (89.70, 99.55) 90.38 (86.13, 94.63) 93.19 (90.66, 95.73) – –
Both Length log(TG) 4.36 (4.30, 4.42) 4.32 (4.24, 4.40) 4.35 (4.27, 4.42) 4.37 (4.32, 4.42) – –
Both Length TG:HDL
ratio
1.85 ( NA, NA) 1.18 (1.15, 1.20) 0.42 ( NA, NA) 1.20 (1.18, 1.22) – –
Both Weight HDL-C 40.70 (39.56, 41.85) 39.81 (38.61, 41.01) 39.81 (37.95, 41.67) 41.73 (39.80, 43.67) – –
Both Weight LDL-C 95.52 (93.01, 98.02) 95.26 (92.54, 97.99) 89.05 (84.87, 93.23) 89.97 (85.79, 94.14) – –
Both Weight log(TG) 4.36 (4.32, 4.41) 4.37 (4.32, 4.42) 4.34 (4.26, 4.42) 4.34 (4.25, 4.42) – –
Both Weight TG:HDL
ratio
1.20 (1.18, 1.21) 1.19 (1.17, 1.20) 1.17 (1.14, 1.20) 1.19 (1.16, 1.22) – –
Both WFL HDL-C 40.70 (39.53, 41.86) 39.83 (38.53, 41.13) 39.90 (38.01, 41.78) 41.07 (39.11, 43.03) – –
Both WFL LDL-C 95.25 (92.66, 97.84) 95.58 (92.62, 98.53) 90.20 (86.13, 94.27) 90.17 (86.12, 94.21) – –
Both WFL log(TG) 4.35 (4.31, 4.40) 4.35 (4.30, 4.41) 4.36 (4.28, 4.44) 4.35 (4.27, 4.43) – –
Both WFL TG:HDL
ratio
1.18 (1.15, 1.21) 1.19 (1.16, 1.22) 1.19 (1.17, 1.21) 1.19 (1.17, 1.20) – –
Female Length HDL-C 43.41 (41.50, 45.32) 43.72 (41.75, 45.68) 42.48 (40.05, 44.91) 42.09 (39.91, 44.28) – –
Female Length LDL-C 97.17 (93.09, 101.26) 93.83 (89.58, 98.08) 93.74 (88.08, 99.40) 98.06 (93.07, 103.06) – –
Female Length log(TG) 4.37 (4.30, 4.44) 4.41 (4.33, 4.49) 4.36 (4.27, 4.46) 4.31 (4.23, 4.39) – –
Female Length TG:HDL
ratio
1.21 (1.13, 1.29) 1.17 (1.14, 1.19) 1.11 (1.01, 1.22) 1.17 (1.14, 1.21) – –
Female Weight HDL-C 40.91 (39.10, 42.72) 41.47 (39.47, 43.47) 45.67 (43.40, 47.95) 44.58 (42.35, 46.80) – –
Female Weight LDL-C 97.33 (92.89, 101.77) 96.65 (91.75, 101.55) 93.83 (89.38, 98.28) 94.77 (90.28, 99.26) – –
Female Weight log(TG) 4.37 (4.29, 4.44) 4.36 (4.28, 4.44) 4.36 (4.28, 4.44) 4.37 (4.29, 4.46) – –
Female Weight TG:HDL
ratio
1.18 (1.15, 1.21) 1.19 (1.16, 1.21) 1.16 (1.13, 1.20) 1.15 (1.12, 1.18) – –
Female WFL HDL-C 42.62 (41.00, 44.24) 42.37 (40.72, 44.01) 43.89 (41.14, 46.63) 44.36 (41.46, 47.25) – –
Female WFL LDL-C 97.37 (93.54, 101.21) 97.42 (93.49, 101.34) 92.42 (87.50, 97.33) 92.01 (86.46, 97.55) – –
Female WFL log(TG) 4.36 (4.29, 4.42) 4.35 (4.29, 4.42) 4.39 (4.29, 4.49) 4.39 (4.29, 4.50) – –
Female WFL TG:HDL
ratio
1.16 (1.12, 1.20) 1.17 (1.13, 1.21) 1.17 (1.15, 1.20) 1.17 (1.15, 1.19) – –
Male Length HDL-C 37.37 (34.89, 39.85) 36.73 (34.31, 39.15) 38.62 (36.71, 40.53) 39.18 (37.28, 41.08) – –
Male Length LDL-C 93.32 (87.92, 98.72) 92.52 (86.88, 98.16) 90.30 (85.68, 94.93) 91.04 (86.69, 95.39) – –
Male Length log(TG) 4.33 (4.23, 4.43) 4.36 (4.26, 4.46) 4.36 (4.27, 4.44) 4.34 (4.25, 4.42) – –
Male Length TG:HDL
ratio
1.23 (1.18, 1.27) 1.21 (1.17, 1.25) 1.19 (1.15, 1.22) 1.20 (1.17, 1.24) – –
Male Weight HDL-C 37.34 (35.57, 39.11) 37.07 (35.07, 39.06) 38.88 (36.94, 40.83) 39.03 (37.23, 40.82) – –
Male Weight LDL-C 91.98 (87.93, 96.04) 92.60 (88.12, 97.07) 91.25 (86.69, 95.80) 90.90 (86.57, 95.23) – –
Male Weight log(TG) 4.35 (4.28, 4.43) 4.35 (4.27, 4.44) 4.34 (4.25, 4.42) 4.34 (4.26, 4.42) – –
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Table 5.5: (MS2: Table 5): Mean distal lipid value by growth class and type of growth measure (continued)
Latent Class Groups
Categories Slower Faster Fastest
Sex Outcome Lipid Not adjusted Adjusteda Not adjusted Adjusteda Not adjusted Adjusteda
Male Weight TG:HDL
ratio
1.19 (1.16, 1.23) 1.20 (1.16, 1.23) 1.22 (1.18, 1.25) 1.21 (1.18, 1.24) – –
Male WFL HDL-C 37.75 (34.37, 41.13) 37.05 (33.27, 40.82) 37.87 (36.21, 39.52) 38.64 (36.82, 40.47) 38.98 (35.31, 42.65) 37.72 (34.18, 41.27)
Male WFL LDL-C 101.34 (93.72, 108.95) 100.42 (92.96, 107.87) 89.75 (85.83, 93.67) 88.46 (84.04, 92.87) 87.39 (79.79, 95.00) 92.66 (84.73, 100.59)
Male WFL log(TG) 4.38 (4.25, 4.51) 4.32 (4.21, 4.43) 4.33 (4.25, 4.41) 4.36 (4.27, 4.45) 4.36 (4.21, 4.50) 4.34 (4.20, 4.48)
a Adjusted for sex of child in pooled sample, randomization status, breastfeeding at 6 months, and socioeconomic status.
111
Table 5.6: (MS2: Table 6) Counts of people in each latent class, n
Categories Slower Faster Fastest
Sex of child Trajectory type Not adjusted Adjusted Not adjusted Adjusted Not adjusted Adjusted
Length 354 148 242 435 – –
Weight 430 404 166 179 – –Both
WFL 413 384 183 199 – –
Length 174 153 111 124 – –
Weight 159 139 126 138 – –Female
WFL 199 192 86 85 – –
Length 130 125 181 181 – –
Weight 169 138 142 168 – –Male
WFL 59 48 196 182 56 76
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5.7 Figures
Figure 5.1: (MS2: Figure 1) Growth trajectories by type of trajectory, sex of child and
adjustment status.
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Figure 5.2: (MS2: Figure 2) Plot of mean lipid values by class and type of distal outcome by type of trajectory, lipid outcome,
sex of child, and adjustment status
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CHAPTER 6: MANUSCRIPT 3 — INFANT GROWTH AS AN EFFECT
MODIFIER OF GENETIC-LIPID ASSOCIATIONS: EVIDENCE FROM A
CHILEAN INFANCY COHORT
6.1 Overview
Background
The postnatal period can function as a window of time for metabolic programming.
As evidence from human observational studies is scarce, we examined the role of postnatal
weight, length (linear growth), and weight-for-length (WFL) growth trajectories as effect
modifiers of established single nucleotide polymorphism (SNP) associations on lipid levels in
a cohort of adolescents from the Santiago Longitudinal Study (SLS) (n=480).
Methods
Growth trajectories were characterized with latent growth mixture models (LGMM) and
a nonlinear mixed effects method, SuperImposition by Translation And Rotation (SITAR). In
the LGMM approach, we assessed effect modification by stratifying additive single nucleotide
polymorphism (SNP)-lipid associations by latent growth patterns. We estimated statistical
interaction in SITAR models by stratifying continuous growth measure and lipid trait
associations by the three allele groups for each SNP. Bonferroni-corrected significant findings
are reported.
Results
LGMM patterns broke down into two groups: one group of infants had lower velocity and
lower deceleration; another group had higher velocity and higher deceleration. One variant,
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rs11076175 (CETP), demonstrated an inverse association between the G allele and LDL-C
for males in the high velocity/high deceleration weight trajectory group (adjusted coefficient
= -14.9, 95% CI = -26.37, -2.21; n ∼ 149) compared to the low velocity/low deceleration
group (adjusted coefficient = 22.6; 95% CI = 10.5, 34.8; n ∼ 105). No significant findings
were detected in the SITAR analyses.
Summary
Little evidence supports infant growth functioning as an effect modifier of SNP-lipid
associations. The one significant association supports a protective role of faster growth
against a deleterious SNP-lipid association. Further research and focus on this early postnatal
period may reveal heterogeneity of SNP-lipid association across growth patterns, suggesting
plasticity of response on a molecular level.
6.2 Introduction
Dyslipidemia is one of the strongest risk factors for cardiovascular disease, a chronic
disease that remains the highest cause of mortality in the world (Roth et al. 2017). In the
United States one in five children have dyslipidemia (Kit et al. 2015), and strong evidence
of tracking into adulthood makes lipid levels a target for early prevention. Contemporary
evidence has linked early postnatal growth with cardiovascular risk factors, including dys-
lipidemia, later in life. Evidence includes information derived from both animal (Ahmed
Habbout et al. 2013; Kappeler et al. 2009; Pentinat et al. 2010; Bei et al. 2015) and human
observational studies (Howe et al. 2010; Oostvogels et al. 2014; Ekelund et al. 2007; Kajantie
et al. 2008; Tzoulaki et al. 2010). Furthermore, a genetic component to dyslipidemia also
exists. Many studies have found and replicated genetic components underlying lipid levels
(Kuivenhoven and Hegele 2014; Willer et al. 2013; Teslovich et al. 2010; Graff et al. 2017),
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and heritability of lipid levels may exceed 50 percent (Kuivenhoven and Hegele 2014). Given
the evidence in both environmental and genetic domains linking both early postnatal growth
and genetic factors with lipid levels, respectively, there is the potential for effect modification
of genetic and lipid trait associations by early postnatal growth.
Prior investigations have found evidence of gene-environment interactions as they relate
to dyslipidemia (Cole, Nikpay, and McPherson 2015) including environmental factors such
as smoking, exercise and nutrients. One finding of note, and of particular relevance to the
proposed aim, provides evidence that adult adiposity functions as an effect modifier of the
relationship between TG and HDL-C traits and their respective genetic risk scores (Cole et
al. 2014). Studies in this gene-environment context focus on exposures during adulthood,
and there is the potential for environmental exposures, perhaps different from ones found
in adulthood, to occur earlier in the life course. To our knowledge there are no studies
examining the modification of associations between genetic variants and lipid outcomes across
different levels of early postnatal growth. Investigating infant growth as an effect modifier
of the association between genetic variants and lipid traits can shed more light on any role
earlier exposures may play in lipid metabolism programming, which can ultimately inform
interventions.
Our aim in this paper is to assess differences in the additive SNP-lipid associations
across early infant growth patterns. We hypothesize that postnatal growth, serving as the
exposure, has the potential to modify the association between adolescent lipid profiles and
genotypes. We will categorize infant growth patterns from an infancy cohort using two
different approaches to characterize early infant growth. Subsequent to categorization of
growth patterns we will estimate additive genetic associations with lipids across these latent
infant growth groups to assess effect modification. This exploratory work can generate further
hypotheses regarding the role of early infant growth in lipid metabolic programming. In turn,
this research can help inform future interventions aimed at unfavorable child growth patterns
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linked with chronic disease risk factors including dyslipidemia.
6.3 Methods
6.3.1 Sample
The Santiago Longitudinal Study (SLS) has been defined in the second aim (Chapter
5). In brief, it is an infancy cohort, which started as an anemia preventive trial, recruiting
participants from 1991-1996 (Lozoff et al. 2003; Lozoff, Kaciroti, and Walter 2006; Gahagan et
al. 2009). In this particular analysis, we used participants with SLS lipid measures collected
at 17 years of age with genotyping (n=480).
6.3.2 Genotyping
We used Illumina’s Infinium Multi-Ethnic Genotyping Array (MEGA) platform to
genotype the sample and imputed to the 1000 Genomes Phase III AMR reference sample.
Quality control included a sample-level call rate of 90% and a SNP-level call rate of 95%.
6.3.3 Anthropometric, lipid, and covariate measures
Three body size measures including weight (kg), length (cm), and weight-for-length
(WFL) (g/cm) are used to characterize growth trajectories. Weight was measured to the
nearest 0.01 kg on an electronic scale at well-baby visits in local public health clinics (Gahagan
et al. 2009). Length was measured on a recumbent board to the nearest 0.1 cm.
Cholesterol values, high density lipoprotein cholesterol (HDL-C) and triglycerides (TG),
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were obtained with venipuncture from participants at an average age of 17 years following
a 12 hour overnight fast. The lipid panel was measured with a dry analytical method in
the Vitros system (Vitros®; Ortho Clinical Diagnostics Inc., Raritan, NJ, USA) (Burrows et
al. 2016). Low density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald
equation (Friedewald, Levy, and Fredrickson 1972): total cholesterol - HDL-C - TG/5. The
TG:HDL ratio was another cardiometabolic outcome.
6.3.4 Statistical Analysis
Summary statistics included median and interquartile range for the continuous variables
and percents with counts for categorical variables. All summary statistics were stratified by
sex of child.
6.3.5 Risk variants
We selected an initial pool lipid risk variants based on novel lipid loci discovered in HL
ancestral groups or known lipid loci from other ancestral groups – primarily European – that
generalized in ancestral HL groups (Graff et al. 2017; Ko et al. 2014; Weissglas-Volkov et al.
2013; Below et al. 2016; Elbers et al. 2012; Zubair et al. 2016) (Appendix D, Table D.1).
From the initial pool of 212 variants we filtered variants with the highest power – greater
than or equal to 0.80 – to detect a main effect for the primary trait given our sample size
of around 500 participants. The final selection included 10 variants (Table 2) and additive
associations were estimated with the lipid trait given the coded allele.
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6.3.6 Genetic Risk Score (GRS)
We calculated lipid-specific unweighted genetic risk scores as exposure measures to
incorporate all variants. To obtain the genetic risk score for each lipid trait we summed the
number of trait-increasing risk alleles for each lipid trait from the initial pool of known lipid
loci described above (Appendix D, Table D.1) using the PredictABEL R package (Kundu,
Aulchenko, and Janssens 2014). We used 86, 71, and 54 SNPs for HDL-C, LDL-C, and TG
traits, respectively.
6.3.7 Growth estimates
Body size trajectories spanned six time points at monthly intervals with no more than
seven percent of observations missing at each month and no missing for measures at birth.
All participants had at least two anthropometric observations for this time range, and an
average of six observations per individual.
6.3.7.1 Latent Growth Mixture Models (LGMM)
To estimate the association between early infant growth and lipid measures, we used
a latent growth mixed effects models (LGMM) (Muthén and Shedden 1999; Muthén et
al. 2002). This data-driven approach identifies different growth classes that are sample-
dependent and any association requires replication. The nature of these analyses renders
any results as exploratory in nature and hypothesis generating. We described this same
approach to characterize growth in the second aim (Chapter 5). In brief, the LGMM relaxes
the assumption of fixed intercepts and slopes in determining growth classes from polynomial
growth models, thus the “mixed” part of the description. Also, we selected the number of
latent classes based on an extensive fitting process. Unlike the process we used in aim 2,
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we restricted the number of classes to two for all trajectories and type of sample (pooled,
female, and male) so that we could have an adequate sample size of at least 50 participants
to characterize the SNP-lipid association with confounders. The distal outcome in these
analyses was the additive SNP-lipid association, which was compared across the growth
classes (Figure 6.1) to characterize the gene-environment interaction. We tested differences
between the estimated lipid-SNP additive associations using a Wald Chi-square test with a
Bonferroni p-value adjustment at an alpha level of 0.05 to control for multiple comparisons.
Unless otherwise indicated, we only discuss results meeting this threshold, but all tests can
be found in Appendix E (Table E.1).
6.3.7.2 SuperImposition by Translation And Rotation (SITAR)
In addition to a latent method to capture early infant growth characteristics we also
used a nonlinear mixed effects model that produces three person-level growth characteristics
that can be used as covariates in subsequent analyses. This approach is the same as the
SITAR approach (Cole, Donaldson, and Ben-Shlomo 2010) defined in the methods section
for the first manuscript (Chapter 4). In brief, we extract up to three different measures of
growth including: a) size, b) tempo, and c) velocity. On a person-level these three measures
represent shifts for each individual away from the average growth curve in the sample for: a)
up and down on the vertical axis to indicate overall higher or lower anthropometric measures,
b) to the left and right on the time axis to indicate a slower or faster start to growth, and c)
shrinking or stretching the growth curve to indicate faster or slower growth change.
After obtaining up to three of these individual-level growth characteristics for each
of the three anthropometric measures we then proceeded in a second step to estimate
gene-environment interactions in separate models. In the linear regression model, a) the
SITAR growth parameters were continuous early infant growth covariates representing the
environmental effect, b) the allele frequencies from the selected SNPs were the genetic factors,
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and c) the continuous lipid traits were the outcomes. Instead of a cross-product term between
the genetic and environmental factor in the linear regression model, we used a more accurate
approach (Aliev et al. 2014) to test gene-environment interactions with the exception of
continuous genetic risk scores. For analyses with risk scores we did use a simple cross product
term to test for statistical interaction. As with the LGMM models, we used a Bonferroni
correction of 0.05 for multiple comparisons.
6.3.8 Confounders
Confounders for the SNP-lipid association in the LGMM model (Figure 1) were sex
of child, randomization status, and the first five principal components for ancestry, when
possible. There were some circumstances in which the LGMM model for height trajectories
would not converge with more than two principal components. Finally, randomization status,
gestational age, socioeconomic status, and sex of child were allowed to predict latent growth
factors including intercept, slope and the quadratic term in the quadratic polynomial model
(Figure 1).
We used Mplus version 8.0 to fit all LGMM (Muthen and Muthen 1998), and we used
R for data handling with the MplusAutomation package (Hallquist and Wiley 2017). The
specified models uses a full information maximum likelihood (FIML) (Collins, Schafer, and
Kam 2001) in Mplus (Muthen and Muthen 1998; Jung and Wickrama 2008) to handle missing
data, which is valid in cases of missing at random (MAR) data – an assumption we make
with these data.
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6.4 Results
Of the 480 participants, the median (25th, 75th percentile) TG, LDL-C, and HDL-C
(mg/dL) at an average age of 17 years was 73.7 (56.5, 100.6), 92.0 (78.3, 106.9), and 39.4
(33.2, 46.2), respectively (Table 1). Around half (53%, n=254) of the participants were male
and close to half (46%, n=220) were randomized to no added iron in the infancy preventive
trial.
LGMM growth characteristics for weight, length and WFL followed the same patterns
as outlined in the second aim (Chapter 5). One group, termed “faster growth”, had a faster
rate of growth paired with higher deceleration and another group, termed “slower growth”,
demonstrated a slower rate of growth and lower deceleration (Tables 3-4 and Figure 2).
Ten SNPs met the statistical power threshold exceeding 0.80 to detect main effects
(Table 2). Of those selected SNPs, half met a nominal statistical significance of 0.05. Lack of
statistical significance for the remaining SNPs may be due to differences between the sample
and assumptions made in power calculations including allele frequency and effect size. All
five of the significant SNPs matched the direction of the association found in the source
studies. The traits represented by these five significant SNPs included HDL-C (n=2), LDL-C
(n=1), and TG (n=2). We also evaluated main effects for the three lipid-specific risk scores,
and the LDL-C risk score (0.81, SD=0.44, p=0.07) was not significant at the specified alpha
level of 0.05 unlike the risk scores for HDL-C (0.50, SD=014, p<0.001) and log(TG) (0.02,
SD=0.01, p=0.01).
Upon analyses for effect modification, one candidate SNP was statistically significant
after correction for multiple comparisons in the LGMM analyses. The rs11076175 G allele
indicated a negative additive association with LDL-C (mg/dL) for the higher weight velocity
group (-14.29, 95% CI = -26.37, -2.21) compared to the low velocity group that had a positive
association with LDL-C (22.63, 95% CI = 10.47, 34.78) (Tables 5 and 6). Lastly, we did not
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find any significant differences between the growth classes and risk score-lipid associations
(Appendix E, Tables E.3 and E.6).
No product terms representing gene-environment interaction in the models using SITAR
growth parameters were significant after correction for multiple comparisons (Appendix E.
Table E.7). We provide a figure of the model (Figure 3) for the rs11076175 variant (G allele)
described above and its relationship with the weight velocity SITAR parameter and LDL-C
trait to illustrate the alternate approach to characterizing the gene-environment interaction,
although not nominally significant at the 0.05 level. These estimates also serve as a means to
verify the direction of association found in the latent growth groups. First, the LDL-C levels
remain constant across different rates of weight growth for the group with zero G alleles.
With one or more more G alleles, there is an inverse relationship between the weight velocity
SITAR parameter and LDL-C suggesting a protective role of faster velocity as also suggested
in the LGMM model for the same variant.
6.5 Discussion
In these analyses we assessed the potential for infant growth classes to function as
effect modifiers of SNP-lipid associations. Using two different approaches to assess infant
growth, we found little evidence to support the hypothesis that growth modified SNP-lipid
associations. The one finding from LGMM analyses suggested that slower weight growth
for males demonstrated a deleterious association between the G allele of rs11076175 and
LDL-C compared to the faster weight growth group, which displayed an inverse and protective
association with LDL-C. Interestingly, the lipid trait identified in this analysis, LDL-C, was
different from the primary lipid trait identified in the source – HDL-C (Zubair et al. 2016).
Prior to the assessment of infant growth as an effect modifier we examined infant growth
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groups as an exposure and lipid traits as outcomes in the second aim. Parallel to the finding
from these LGMM analyses, we found a deleterious role of slower WFL growth during
infancy influencing unfavorable lipid outcomes later in life. In the second aim, the strongest
associations were between the slower WFL growth class and higher LDL-C. In the third aim,
when estimating the additive association between the G allele for rs11076175 and LDL-C,
we only found a positive, deleterious, association in the slower weight growth class versus
the faster weight growth class. Conversely faster weight growth appeared to be protective
when evaluating infant growth groups as both an exposure with lipid traits as outcomes or
an effect modifier of SNP-lipid associations.
This extension of a protective of effect found in faster growth, either as an exposure or
effect modifier, also applies to the SITAR analytic approach. In the second aim, we found
a positive association between the SITAR length velocity parameter and HDL-C, which
indicates a protective role of faster length growth. Although not statistically significant in the
third aim, the product term for the HDL-C genetic risk score and length velocity suggests a
protective positive increase in the GRS-lipid association upon increasing length velocity (1.37,
SE=1.33) (Appendix E, Table E.7). This same protective direction of effect for the length
velocity parameter was also consistent for other lipid outcomes such as LDL-C and TG.
No risk scores demonstrated statistical significance as effect modifiers following adjust-
ment for multiple comparisons, and these measures were expected to be better powered
than single candidate variants. Besides the low sample size, heterogeneity in the statistical
interaction product term is another reason that may explain the lack of effect found in these
analyses (Aschard 2016). As a post-hoc analysis we examined the distribution of two different
statistical interaction terms from the SITAR analyses representing the difference in slopes
for the association between continuous growth parameter terms and continuous lipid traits
across different genotypes (Figures 4 and 5). Upon visual inspection, these plots confirm
heterogeneity of the direction of the product term as shown with distributions centered around
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a median of zero. Although the sample size is small, the consistency of the distribution
across different growth parameters and lipid outcomes in the plots do suggest a lack of shared
mechanism for all the SNPs used in the risk score that would shift the distribution – reflecting
the lipid-specific risk scores – of the products terms away from zero. Given the complex
and diverse nature of the genetic architecture of lipid metabolism, a variety in mechanisms
as reflected by the distribution of interaction terms is a plausible explanation. Risk scores
appear to have low power to detect effect modification in this context, and a more meaningful
approach may be to focus on individual SNPs in the tails of these distributions and their
respective unique mechanisms.
The rs11076175 G allele, found to have different additive associations with LDL-C across
growth classes, is an intronic variant of the CETP gene, associated with LDL-C, HDL-C
and TG (Willer et al. 2013) as well as being related to liver tissue expression levels (“CETP
Gene - GeneCards” 2018) and reverse cholesterol transport. An inverse association has been
reported between the G allele and HDL-C traits (Zubair et al. 2016) (Appendix D, Table
D.1), indicating a deleterious effect, i.e. lowering HDL-C levels. Our results indicate an
inverse association between the G allele and LDL-C for the faster weight growth group of
male participants (adjusted beta = -13.67, 95% CI = -25.05, -2.29) compared to the slower
weight growth males (adjusted beta = 21.07, 95% CI = 8.98, 33.16) (Table 6). Considering
prior evidence demonstrates a deleterious effect for this variant, we would expect a positive
association between the G allele and LDL-C, also considered a deleterious effect. However,
this association only exists for the slower weight growth group indicating a protective effect
given fast weight growth in the early infancy period. This protective effect within the male
faster weight growth group extends to the association between the rs11076175 G allele and
HDL-C, although the difference is not significant after adjusting for multiple comparisons
(Appendix E, Table E.1).
In addition to the source study of this variant (Zubair et al. 2016), rs11076175 was
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also inversely associated with HDL-C in two other studies (Carlquist et al. 2011; Radovica
et al. 2013) as well as this one, further confirming its overall deleterious role. A more
recent study demonstrated a strong association between rs11076175 and LDL subfractions,
replicated across studies, and no statistically significant association with total LDLs (Shim et
al. 2015) in a European ancestral group (n=1,868). These studies reflect the complex role
that this variant has in lipid metabolism, linking both LDL-C and HDL-C via the transport
mechanism. Our results add to this complexity by providing evidence that direction of a
SNP-lipid association may depend on early life growth patterns.
Mechanisms that may explain effect modification of the SNP-lipid association through
infant growth patterns may be mediating factors, such as epigenetic activity, on a causal
pathway to disordered lipid metabolism. Prior studies suggest that the early postnatal period
may be a window for epigenetic activity leading to permanent lipid metabolism outcomes
(Hanson and Gluckman 2014; L. Liu, Li, and Tollefsbol 2008b; Lee et al. 2013). Investigations
of epigenetic processes have provided a plausible biological mechanism explaining the rela-
tionship between abnormal postnatal growth and lipid outcomes in later life (Vo and Hardy
2012; Sohi et al. 2011; Khanal et al. 2015; Yates et al. 2009; Chechi, McGuire, and Cheema
2009). In particular, dietary manipulations inducing abnormal growth prior to weaning in
animal models are associated with methylation and histone modifications (Heerwagen et
al. 2010; Robertson 2005; Cedar and Bergman 2009; Guéant et al. 2014a; Rueda-Clausen,
Morton, and Davidge 2011; Feil and Fraga 2012; Kanherkar, Bhatia-Dey, and Csoka 2014).
This epigenetic activity following altered postnatal growth in the animal models may signal
effect mediation (Ong, Lin, and Holbrook 2015; Ladd-Acosta and Fallin 2016) along the
path between postnatal growth and lipid metabolism. Given the strong association between
epigenetic activity and gene-environment interactions (Grishkevich and Yanai 2013; L. Liu,
Li, and Tollefsbol 2008a) this mechanism may explain differences in SNP-lipid associations
found across early infant growth patterns.
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6.5.1 Strengths and Limitations
The LGMM statistical approach to characterize infant growth is one limitation, which
uses latent classes to categorize growth. In terms of the approach to categorize growth,
latent classes offer the opportunity to separate out unobserved, but heterogeneous groups
allowing for greater power to detect effects. However, even after following best practices in
characterizing these latent classes, this data driven approach may lead to reified concepts of
growth that do not relate to actual growth patterns found in the population from which the
sample was drawn. We attempted to counter this problem by concurrently analyzing the
data using another method to characterize growth that confirmed the direction of association
found in the latent approach using observed data and parameters.
The sample size less than 500 participants also affected our power to detect effects, and
although we did not detect statistically significant associations, that does not mean effects
do not exist. We may have missed other associations given lack of precision. Coefficients for
some associations were clinically meaningful and future analyses with similar aims but larger
sample sizes may have more breadth in conclusions than we were able to produce. Similarly,
we found one association suggesting a protective effect for faster growth in early infancy,
but the variation in effect sizes as indicated in the post-hoc analyses of gene-environment
interaction terms suggest that effects in the other direction, i.e. deleterious, may occur.
Some strengths of this study include a rare combination of well-characterized growth
measures in the early postnatal period, genotyping, and measurement of cardiovascular
disease risk factors in adolescence in an infancy cohort. Also, we chose candidate variants
that have been rigorously tested in previous GWAS, generalize to HL groups, and further
filtered in these analyses to provide strong evidence of marginal effects in our relatively small
sample. Finally, we used a novel latent class approach to distinguish growth when assessing
gene-environment interactions.
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6.5.2 Conclusion
We found little evidence to support the hypothesis that early infant growth is an exposure
modifying SNP-lipid associations. Although the latent growth approach may distinguish
heterogeneous growth patterns, the sample size did not exceed 500 people preventing more
precise estimates despite some large estimated differences across growth patterns. Further
study with larger sample sizes can offer more precise estimates to assess effect modification of
SNP-lipid associations – both the individual estimates for certain SNPs and their combination
in the form of risk scores. Lipid metabolism is a complex interplay of genetic and environmental
factors across the lifespan, and the potential for gene-environment interactions in the early
postnatal period remains of interest and a promising area of investigation.
6.6 Tables
Table 6.1: (MS3: Table 1) Descriptive statistics for sample stratified by sex of child.
Male Female Overall
n 254 226 480
Maternal Age (years) (median [IQR]) 26.2 [21.2, 31.0] 26.4 [21.9, 31.0] 26.3 [21.6, 31.0]
Graffar Index (median [IQR]) 32.0 [27.0, 38.0] 32.0 [27.0, 37.0] 32.0 [27.0, 37.0]
Maternal education (years) (median [IQR]) 10.0 [8.0, 12.0] 10.0 [8.0, 12.0] 10.0 [8.0, 12.0]
Randomization status = No added iron (%) 126 (49.6) 94 (41.6) 220 (45.8)
LDL-C (mg/dL) (median [IQR]) 89.3 [76.1, 104.4] 94.9 [82.1, 109.2] 92.0 [78.3, 106.9]
HDL-C (mg/dL) (median [IQR]) 37.0 [31.2, 42.7] 41.7 [35.7, 49.5] 39.4 [33.2, 46.2]
TG (mg/dL) (median [IQR]) 71.5 [55.9, 100.8] 75.6 [57.6, 99.5] 73.7 [56.5, 100.6]
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Table 6.2: (MS3: Table 2) Comparison of candidate SNP-lipid associations from literature
and in the SLS sample.
Source Studies SLS estimates
p-value<0.05a SNP/risk score Authorb Chr Trait Coded allele Beta EAF Coded allelec Uncoded allele Estimate (SE), p-value MAF
rs11604424 Wu 11 TG T -0.101 - T C -0.05 (0.03), 0.0743 0.46
rs12678919 Teslovich 8 TG G -0.17 - G A 0 (0.05), 0.9471 0.07
rs12740374 Zubair 1 LDL A/C -7.9 0.21 T G -3.36 (1.76), 0.0578 0.21
rs3135506 Wu 11 TG C 0.121 - C G -0.03 (0.05), 0.5487 0.1
rs3741298 Wu 11 TG T -0.108 - T C -0.05 (0.03), 0.0756 0.45
No
risk score - - LDL - - - - - 0.81 (0.44), 0.0666 -
rs11076175 Zubair 16 HDL A/G 2.76 0.79 G A -2.21 (0.93), 0.0173 0.17
rs1260326 Teslovich 2 TG T 0.115 - C T -0.07 (0.03), 0.0146 0.31
Tada 16 HDL A 0.21 - A C 3.14 (0.75), 0 0.3
rs247617
Zubair 16 HDL A/C 3.11 0.3 A C 3.14 (0.75), 0 0.3
Wu 19 LDL T -0.505 - T C -11.93 (4.61), 0.01 0.02
rs7412
Zubair 19 LDL A/G -16.91 0.05 T C -11.93 (4.61), 0.01 0.02
Ko A 11 TG G 1.89 NR C G -0.07 (0.03), 0.0161 0.36
rs964184
Teslovich 11 TG C -0.234 - C G -0.07 (0.03), 0.0161 0.36
- - HDL - - - - - 0.5 (0.14), 6e-04 -
Yes
risk score
- - log(TG) - - - - - 0.02 (0.01), 0.0108 -
a p-value < 0.05 for SNP-lipid additive association in Santiago Longitudinal Study (SLS).
b Sources (and reference for beta units): Ko 2014 (Ko et al. 2014), Below 2016 (Below
et al. 2016), Teslovich 2010 (Teslovich et al. 2010), Zubair 2016 (Zubair et al. 2016), Tada
2014 (Tada et al. 2014), Wu (Wu et al. 2013).
c Coded allele in SLS is minor allele.
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Table 6.3: (MS3: Table 3) Parameters for the growth classes
Categories Intercept Slope Quadratic
Sex of child Trajectory type Class Order Not adjusted Adjusteda Not adjusted Adjusteda Not adjusted Adjusteda
Low 50.119 50.252 3.343 3.165 -0.098 -0.100
Height High 52.064 50.815 3.654 3.397 -0.182 -0.124
Low 3.573 3.582 1.016 0.907 -0.054 -0.041
Weight High 3.527 3.493 1.376 1.259 -0.085 -0.073
Low 70.877 71.167 13.114 11.706 -0.943 -0.765
Both
WFL High 67.953 67.880 19.684 18.177 -1.781 -1.595
Low 49.742 50.532 3.272 3.171 -0.092 -0.099
Height High 51.892 50.835 3.425 3.406 -0.160 -0.124
Low 3.481 3.632 0.847 0.853 -0.030 -0.031
Weight High 3.655 3.474 1.188 1.264 -0.072 -0.083
Low 69.770 70.610 11.736 11.719 -0.736 -0.738
Female
WFL High 70.466 70.455 18.220 18.342 -1.641 -1.648
Low 49.851 50.398 2.629 3.351 0.077 -0.116
Height High 51.067 51.345 3.641 3.623 -0.158 -0.144
Low 3.577 3.515 0.972 0.986 -0.041 -0.039
Weight High 3.606 3.742 1.408 1.359 -0.101 -0.100
Low 71.112 68.958 13.092 12.701 -0.878 -0.718
Male
WFL High 69.085 71.761 20.030 18.129 -1.871 -1.666
a Adjusted for sex of child in pooled sample, randomization status, and socioeconomic status.
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Table 6.4: (MS3: Table 4) Counts of people in each latent class, n
Categories Low High
Sex of child Trajectory type no yes no yes
Height 342 149 138 331
Weight 414 392 66 88Both
WFL 365 355 115 125
Height 149 79 77 147
Weight 158 172 68 54Female
WFL 178 181 48 45
Height 12 72 242 182
Weight 141 149 113 105Male
WFL 139 88 115 166
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Table 6.5: (MS3: Table 5) Latent growth class pairwise differences (95% CI) in coefficient of
association between distal lipid outcome (mg/dL) and candidate SNP at nominal significance
levels.
Categories Slower vs Faster Overall test: p-value, (Chi-sq, df)
Sex of child Outcome Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Female Height LDL rs3135506 21.57 (5.35, 37.78) 18.41 (-2.23, 39.06) 0.009, (6.79,1) 0.080, (3.06,1)
Female Weight LDL rs247617 22.42 (9.08, 35.76) -1.91 (-19.52, 15.70) 0.001, (10.85,1) 0.832, (0.04,1)
Female WFL LDL rs247617 19.29 (5.90, 32.69) 26.19 (-25.13, 77.51) 0.005, (7.97,1) 0.317, (1.00,1)
Male Height HDL HDL risk score 3.61 (1.28, 5.94) 0.44 (-0.80, 1.68) 0.002, (9.24,1) 0.488, (0.48,1)
Male Height LDL rs11076175 -10.89 (-32.92, 11.14) 36.48 (14.82, 58.14) 0.333, (0.94,1) 0.001, (10.90,1)
Male Weight LDL rs11076175 21.09 (6.60, 35.57) 34.74 (17.00, 52.48) 0.004, (8.14,1) 0.000, (14.73,1)
Male WFL LDL rs11076175 20.01 (5.98, 34.04) – 0.005, (7.81,1) NA, ( NA,NA)
Note:
Bold values indicate Bonferroni corrected statistical significance at alpha level = 0.05.
a Adjusted for sex of child in pooled sample, randomization status, and principal components.
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Table 6.6: (MS3: Table 6) Coefficient for association between lipid distal outcome and SNPs for SNPs with pairwise differences
across growth class groups meeting a nominal significance at an alpha level of 0.05.
Latent Class Growth Groups
Categories Slower Faster
Sex Outcome Lipid snp Not adjusted Adjusteda Not adjusted Adjusteda
Female Height LDL-C rs3135506 4.58 (-5.76, 14.91) 9.72 (-4.08, 23.53) -16.99 (-27.83, -6.16) -8.69 (-20.28, 2.90)
Female Weight LDL-C rs247617 3.41 (-3.10, 9.93) -1.53 (-10.21, 7.16) -19.01 (-29.15, -8.86) 0.38 (-12.64, 13.41)
Female WFL LDL-C rs247617 0.52 (-5.33, 6.38) 3.47 (-11.39, 18.32) -18.77 (-29.39, -8.15) -22.72 (-63.04, 17.60)
Male Height HDL-C HDL risk score 3.89 (1.53, 6.25) 1.13 (0.15, 2.11) 0.28 (-0.15, 0.71) 0.69 (0.12, 1.26)
Male Height LDL-C rs11076175 -8.90 (-27.65, 9.84) 25.43 (11.97, 38.90) 1.99 (-4.79, 8.76) -11.05 (-23.73, 1.64)
Male Weight LDL-C rs11076175 11.02 (0.86, 21.18) 21.07 (8.98, 33.16) -10.06 (-17.92, -2.21) -13.67 (-25.05, -2.29)
Male WFL LDL-C rs11076175 9.83 (0.15, 19.51) 30.93 ( NA, NA) -10.18 (-17.90, -2.46) -13.49 ( NA, NA)
a Adjusted for sex of child in pooled sample, randomization status, and principal components.
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6.7 Figures
Figure 6.1: (MS3: Figure 1) Representation of structural equation model for adjusted
analysis
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Figure 6.2: (MS3: Figure 2) Growth trajectories by type of trajectory, sex of child and adjustment status.
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Figure 6.3: (MS3: Figure 3) Plot of association between infant weight SITAR growth
velocity parameter and LDL-C levels by rs11076175 allele frequency.
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Figure 6.4: (MS3: Figure 4) Histogram for slope differences between group with 2 alleles
and 0 alleles of SNPs used in lipid-specific risk scores. (Slope represents association between
SITAR growth parameters and lipid traits)
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Figure 6.5: (MS3: Figure 5) Histogram for slope differences between group with 1 allele
and 0 alleles of SNPs used in lipid-specific risk scores. (Slope represents association between
SITAR growth parameters and lipid traits)
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CHAPTER 7: DISCUSSION
7.1 Summary of overall study aims and results
7.1.1 Study aims
This project contained three aims, the first of which characterized growth trajectories in
the SLS sample and estimated their association with sociodemographic predictors. The second
part contained the central premise of the dissertation: to estimate the association between
infant growth as an exposure and lipid levels during adolescence as an outcome. The last aim
estimated effect modification of the exposure-outcome association between genetic variants
linked and lipid traits. The overarching goal uniting these aims is to better understand the
role of infant growth patterns as a factor influencing dyslipidemia in adolescence.
To summarize, the three aims are as follows:
• Aim 1: Characterize individual infant growth trajectories and identify sociodemo-
graphic predictors of such growth in a Chilean infancy cohort.
– Aim 1.1: Characterize infant growth trajectories with nonlinear mixed effects
models (Cole, Donaldson, and Ben-Shlomo 2010), which measure individual shifts
relative to the population average curve in: (a) size (above or below on the outcome
scale), (b) tempo (to the right or left on the age scale), and (c) velocity (steep or
shallow slope). Assess the association between postnatal growth characteristics and
sociodemographic predictors of these postnatal growth characteristics including a
socioeconomic index and maternal education.
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– Aim 1.2: Determine presence of child growth trajectory latent classes with latent
growth mixture models (LGMM).
• Aim 2: Examine the association between infant growth trajectory characteristics and
lipid levels at 17 years of age.
• Aim 3: Assess gene-environment interaction between growth trajectory characteristics
and genetic variants underlying lipid metabolism at 17 years of age.
Several points regarding lipids support investigation of these three proposed aims. First,
current estimates put the prevalence of dyslipidemia in children age 6 to 19 years at around
one in five children. This high level of a well established modifiable risk factor for ASCVD
alongside the known properties of dyslipidemia tracking into adulthood makes for a prime
interventional target. Second, race/ethnic groups show substantial heterogeneity in prevalence
levels with certain groups such as HL groups experiencing higher levels of dyslipidemia than
others putting this group at higher risk for later disease. Third, there are polygenic factors at
play as well. These polygenic factors include over 150 variants and can explain over twenty
percent of lipid trait variability making them viable variables to consider in the context of
GXE analyses.
Examining lipid outcomes following infant growth, results are inconsistent from obser-
vational human studies. However, the majority of studies underscore faster than average
growth being associated with adverse lipid outcomes such as higher TC and TG following
faster than average growth. These associations also found in animal studies operating under
a more controlled environment, which reinforces the idea that adverse levels of ASCVD risk
factors in later life may follow earlier abnormal growth patterns.
Molecular processes form one biologically plausible explanation linking postnatal growth
with lipid outcomes. Some of these domains relate to liver function, gene expression timing
windows during the postnatal period, and epigenetic changes following postnatal diet and
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subsequent growth manipulation. Thus far the most convincing evidence arises from animal
models, and these reflect a growing body of literature that demonstrate a programming effect
of postnatal growth on lipid metabolism later in life span.
In sum, these aims can 1) provide a detailed characterization of infant growth and its
association with lipids, 2) assess postnatal growth as an effect modifier, and 3) describe
these relationships in a HL sample – the combination of which is previously lacking in prior
research on these topics. These three areas can provide information that is needed to clarify
the role of infant growth as a factor influencing adverse lipid levels and metabolism in diverse
populations.
7.1.2 Results
In assessing the relationship between early infancy anthropometric growth and sociode-
mographic position in manuscript 1 (Chapter 4), we observed that slower linear (length)
growth was associated with lower socioeconomic position. Previous studies have reported a
similar association between linear growth and maternal education. Furthermore, lower SEP
was also associated with a later WFL growth timing. We restricted our investigation down
to a narrower window of time, and this association matches those found in larger spans of
time of the first year of life or beyond.
In the second manuscript (Chapter 5), we examined both latent and observed early
infancy growth constructs and their association with lipid levels in adolescence. Both of these
approaches supported an association between faster growth and favorable lipid levels. In
the SITAR model we found a positive association between linear (length) growth from birth
to five months and HDL-C levels at 17 years. In the latent growth mixture model models
the strongest associations were between slower weight and WFL growth and higher LDL-C
values. In either situation faster growth appears to act as a protective role instead of the
142
deleterious one as hypothesized.
Lastly, in the third manuscript (Chapter 6) we estimated SNP-lipid associations across
different latent infant growth groups as a way to assess gene-environment interaction. We
found one SNP, rs11076175 (CETP), in which the faster growth group demonstrated a
favorable association between the coded G allele and the LDL-C trait. We found only one
significant gene-environment interaction that supports a hypothesis of growth during early
infancy influencing lipid metabolism at a molecular level. Notably, lipid-specific risk scores
were one measure we expected to be adequately powered to find effect modifications. However,
we did not detect significant terms, perhaps due to the heterogeneity in the direction of
interaction terms for the SNPs forming the risk scores. This finding is interesting and a
reminder of the diverse genetic pathways to lipid metabolism changes.
The hypotheses in this research project pivoted around the idea that faster growth
during early infancy would be an unfavorable exposure. However, the findings from these last
two aims offer support that faster growth during early infancy, i.e. prior to six months, may
be protective. The fact that this period has been understudied, partly due to the dearth of
high quality data available for analysis, may explain the novelty of these findings. If true, and
future studies are able to confirm these findings, it underscores the need to collect more data
during this period, which may offer a great potential for public health returns on intervention.
7.2 Strengths and Limitations
7.2.1 Strengths
First, this research project, which includes detailed postnatal growth trajectory infor-
mation and its association with lipid levels, offers information on a common and strong
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predictor of a disease risk factor in a HL population. The HL group currently experiences a
high prevalence of cardiovascular disease risk factors relative to people of European ancestry
(Rodrigues et al. 2013; Daviglus et al. 2012; Frank et al. 2014). Also, the HL population is a
fast growing demographic group and will compose ever larger proportions of those suffering
from ASCVD, highlighting the importance of prevention. Focusing attention on early life risk
factors such as dyslipidemia, and their effects on ASCVD, is one way to stress the importance
of preventing future disease in an underserved group.
Second, having both anthropometric observations in an infancy cohort combined with
genotyping in normal birthweight groups and outcome measures in adolescence is uncommon
in cohort data. Another strength of this work is the availability of extensive anthropometric
measures during early infancy combined with growth analyses that can leverage this large
number of measures. These unique features can further confirm the relationship between
accelerated postnatal growth and abnormal lipid metabolism – fine-scale evidence currently
lacking in human observational studies.
Finally, these three aims converge into targeted hypotheses using information from prior
genetic and environmental studies relating to infant growth and lipids. Analyses stemming
from these hypotheses were unique and offered evidence regarding the concept that changes
in postnatal growth may also result in changes to the association between genetic structures
and lipid outcomes later in life.
7.2.2 Limitations
First, in aim 2, there is only an estimate of the total effect with postnatal growth as an
exposure and dyslipidemia in adolescence as the outcome (Figure 2.1). Estimating direct
and indirect effects (Richiardi, Bellocco, and Zugna 2013), i.e. paths through mediators, is
important and an area for potential future research. Estimating the impact of growth on
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Figure 7.1: Directed Acyclic Diagram (DAG) to describe paths composing total effect.
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later weight and the subsequent consequences on lipid levels in adolescence (the blue arrows
in Fig. 7.1) would be of interest relative to the size of effect through other paths including
the hypothesized epigenotype (the red arrows in Fig. 7.1).
Although animal evidence demonstrates a link between postnatal growth and lipid levels
later in life, environmental conditions for humans are not controlled. Many cumulative
stressors over the lifetime may account for the variation in the health outcome (Koletzko
2009). In fact, there are arguments that early life exposures are overstated and it is really
later life exposures such as socioeconomic status in the lifecourse that affect and are more
proximal to cardiometabolic outcomes in later life (Gustafsson et al. 2010). Future research
delineating the importance of each path will be of interest.
Also, several other limitations of this research include at the very least several items
such as residual confounding (Koletzko 2009), a frequently mentioned limitation for any
research based on observational data. Whether results generalize from this sample to other
racial/ethnic groups is also a question. Associations between the growth exposure and
dyslipidemia outcomes from one HL subgroup may not generalize to other subgroups given
the variability in outcome measures present in HL subgroups (Rodriguez et al. 2014).
Lastly, this infancy cohort selected healthy normal birthweight infants into the cohort so any
information on low birthweight babies is lacking.
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7.3 Contributions to Public Health
The collection of aims described here will provide an epidemiological perspective on
early life determinants of chronic disease in an understudied HL subgroup. This work
is one step towards streamlining strong experimental evidence from animal models with
observational human data to better understand potential causes of lipid dysregulation later
in life. Confirming results found in animal models in human studies is essential prior to any
steps towards prevention (Tain and Joles 2015). Specifically, abnormal postnatal growth
may stem from overnutrition, which in turn may permanently and adversely alters genetic
expression levels relating to lipid metabolism. If reversible, insight into this process can also
enable a better understanding of potential public health interventions that generalize to more
diverse populations than those of European descent.
Interventions addressing postnatal growth will be a challenging area to address. In
animal models, modifiable factors also exist including dietary changes and supplements such
as folic acid, fish oil and resveratrol, which promote favorable lipid metabolism later in life (Vo
and Hardy 2012; Sohi et al. 2015; Li et al. 2015; Lillycrop and Burdge 2012). However, using
supplements as an intervention is in its early phase and may not always yield anticipated
beneficial results (Costa et al. 2016). Very recent work points towards epigenetic interventions
that target target ”lysine and arginine histone methyltransferases” (Keating and El-Osta
2015), also indicating the importance of considering causal factors on the molecular level.
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Figure 7.2: Intervention across the life course and chronic disease (Hanson et al 2011).
Given the DOHaD paradigm, a window of exposure with potential for risk also implies
a window for prevention. Identifying a modifiable factor would have the potential for
downstream public health significance with small shifts in development at an early age leading
to very large differences in health at later ages (Fig. 7.2 (Hanson et al. 2011)) when efforts
at changing behavior are more difficult. Furthermore, these shifts may extend to future
generations within the metabolic disease paradigm given recent evidence from animal models
that demonstrate persistence of early life programming across generations (Gonzalez-Bulnes
et al. 2014). This area of study has the potential to addresses a “vicious cycle” of metabolic
impairment (Loche and Ozanne 2016; Wells 2016).
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APPENDIX A: GRAFFAR INDEX COMPONENT DESCRIPTION
Table A.1: Description of items used for Graffar index
Graffar item Scale n(%)
n 1412
No. people in hh ’eating from 1 pot’ (%) 1: 1-3 230 (16.3)
2: 4-6 865 (61.3)
3: 7-9 254 (18.0)
4: 10-12 55 ( 3.9)
5: 13-15 6 ( 0.4)
6: over 16 2 ( 0.1)
Father’s presence in household (%) 1: father is present; not left hh 1197 (84.8)
3: left hh but sends money 66 ( 4.7)
4: partially left hh 38 ( 2.7)
6: completely gone 111 ( 7.9)
Head of household’s highest educational level
(%)
1: university completed 12 ( 0.9)
2: university not completed 9 ( 0.6)
3: h.s. or technical studies completed 325 (23.0)
4: completed 8th grade 664 (47.1)
5: did not reach 8th grade 382 (27.1)
6: no schooling 19 ( 1.3)
Property ownership (%) 1: owned 269 (19.1)
2: home mortgage 83 ( 5.9)
3: rent 243 (17.2)
4: given to you as a gift 117 ( 8.3)
5: squatters w tents or construction 7 ( 0.5)
6: lving in back of main house 693 (49.1)
Type of house construction (%) 1: very large house 15 ( 1.1)
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Table A.1: Description of items used for Graffar index (continued)
Graffar item Scale n(%)
2: smaller house 181 (12.8)
3: tiny concrete house 330 (23.4)
4: self-constructed home 398 (28.2)
5: wooden house 94 ( 6.7)
6: wooden house w/ less than three rooms 394 (27.9)
Characteristics of the kitchen (%) 1: independent kitchen in one room 931 (65.9)
6: kitchen in a room with multiple uses 481 (34.1)
Sewage,plumbing (%) 1: inside plumbing 1402 (99.3)
5: out house 9 ( 0.6)
6: just go in woods 1 ( 0.1)
Water (%) 1: water from inside home faucet 949 (67.2)
6: water from outside faucet 463 (32.8)
No. times garbage collected per week (%) 1: more than 4x/week 6 ( 0.4)
2: 3 times/week 1288 (91.2)
3: 2 times/week 117 ( 8.3)
6: never 1 ( 0.1)
Total count of previous six goods,possessions
(tv, washing machine, stereo, refrig., car) (%)
1: 13-15 (own all six goods) 77 ( 5.5)
2: 10-12 311 (22.3)
3: 7-9 302 (21.6)
4: 4-6 277 (19.9)
5: 1-3 374 (26.8)
6: 0 54 ( 3.9)
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APPENDIX B: SITAR MODEL FIT
Table B.1: Nonlinear mixed effects model fit e valuation: BIC for all evaluated models
Trajectory type Model ID Model description BICa
no random effects no random effects NA
m2 random size (alpha0) -19546.4
m3 random tempo (beta0) -17232
m4 random velocity (beta1) -18323
m5 random tempo and velocity (beta0 and beta1) -21901.5
m5.strat m5 + sex-spec effects -22123.4
m5.strat2 m5.strat + sex-spec corr structure -22107.5
m6 random size and tempo (alpha0 and beta0) -21740.4
m7 random size and velocity (alpha0 and beta1) -21629.8
Weight
m8 random size, tempo and velocity (alpha0, beta0, and beta1) -22940.66
no random effects no random effects NA
m2 random size (alpha0) -37399.5
m3 random tempo (beta0) -36684.1
m4 random velocity (beta1) -34985.7
m5 random tempo and velocity (beta0 and beta1) -37820
m5.strat m5 + sex-spec effects -38000.74
m5.strat2 m5.strat + sex-spec corr structure -37978.2
m6 random size and tempo (alpha0 and beta0) -37381.5
Length
m7 random size and velocity (alpha0 and beta1) -37819.9
no random effects no random effects NA
m2 random size (alpha0) -21147.2
m3 random tempo (beta0) -18852.1
m4 random velocity (beta1) -20549.9
m5 random tempo and velocity (beta0 and beta1) -22598
m5.strat m5 + sex-spec effects -22761.2
m5.strat2 m5.strat + sex-spec corr structure -22751.3
m6 random size and tempo (alpha0 and beta0) -22808.5
WFL
m7 random size and velocity (alpha0 and beta1) -22484.6
a Bold values indicate lowest value within a trajectory evaluation.
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Table B.2: Model variance and covariance for random effects of all evaluated models
Trajectory type Model id Model type random effect Variance SD Correlation
Weight m2 random size (alpha0) alpha0 0.01 0.09 NA
Weight m2 random size (alpha0) Residual 0.00 0.06 NA
Weight m3 random tempo (beta0) beta0 0.27 0.52 NA
Weight m3 random tempo (beta0) Residual 0.00 0.07 NA
Weight m4 random velocity (beta1) beta1 0.08 0.28 NA
Weight m4 random velocity (beta1) Residual 0.00 0.06 NA
Weight m5 random tempo and velocity (beta0 and beta1) beta0 0.13 0.36 beta0
Weight m5 random tempo and velocity (beta0 and beta1) beta1 0.06 0.23 0.141
Weight m5 random tempo and velocity (beta0 and beta1) Residual 0.00 0.04
Weight m5.strat m5 + sex-spec effects beta0 0.13 0.36 beta0
Weight m5.strat m5 + sex-spec effects beta1 0.05 0.22 0.106
Weight m5.strat m5 + sex-spec effects Residual 0.00 0.04
Weight m5.strat2 m5.strat + sex-spec corr structure beta0.Male 0.12 0.34 NA
Weight m5.strat2 m5.strat + sex-spec corr structure beta1.Male 0.05 0.22 NA
Weight m5.strat2 m5.strat + sex-spec corr structure beta0.Female 0.14 0.37 NA
Weight m5.strat2 m5.strat + sex-spec corr structure beta1.Female 0.04 0.21 NA
Weight m5.strat2 m5.strat + sex-spec corr structure Residual 0.00 0.04 NA
Weight m6 random size and tempo (alpha0 and beta0) alpha0 0.02 0.13 alpha0
Weight m6 random size and tempo (alpha0 and beta0) beta0 0.25 0.50 0.734
Weight m6 random size and tempo (alpha0 and beta0) Residual 0.00 0.04
Weight m7 random size and velocity (alpha0 and beta1) alpha0 0.01 0.10 alpha0
Weight m7 random size and velocity (alpha0 and beta1) beta1 0.06 0.25 0.462
Weight m7 random size and velocity (alpha0 and beta1) Residual 0.00 0.04
Weight m8 random size, tempo and velocity (alpha0, beta0, and beta1) alpha0 0.01 0.12 alpha0
Weight m8 random size, tempo and velocity (alpha0, beta0, and beta1) beta0 0.23 0.47 0.604
Weight m8 random size, tempo and velocity (alpha0, beta0, and beta1) beta1 0.06 0.25 0.346
Weight m8 random size, tempo and velocity (alpha0, beta0, and beta1) Residual 0.00 0.03
Length m2 random size (alpha0) alpha0 0.00 0.03 NA
Length m2 random size (alpha0) Residual 0.00 0.02 NA
Length m3 random tempo (beta0) beta0 0.31 0.56 NA
Length m3 random tempo (beta0) Residual 0.00 0.02 NA
Length m4 random velocity (beta1) beta1 0.04 0.21 NA
Length m4 random velocity (beta1) Residual 0.00 0.02 NA
Length m5 random tempo and velocity (beta0 and beta1) beta0 0.17 0.41 beta0
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Table B.2: Model variance and covariance for random effects of all evaluated models (continued)
Trajectory type Model id Model type random effect Variance SD Correlation
Length m5 random tempo and velocity (beta0 and beta1) beta1 0.02 0.13 0.327
Length m5 random tempo and velocity (beta0 and beta1) Residual 0.00 0.02
Length m5.strat m5 + sex-spec effects beta0 0.16 0.41 beta0
Length m5.strat m5 + sex-spec effects beta1 0.01 0.12 0.268
Length m5.strat m5 + sex-spec effects Residual 0.00 0.02
Length m5.strat2 m5.strat + sex-spec corr structure beta0.Male 0.17 0.42 NA
Length m5.strat2 m5.strat + sex-spec corr structure beta1.Male 0.01 0.11 NA
Length m5.strat2 m5.strat + sex-spec corr structure beta0.Female 0.15 0.39 NA
Length m5.strat2 m5.strat + sex-spec corr structure beta1.Female 0.02 0.12 NA
Length m5.strat2 m5.strat + sex-spec corr structure Residual 0.00 0.02 NA
Length m6 random size and tempo (alpha0 and beta0) alpha0 0.00 0.03 alpha0
Length m6 random size and tempo (alpha0 and beta0) beta0 0.00 0.00 -0.002
Length m6 random size and tempo (alpha0 and beta0) Residual 0.00 0.02
Length m7 random size and velocity (alpha0 and beta1) alpha0 0.00 0.03 alpha0
Length m7 random size and velocity (alpha0 and beta1) beta1 0.02 0.13 0.327
Length m7 random size and velocity (alpha0 and beta1) Residual 0.00 0.02
WFL m2 random size (alpha0) alpha0 0.00 0.07 NA
WFL m2 random size (alpha0) Residual 0.00 0.05 NA
WFL m3 random tempo (beta0) beta0 0.32 0.56 NA
WFL m3 random tempo (beta0) Residual 0.00 0.06 NA
WFL m4 random velocity (beta1) beta1 0.12 0.34 NA
WFL m4 random velocity (beta1) Residual 0.00 0.05 NA
WFL m5 random tempo and velocity (beta0 and beta1) beta0 0.13 0.36 beta0
WFL m5 random tempo and velocity (beta0 and beta1) beta1 0.10 0.31 0.125
WFL m5 random tempo and velocity (beta0 and beta1) Residual 0.00 0.04
WFL m5.strat m5 + sex-spec effects beta0 0.13 0.36 beta0
WFL m5.strat m5 + sex-spec effects beta1 0.08 0.29 0.107
WFL m5.strat m5 + sex-spec effects Residual 0.00 0.04
WFL m5.strat2 m5.strat + sex-spec corr structure beta0.Male 0.11 0.34 NA
WFL m5.strat2 m5.strat + sex-spec corr structure beta1.Male 0.09 0.30 NA
WFL m5.strat2 m5.strat + sex-spec corr structure beta0.Female 0.16 0.40 NA
WFL m5.strat2 m5.strat + sex-spec corr structure beta1.Female 0.08 0.27 NA
WFL m5.strat2 m5.strat + sex-spec corr structure Residual 0.00 0.04 NA
WFL m6 random size and tempo (alpha0 and beta0) alpha0 0.01 0.10 alpha0
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Table B.2: Model variance and covariance for random effects of all evaluated models (continued)
Trajectory type Model id Model type random effect Variance SD Correlation
WFL m6 random size and tempo (alpha0 and beta0) beta0 0.26 0.51 0.725
WFL m6 random size and tempo (alpha0 and beta0) Residual 0.00 0.04
WFL m7 random size and velocity (alpha0 and beta1) alpha0 0.01 0.08 alpha0
WFL m7 random size and velocity (alpha0 and beta1) beta1 0.12 0.34 0.486
WFL m7 random size and velocity (alpha0 and beta1) Residual 0.00 0.04
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APPENDIX C: LGMM MODEL FIT
Table C.1: LGMM fit statistics by type of outcome, pooled sample
AIC aBIC BLRT: chi-sq (df); p-value VLMR: chi-sq (df); p-value Entropy Observations
Outcome Number of classes quadratic cubic quadratic cubic quadratic cubic quadratic cubic quadratic cubic quadratic cubic
1 13564 13537 13583 13556 NA (NA); NA NA (NA); NA NA(NA); NA NA(NA); NA NA NA 667 667
2 13534 13496 13559 13523 39.92 (5); 0 52.942 (6); 0 39.92(5); 0.3786 52.942(6); 0.0728 0.302 0.313 667 667Length
3 13528 13487 13560 13523 15.835 (5); 0.08 20.152 (6); 0 15.835(5); 0.6147 20.152(6); 0.4961 0.546 0.672 667 667
1 24350 24350 24369 24370 NA (NA); NA NA (NA); NA NA(NA); NA NA(NA); NA NA NA 667 667
2 24105 24085 24130 24113 255.724 (5); 0 277.221 (6); 0 255.724(5); 0 277.221(6); 0 0.579 0.587 667 667
3 24070 24022 24102 24058 44.621 (5); 0 75.121 (6); 0 44.621(5); 0.0932 75.121(6); 0.3445 0.571 0.668 667 667WFL
4 NA 23989 NA 24033 NA 44.821 (6); 0 NA 44.821(6); 0.1693 NA 0.737 NA 667
1 3485 3428 3503 3448 NA (NA); NA NA (NA); NA NA(NA); NA NA(NA); NA NA NA 667 667
2 3205 3127 3230 3155 289.94 (5); 0 313.283 (6); 0 289.94(5); 0 313.283(6); 0 0.607 0.602 667 667Weight
3 3152 3035 3184 3071 62.699 (5); 0 104.416 (6); 0 62.699(5); 0.01 104.416(6); 0.0035 0.71 0.721 667 667
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APPENDIX D: MANUSCRIPT 3: LIPID LOCI IN HISPANIC ANCESTRY POPULATIONS (BOTH
THOSE UNIQUE TO HL ANCESTRAL POPULATIONS AND GENERALIZED TO EUROPEAN
ANCESTRAL POPULATIONS).
D.1 List of genetic variants used for the trait specific genetic risk scores and considered
in power calculations.
Table D.1: List of genetic variants used for the trait specific genetic risk scores.
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
1 HDL 1 rs4660293 Teslovich G A -0.035 NA G A -0.35 (1.03), 0.7349 0.14
2 HDL 1 rs1689800 Teslovich G A -0.034 NA G A -0.86 (0.74), 0.2464 0.31
3 HDL 2 rs1042034 Zubair A/G NA -1.080 0.77 T C -0.47 (0.79), 0.5568 0.27
4 HDL 3 rs2013208 Willer T C 0.025 NA T C -1.1 (0.73), 0.13 0.40
5 HDL 3 rs6805251 Willer T C 0.020 NA C T 0.42 (0.71), 0.5514 0.34
6 HDL 4 rs3822072 Willer A G -0.025 NA A G 0.49 (0.72), 0.4986 0.37
7 HDL 6 rs998584 Willer A C -0.026 NA A C -0.72 (0.73), 0.3242 0.43
8 HDL 7 rs4731702 Teslovich T C 0.029 NA T C 1 (0.7), 0.1564 0.33
9 HDL 8 rs28526159 Below JE T NA 0.077 0.62 T C 1.05 (0.74), 0.1533 0.42
10 HDL 8 rs17482753 Tada T G 0.133 NA T G -0.32 (1.36), 0.8127 0.07
11 HDL 8 rs17489282 Tada T C 0.088 NA T C -0.06 (0.81), 0.9398 0.26
12 HDL 8 rs6999158 Tada A T 0.068 NA A T 0.27 (0.81), 0.7398 0.25
13 HDL 8 rs9987289 Teslovich A G -0.082 NA G A 1.33 (0.82), 0.1079 0.20
14 HDL 8 rs12678919 Teslovich G A 0.155 NA G A -0.94 (1.35), 0.4886 0.07
15 HDL 8 rs2954029 Teslovich T A 0.040 NA T A -0.76 (0.68), 0.2592 0.41
16 HDL 8 rs326 Willer A G -0.089 NA G A 0.85 (0.78), 0.2739 0.30
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Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
17 HDL 8 rs15285 Wu T C 0.047 NA T C 0.87 (0.78), 0.2675 0.29
18 HDL 8 rs4407894 Wu T C -0.031 NA C T 1.03 (0.71), 0.1462 0.42
19 HDL 8 rs4841132 Zubair A/G NA -1.800 0.17 G A 1.3 (0.84), 0.1208 0.20
20 HDL 8 rs3208305 Zubair A/T NA -1.370 0.69 T A 0.85 (0.78), 0.2733 0.29
21 HDL 8 rs66462329 Zubair A/G NA 1.000 0.27 A G 0.39 (0.83), 0.6345 0.24
22 HDL 8 rs2954038 Zubair A/C NA 0.850 0.75 A C -0.22 (0.8), 0.78 0.23
23 HDL 9 rs2472386 Below A G 0.140 NA A G 1.09 (0.7), 0.1198 0.44
24 HDL 9 rs2853579 Tada T G 0.042 NA T G 0.79 (0.84), 0.3454 0.23
25 HDL 9 rs11789603 Tada T C 0.071 NA T C 3.8 (1.49), 0.0114 0.06
26 HDL 9 rs3847302 Tada A G 0.070 NA G A -2.17 (1.32), 0.1025 0.09
27 HDL 9 rs1800978 Tada C G 0.043 NA G C 0.02 (0.97), 0.9796 0.14
28 HDL 9 rs1883025 Teslovich T C -0.070 NA T C -0.52 (0.8), 0.5165 0.23
31 HDL 9 rs2575876 Zubair A/G NA -0.890 0.26 A G -0.57 (0.81), 0.4776 0.22
32 HDL 10 rs970548 Willer C A 0.026 NA C A 0.57 (0.76), 0.4561 0.30
33 HDL 11 rs2367970 Below JE G NA 0.097 0.78 A G -0.25 (0.71), 0.7214 0.35
34 HDL 11 rs11216230 Ko A G 0.220 NA A G 3.7 (1.47), 0.0124 0.06
35 HDL 11 rs174546 Teslovich T C -0.039 NA T C -0.67 (0.7), 0.3365 0.37
36 HDL 11 rs964184 Teslovich C G 0.106 NA C G 1 (0.72), 0.1655 0.36
37 HDL 11 rs7941030 Teslovich C T 0.027 NA C T 2.03 (0.74), 0.0062 0.31
38 HDL 11 rs12801636 Willer A G 0.024 NA A G -0.74 (0.71), 0.2994 0.46
39 HDL 11 rs499974 Willer A C -0.026 NA A C -1.64 (1), 0.1038 0.12
40 HDL 11 rs174537 Zubair A/C NA -0.760 0.48 T G -0.66 (0.7), 0.3402 0.37
41 HDL 11 rs180360 Zubair A/G NA -1.380 0.70 G A 1.04 (0.79), 0.1888 0.29
42 HDL 11 rs3135506 Zubair C/G NA 1.830 0.88 C G -0.43 (1.2), 0.7196 0.10
156
Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
43 HDL 11 rs662799 Zubair A/G NA 1.380 0.86 A G 1.04 (0.77), 0.1768 0.25
44 HDL 11 rs1263173 Zubair C T -1.030 NA A G 0.87 (0.69), 0.2104 0.47
45 HDL 12 rs863750 Tada T C -0.025 NA T C -1.29 (0.72), 0.073 0.46
46 HDL 12 rs7298751 Tada A G -0.041 NA A G -2.07 (1.16), 0.0755 0.09
47 HDL 12 rs7134375 Teslovich A C 0.021 NA A C -0.16 (0.69), 0.8163 0.39
48 HDL 12 rs7134594 Teslovich C T -0.035 NA T C -0.76 (0.7), 0.278 0.49
49 HDL 12 rs4759375 Teslovich T C 0.056 NA T C 0.25 (0.88), 0.7767 0.17
50 HDL 14 rs4983559 Willer G A 0.020 NA A G 0.58 (0.68), 0.3922 0.45
51 HDL 15 rs261334 Below G C 0.116 NA C G -2.11 (0.71), 0.003 0.40
52 HDL 15 rs12148399 Tada A T -0.061 NA A T -2.31 (1.08), 0.0327 0.12
53 HDL 15 rs1800588 Tada T C 0.093 NA T C 2.16 (0.69), 0.0018 0.42
54 HDL 15 rs1532085 Teslovich A G 0.107 NA G A -0.68 (0.74), 0.3592 0.32
56 HDL 15 rs10468017 Wu T C 0.051 NA T C 1.67 (0.8), 0.0381 0.22
57 HDL 15 rs1077834 Wu T C -0.050 NA C T 2.16 (0.69), 0.0018 0.42
58 HDL 15 rs35853021 Zubair A/C NA 1.230 0.37 T G 1.33 (0.75), 0.0779 0.32
59 HDL 15 rs8033940 Zubair A/G NA 1.190 0.51 A G 1.82 (0.68), 0.0075 0.48
60 HDL 16 rs7499892 Below JE C NA 0.243 0.77 T C -2.51 (0.92), 0.0065 0.17
61 HDL 16 rs9989419 Ko G A 0.140 NA G A 0.42 (0.73), 0.5624 0.38
62 HDL 16 rs247617 Tada A C 0.210 NA A C 3.14 (0.75), 0 0.30
63 HDL 16 rs11076174 Tada T C 0.237 NA C T 0.45 (1.62), 0.7796 0.06
64 HDL 16 rs5880 Ko A C NA 0.290 NA C G -3.87 (1.09), 4e-04 0.11
65 HDL 16 rs9923854 Tada T G -0.075 NA G T 1.14 (1.83), 0.5328 0.05
66 HDL 16 rs289742 Tada C G 0.129 NA G C 0.07 (0.92), 0.9369 0.17
67 HDL 16 rs3764261 Teslovich A C 0.241 NA A C 3 (0.76), 1e-04 0.30
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Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
68 HDL 16 rs16942887 Teslovich A G 0.083 NA A G 1.62 (0.78), 0.0372 0.27
69 HDL 16 rs2925979 Teslovich T C -0.035 NA C T 0.46 (0.99), 0.6404 0.14
71 HDL 16 rs56156922 Wu T C -0.090 NA C T 2.87 (0.76), 2e-04 0.29
72 HDL 16 rs17231506 Wu T C 0.090 NA T C 2.87 (0.76), 2e-04 0.29
73 HDL 16 rs17231520 Wu A G 0.175 NA A G 1.02 (4.78), 0.8317 0.01
74 HDL 16 rs12720922 Wu A G -0.098 NA A G -2.28 (0.9), 0.0118 0.18
75 HDL 16 rs5883 Wu T C 0.088 NA T C 3.98 (2.35), 0.0913 0.02
76 HDL 16 rs255054 Wu A G -0.044 NA G A 1.57 (0.77), 0.0407 0.28
77 HDL 16 rs11076175 Zubair A/G NA 2.760 0.79 G A -2.21 (0.93), 0.0173 0.17
78 HDL 17 rs11869286 Teslovich G C -0.032 NA C G 0.4 (0.69), 0.5623 0.42
79 HDL 18 rs4939883 Tada T C -0.079 NA C T 1.91 (1.08), 0.0765 0.11
80 HDL 18 rs9964067 Tada T C -0.037 NA C T 0.65 (0.67), 0.3313 0.43
81 HDL 19 rs103294 Tada T C 0.045 NA T C -0.38 (0.78), 0.6248 0.25
82 HDL 19 rs737337 Teslovich C T -0.056 NA C T -1.81 (0.81), 0.0256 0.25
83 HDL 19 rs4420638 Teslovich G A -0.067 NA G A -1.93 (1.16), 0.0961 0.09
85 HDL 20 rs1800961 Teslovich T C -0.127 NA T C 0.77 (1.84), 0.6775 0.03
86 HDL 22 rs181362 Teslovich T C -0.038 NA T C -0.82 (0.69), 0.2365 0.45
87 LDL 1 rs660240 Below JE C NA 0.179 0.79 C T 3.69 (1.78), 0.0385 0.20
88 LDL 1 rs10903129 Tada A G -0.029 NA G A 0.42 (1.49), 0.7783 0.47
89 LDL 1 rs12117661 Tada C G 0.048 NA G C 2.75 (1.86), 0.139 0.17
90 LDL 1 rs17111503 Tada A G -0.061 NA G A -0.18 (1.52), 0.9068 0.39
91 LDL 1 rs287227 Tada T G -0.066 NA T G -0.33 (1.9), 0.8614 0.17
92 LDL 1 rs3850634 Tada T G 0.042 NA G T -0.01 (1.48), 0.9969 0.32
93 LDL 1 rs599839 Tada A G 0.149 NA A G 3.82 (1.72), 0.0266 0.23
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Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
94 LDL 1 rs2479409 Teslovich G A 0.064 NA A G 0.26 (1.54), 0.868 0.37
95 LDL 1 rs2131925 Teslovich G T -0.049 NA T G 0.93 (1.46), 0.5255 0.34
96 LDL 1 rs629301 Teslovich G T -0.167 NA T G 3.17 (1.77), 0.0732 0.21
97 LDL 1 rs2642442 Teslovich C T -0.036 NA T C 0.82 (1.89), 0.6663 0.18
98 LDL 1 rs11591147 Wu T C -0.384 NA T G -16.25 (11.54), 0.1599 0.01
99 LDL 1 rs2495477 Wu A G 0.086 NA G A 1.69 (1.53), 0.2687 0.33
100 LDL 1 rs28362263 Wu A A -0.206 NA A G -11.39 (9.45), 0.2286 0.01
101 LDL 1 rs28362286 Wu A C -0.956 NA A C NA (NA), NA 0.00
102 LDL 1 rs12740374 Zubair A/C NA -7.900 0.21 T G -3.36 (1.76), 0.0578 0.21
103 LDL 2 rs13392272 Below JE T NA 0.095 0.39 T C 2.87 (1.59), 0.0722 0.37
104 LDL 2 rs562338 Tada A G -0.123 NA G A 3 (2.05), 0.1436 0.16
105 LDL 2 rs4953023 Tada A G -0.123 NA A G 1.37 (2.81), 0.6251 0.08
106 LDL 2 rs1367117 Teslovich A G 0.119 NA A G 2.53 (1.71), 0.1383 0.26
107 LDL 2 rs4299376 Teslovich G T 0.081 NA T G -0.02 (1.82), 0.9921 0.19
108 LDL 2 rs11563251 Willer T C 0.034 NA T C -1.58 (2.59), 0.5403 0.08
109 LDL 2 rs934198 Wu T G 0.116 NA T G 1.96 (1.67), 0.2398 0.27
110 LDL 2 rs668948 Wu A G 0.102 NA A G 3 (2.05), 0.1436 0.15
111 LDL 2 rs568938 Wu T C 0.109 NA T C 3.53 (2), 0.0787 0.16
112 LDL 2 rs934197 Zubair A/G NA 4.050 0.27 A G 2.34 (1.71), 0.1717 0.26
113 LDL 2 rs780093 Zubair A/G NA 2.630 0.33 C T 1.76 (1.59), 0.2688 0.32
114 LDL 2 rs4245791 Zubair A/G NA -3.320 0.79 T C -0.73 (1.82), 0.6875 0.19
115 LDL 2 rs66900043 Zubair C G 6.950 NA G C -3.48 (4.64), 0.4541 0.03
116 LDL 5 rs1423527 Tada A C 0.066 NA A C 1.21 (1.58), 0.4433 0.36
117 LDL 5 rs1501908 Tada C G 0.045 NA C G 1.04 (1.72), 0.5441 0.24
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Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
118 LDL 5 rs12916 Teslovich C T 0.073 NA C T 1.34 (1.59), 0.3986 0.35
119 LDL 5 rs6882076 Teslovich T C -0.046 NA C T 1.04 (1.72), 0.5441 0.24
120 LDL 6 rs10455872 Tada A G -0.089 NA G A 4.18 (3.64), 0.2516 0.04
121 LDL 6 rs3757354 Teslovich T C -0.038 NA T C 0.88 (1.63), 0.5905 0.34
122 LDL 6 rs1800562 Teslovich A G -0.062 NA A G -10.07 (5.67), 0.0765 0.02
123 LDL 6 rs1564348 Teslovich C T 0.048 NA C T 1.21 (1.65), 0.4639 0.29
124 LDL 6 rs3798168 Zubair A/C NA -3.270 0.15 A C 0.84 (1.96), 0.669 0.17
125 LDL 8 rs2954029 Teslovich T A -0.056 NA T A -0.61 (1.47), 0.6773 0.41
126 LDL 8 rs11136341 Teslovich G A 0.045 NA G A 2.04 (1.71), 0.2317 0.25
127 LDL 8 rs2980875 Willer A G 0.050 NA G A -0.66 (1.47), 0.6541 0.41
128 LDL 8 rs2980869 Zubair A/G NA -2.890 0.43 T C -0.89 (1.46), 0.5425 0.43
129 LDL 9 rs579459 Tada T C -0.055 NA C T -0.1 (2.03), 0.9595 0.15
130 LDL 9 rs635634 Teslovich T C 0.077 NA T C 0.57 (2.14), 0.7914 0.14
131 LDL 10 rs7096937 Tada T C 0.029 NA C T 1.31 (1.65), 0.4273 0.31
132 LDL 10 rs2255141 Teslovich A G 0.030 NA G A 1.17 (1.66), 0.4805 0.32
133 LDL 11 rs174546 Teslovich T C -0.051 NA T C -1.83 (1.51), 0.2265 0.37
134 LDL 11 rs964184 Teslovich C G -0.086 NA C G -1.03 (1.57), 0.5116 0.36
135 LDL 11 rs174583 Tada T C -0.045 NA T C -2.22 (1.53), 0.1483 0.35
136 LDL 11 rs11220462 Teslovich A G 0.059 NA A G -0.75 (2.28), 0.7434 0.12
137 LDL 12 rs1169288 Teslovich C A 0.038 NA C A -1.53 (1.56), 0.327 0.46
138 LDL 16 rs2000999 Teslovich A G 0.065 NA A G 1.24 (2.08), 0.5526 0.16
139 LDL 17 rs1801689 Willer C A 0.103 NA C A 7.44 (4.33), 0.0864 0.03
140 LDL 19 rs4420638 Teslovich G A 0.225 NA G A 8.76 (2.48), 5e-04 0.09
141 LDL 19 rs2238675 Below JE C NA 0.125 0.89 T C -3.51 (1.79), 0.0504 0.22
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Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
142 LDL 19 rs3786722 Tada A C -0.066 NA A C -1.03 (2.15), 0.6311 0.14
143 LDL 19 rs688 Tada T C 0.054 NA T C 0.36 (1.49), 0.8108 0.50
144 LDL 19 rs3208856 Tada T C -0.267 NA T C 8.67 (4.99), 0.083 0.02
145 LDL 19 rs12721109 Tada A G -0.382 NA A G 1.72 (13.34), 0.8975 0.01
146 LDL 19 rs516246 Tada T C 0.027 NA T C 0.09 (1.74), 0.9595 0.28
147 LDL 19 rs6511720 Teslovich T G -0.221 NA T G -0.66 (3.19), 0.8362 0.07
148 LDL 19 rs10401969 Teslovich C T -0.118 NA C T -6.48 (3.56), 0.0699 0.04
149 LDL 19 rs73015011 Wu T C 0.202 NA C T -0.66 (3.19), 0.8362 0.07
150 LDL 19 rs114197570 Wu T C -0.689 NA T C NA (NA), NA 0.00
151 LDL 19 rs1038026 Wu A G 0.183 NA G A 0.03 (1.56), 0.9829 0.44
152 LDL 19 rs769449 Wu A A 0.121 NA A G 5.04 (2.77), 0.0697 0.08
153 LDL 19 rs7412 Wu T C -0.505 NA T C -11.93 (4.61), 0.01 0.02
154 LDL 19 rs56131196 Wu A G 0.126 NA A G 8.76 (2.48), 5e-04 0.09
155 LDL 19 rs2074304 Zubair C/G NA 6.790 0.95 C G -3.89 (2.18), 0.0746 0.14
156 LDL 20 rs4297946 Tada C G 0.039 NA C G 0.32 (1.51), 0.8303 0.43
157 LDL 20 rs6029526 Teslovich A T 0.044 NA A T 0.99 (1.52), 0.5139 0.47
158 TG 1 rs2131925 Teslovich G T -0.066 NA T G 0.05 (0.03), 0.0586 0.34
159 TG 1 rs1748195 Tada C G 0.071 NA G C -0.05 (0.03), 0.0502 0.34
160 TG 1 rs631106 Zubair A/C NA -0.030 0.41 A C -0.05 (0.03), 0.0587 0.34
161 TG 2 rs780093 Below JE T NA 0.108 0.36 C T -0.04 (0.03), 0.1254 0.32
162 TG 2 rs673548 Tada A G -0.086 NA A G -0.01 (0.03), 0.8046 0.27
163 TG 2 rs1260326 Teslovich T C 0.115 NA C T -0.07 (0.03), 0.0146 0.31
164 TG 2 rs676210 Wu A G -0.047 NA A G -0.01 (0.03), 0.7711 0.27
165 TG 2 rs13399758 Wu T C 0.083 NA C T 0.04 (0.07), 0.5471 0.05
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Table D.1: List of genetic variants used for the trait specific genetic risk scores. (continued)
Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
166 TG 2 rs11902417 Zubair A/G NA -0.040 0.25 A G -0.01 (0.03), 0.7675 0.28
167 TG 2 rs780094 Zubair A/G NA 0.060 0.34 C T -0.04 (0.03), 0.1256 0.32
168 TG 4 rs442177 Teslovich G T -0.031 NA T G -0.02 (0.03), 0.4524 0.44
169 TG 5 rs9686661 Teslovich T C 0.038 NA T C 0.04 (0.03), 0.1937 0.29
170 TG 6 rs998584 Willer A C 0.029 NA A C 0.03 (0.03), 0.2428 0.43
171 TG 6 rs11752643 Tada T C 0.097 NA T C 0.06 (0.11), 0.5849 0.01
172 TG 7 rs7777102 Tada A G 0.131 NA G A 0 (0.05), 0.9495 0.08
173 TG 7 rs17145738 Teslovich T C -0.115 NA T C 0 (0.05), 0.9984 0.08
174 TG 7 rs38855 Willer G A -0.019 NA G A -0.05 (0.03), 0.0846 0.49
175 TG 7 rs33951980 Zubair A/G NA -0.090 0.07 T C -0.03 (0.05), 0.6441 0.08
176 TG 8 rs17482753 Tada T G -0.184 NA T G -0.02 (0.05), 0.7186 0.07
177 TG 8 rs17489282 Tada T C -0.129 NA T C -0.03 (0.03), 0.4106 0.26
178 TG 8 rs12678919 Teslovich G A -0.170 NA G A 0 (0.05), 0.9471 0.07
179 TG 8 rs2954029 Teslovich T A -0.076 NA T A 0 (0.03), 0.9775 0.41
180 TG 8 rs326 Willer A G 0.087 NA G A -0.01 (0.03), 0.8035 0.30
181 TG 8 rs15285 Wu T C -0.061 NA T C -0.01 (0.03), 0.667 0.29
182 TG 8 rs2954038 Zubair A/C NA -0.050 0.75 A C -0.01 (0.03), 0.7594 0.23
183 TG 8 rs2980875 Tada A G 0.079 NA G A 0 (0.03), 0.8774 0.41
184 TG 8 rs2954031 Below JE G NA 0.098 0.61 T G 0 (0.03), 0.9007 0.38
185 TG 8 rs10106652 Tada A G -0.084 NA A G 0.01 (0.03), 0.8177 0.24
186 TG 8 rs75551077 Wu C G -0.075 NA C G -0.01 (0.05), 0.817 0.07
187 TG 8 rs10096633 Zubair A/G NA -0.080 0.16 T C 0.01 (0.04), 0.8539 0.10
188 TG 8 rs60223219 Zubair A/G NA 0.090 0.92 G A 0.02 (0.05), 0.7284 0.07
189 TG 10 rs10761731 Teslovich T A -0.031 NA T A -0.04 (0.03), 0.1687 0.31
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Source Studiesa SLS estimates
Trait Chr rsid Author Coded
allele
Other
allele
Beta EAF Coded
alleleb
Other
allele
Estimate (SE), p-value MAF
190 TG 11 rs174546 Teslovich T C 0.045 NA T C -0.01 (0.03), 0.5989 0.37
191 TG 11 rs964184 Ko A G NA 1.890 NA C G -0.07 (0.03), 0.0161 0.36
192 TG 11 rs3135506 Wu C G 0.121 NA C G -0.03 (0.05), 0.5487 0.10
193 TG 11 rs1145198 Tada A G -0.061 NA A G 0 (0.04), 0.9724 0.17
194 TG 11 rs508487 Tada T C 0.268 NA T C 0.03 (0.07), 0.638 0.03
195 TG 11 rs11604424 Wu T C -0.101 NA T C -0.05 (0.03), 0.0743 0.46
196 TG 11 rs2075290 Wu T C -0.151 NA T C -0.1 (0.03), 0.0013 0.25
197 TG 11 rs3741298 Wu T C -0.108 NA T C -0.05 (0.03), 0.0756 0.45
198 TG 11 rs651821 Wu T C -0.145 NA T C -0.11 (0.03), 2e-04 0.25
199 TG 11 rs28927680 Zubair C/G NA -0.100 0.86 G C -0.04 (0.05), 0.4426 0.10
200 TG 11 rs2266788 Zubair A/G NA -0.130 0.88 A G -0.12 (0.03), 1e-04 0.24
201 TG 15 rs1532085 Teslovich A G 0.031 NA G A -0.01 (0.03), 0.7434 0.32
202 TG 15 rs1077834 Tada T C -0.043 NA C T 0 (0.03), 0.8683 0.42
203 TG 15 rs2929282 Teslovich T A 0.072 NA T A 0.08 (0.07), 0.2416 0.04
204 TG 16 rs3764261 Teslovich A C -0.040 NA A C 0.02 (0.03), 0.4629 0.30
205 TG 19 rs10401969 Teslovich C T -0.121 NA C T -0.07 (0.07), 0.2915 0.04
206 TG 19 rs8102280 Below G A 0.251 NA A G -0.1 (0.04), 0.0113 0.13
207 TG 19 rs769455 Wu T C 0.185 NA T C 0.38 (0.42), 0.3625 0.00
208 TG 19 rs12721054 Wu A G 0.113 NA G A 0.54 (0.3), 0.0708 0.00
209 TG 19 rs118029212 Zubair A/G NA -0.100 0.06 T C -0.1 (0.04), 0.0126 0.14
210 TG 19 rs58542926 Zubair A/G NA -0.090 0.05 T C -0.08 (0.07), 0.2412 0.04
211 TG 19 rs439401 Zubair A/G NA -0.030 0.47 C T 0.02 (0.03), 0.4134 0.43
212 TG 22 rs5756931 Teslovich C T -0.020 NA C T 0.07 (0.03), 0.0064 0.40
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a Sources (and reference for beta units): Ko 2014 (Ko et al. 2014), Below 2016 (Below et al. 2016), Teslovich 2010 (Teslovich et
al. 2010), Zubair 2016 (Zubair et al. 2016), Tada 2014 (Tada et al. 2014), Wu (Wu et al. 2013).
b Coded allele is minor allele.
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APPENDIX E: MANUSCRIPT 3: ALL PAIRWISE GROWTH CLASS DIFFERENCES IN LIPID
DISTAL OUTCOME AND MEAN LIPID DISTAL OUTCOMES BY LATENT CLASS GROUPS.
E.1 Pairwise differences in selected SNP-lipid associations across growth classes
Table E.1: Latent growth class pairwise differences in coefficient of association between selected distal lipid outcome (mg/dL)
and candidate SNPs
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Both Length HDL rs11076175 -5.16 (-12.21, 1.90) 0.95 (-3.94, 5.85) 0.152, (2.06,1) 0.703, (0.14,1)
Both Length HDL rs247617 2.83 (-3.60, 9.27) -0.63 (-4.69, 3.44) 0.388, (0.74,1) 0.762, (0.09,1)
Both Length LDL rs12740374 -9.85 (-21.30, 1.61) -2.23 (-11.96, 7.50) 0.092, (2.84,1) 0.654, (0.20,1)
Both Length LDL rs7412 -3.59 (-30.24, 23.06) -27.89 (-52.85, -2.93) 0.792, (0.07,1) 0.028, (4.79,1)
Both Length TG rs1260326 0.01 (-0.03, 0.06) -0.00 (-0.04, 0.04) 0.529, (0.40,1) 0.966, (0.00,1)
Both Length TG rs964184 -0.01 (-0.06, 0.03) -0.00 (-0.04, 0.03) 0.539, (0.38,1) 0.892, (0.02,1)
Both Weight HDL rs11076175 1.68 (-5.60, 8.96) 3.43 (-3.42, 10.28) 0.650, (0.20,1) 0.326, (0.96,1)
Both Weight HDL rs247617 -4.37 (-11.26, 2.52) -6.48 (-12.16, -0.80) 0.213, (1.55,1) 0.025, (5.00,1)
Both Weight LDL rs12740374 10.07 (-11.25, 31.39) 10.70 (-10.19, 31.59) 0.354, (0.86,1) 0.315, (1.01,1)
Both Weight LDL rs7412 -14.43 (-47.94, 19.08) -14.57 (-63.02, 33.89) 0.399, (0.71,1) 0.556, (0.35,1)
Both Weight TG rs1260326 0.04 (-0.03, 0.10) 0.04 (-0.02, 0.10) 0.256, (1.29,1) 0.215, (1.54,1)
Both Weight TG rs964184 0.07 (-0.01, 0.14) 0.07 (0.00, 0.13) 0.081, (3.05,1) 0.038, (4.29,1)
Both WFL HDL rs11076175 1.78 (-3.82, 7.38) 0.45 (-5.08, 5.99) 0.533, (0.39,1) 0.872, (0.03,1)
Both WFL HDL rs247617 -1.15 (-6.59, 4.30) -1.31 (-6.19, 3.57) 0.680, (0.17,1) 0.599, (0.28,1)
Both WFL LDL rs12740374 0.65 (-10.74, 12.04) 0.71 (-11.14, 12.56) 0.911, (0.01,1) 0.906, (0.01,1)
Both WFL LDL rs7412 -11.99 (-41.33, 17.36) 3.00 (-23.64, 29.63) 0.423, (0.64,1) 0.826, (0.05,1)
Both WFL TG rs1260326 0.03 (-0.02, 0.08) 0.03 (-0.02, 0.07) 0.241, (1.37,1) 0.216, (1.53,1)
Both WFL TG rs964184 0.03 (-0.01, 0.07) 0.04 (-0.00, 0.08) 0.179, (1.81,1) 0.054, (3.71,1)
Female Length HDL rs11076175 -1.90 (-8.14, 4.34) 4.59 (-4.59, 13.77) 0.551, (0.35,1) 0.327, (0.96,1)
Female Length HDL rs247617 -1.96 (-8.88, 4.95) -4.74 (-12.11, 2.63) 0.578, (0.31,1) 0.208, (1.59,1)
Female Length LDL rs12740374 -3.17 (-14.55, 8.22) 12.84 (-3.49, 29.17) 0.586, (0.30,1) 0.123, (2.38,1)
Female Length LDL rs7412 -17.05 (-44.99, 10.88) – 0.231, (1.43,1) NA, ( NA,NA)
Female Length TG rs1260326 0.02 (-0.03, 0.06) -0.03 (-0.11, 0.05) 0.522, (0.41,1) 0.447, (0.58,1)
Female Length TG rs964184 -0.04 (-0.09, 0.01) -0.05 (-0.12, 0.02) 0.136, (2.23,1) 0.131, (2.28,1)
Female Weight HDL rs11076175 6.08 (-1.02, 13.18) 0.39 (-10.63, 11.41) 0.093, (2.82,1) 0.945, (0.00,1)
Female Weight HDL rs247617 -4.12 (-11.31, 3.07) 3.00 (-5.39, 11.39) 0.261, (1.26,1) 0.483, (0.49,1)
Female Weight LDL rs12740374 -4.05 (-16.78, 8.68) 3.03 (-17.62, 23.69) 0.532, (0.39,1) 0.774, (0.08,1)
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Table E.1: Latent growth class pairwise differences in coefficient of association between selected distal lipid outcome (mg/dL)
and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Female Weight LDL rs7412 -5.33 (-42.59, 31.92) 109.20 (-350.18, 568.59) 0.779, (0.08,1) 0.641, (0.22,1)
Female Weight TG rs1260326 0.04 (-0.02, 0.10) 0.08 (0.00, 0.15) 0.212, (1.55,1) 0.036, (4.41,1)
Female Weight TG rs964184 -0.00 (-0.07, 0.06) 0.08 (0.02, 0.15) 0.917, (0.01,1) 0.015, (5.96,1)
Female WFL HDL rs11076175 2.37 (-5.17, 9.91) 6.59 (-4.07, 17.24) 0.537, (0.38,1) 0.226, (1.47,1)
Female WFL HDL rs247617 -0.22 (-8.69, 8.24) -4.03 (-15.44, 7.38) 0.958, (0.00,1) 0.489, (0.48,1)
Female WFL LDL rs12740374 9.32 (-4.26, 22.90) 2.95 (-27.33, 33.24) 0.179, (1.81,1) 0.849, (0.04,1)
Female WFL LDL rs7412 -3.17 (-40.47, 34.14) – 0.868, (0.03,1) NA, ( NA,NA)
Female WFL TG rs1260326 0.04 (-0.02, 0.10) 0.05 (-0.02, 0.13) 0.183, (1.77,1) 0.176, (1.83,1)
Female WFL TG rs964184 0.06 (0.00, 0.12) 0.06 (-0.01, 0.13) 0.046, (3.98,1) 0.078, (3.10,1)
Male Length HDL rs11076175 2.42 (-9.06, 13.91) -5.91 (-13.49, 1.67) 0.679, (0.17,1) 0.127, (2.33,1)
Male Length HDL rs247617 8.75 (-2.84, 20.34) -5.40 (-13.05, 2.25) 0.139, (2.19,1) 0.167, (1.91,1)
Male Length LDL rs12740374 -3.66 (-31.17, 23.86) 1.33 (-20.54, 23.20) 0.794, (0.07,1) 0.905, (0.01,1)
Male Length LDL rs7412 – 49.02 (-12.25, 110.30) NA, ( NA,NA) 0.117, (2.46,1)
Male Length TG rs1260326 0.23 (-0.03, 0.50) 0.01 (-0.07, 0.09) 0.083, (3.00,1) 0.816, (0.05,1)
Male Length TG rs964184 -0.07 (-0.15, 0.01) 0.01 (-0.05, 0.08) 0.111, (2.54,1) 0.686, (0.16,1)
Male Weight HDL rs11076175 -3.34 (-9.95, 3.27) -10.12 (-18.50, -1.75) 0.323, (0.98,1) 0.018, (5.62,1)
Male Weight HDL rs247617 -1.48 (-7.33, 4.37) 3.39 (-5.07, 11.85) 0.620, (0.25,1) 0.432, (0.62,1)
Male Weight LDL rs12740374 0.43 (-14.77, 15.63) -3.48 (-27.90, 20.93) 0.956, (0.00,1) 0.780, (0.08,1)
Male Weight LDL rs7412 21.48 (-51.19, 94.16) 20.05 (-10.56, 50.67) 0.562, (0.34,1) 0.199, (1.65,1)
Male Weight TG rs1260326 0.00 (-0.05, 0.06) -0.01 (-0.08, 0.07) 0.894, (0.02,1) 0.851, (0.04,1)
Male Weight TG rs964184 0.05 (0.00, 0.10) 0.03 (-0.05, 0.12) 0.047, (3.93,1) 0.435, (0.61,1)
Male WFL HDL rs11076175 -2.96 (-9.47, 3.56) – 0.374, (0.79,1) NA, ( NA,NA)
Male WFL HDL rs247617 -1.67 (-7.46, 4.11) – 0.571, (0.32,1) NA, ( NA,NA)
Male WFL LDL rs12740374 -1.46 (-16.38, 13.46) – 0.848, (0.04,1) NA, ( NA,NA)
Male WFL LDL rs7412 274.59 (-6994.65, 7543.84) – 0.941, (0.00,1) NA, ( NA,NA)
Male WFL TG rs1260326 -0.02 (-0.08, 0.03) 0.03 (-0.05, 0.11) 0.444, (0.58,1) 0.413, (0.67,1)
Male WFL TG rs964184 0.02 (-0.03, 0.07) 0.02 (-0.11, 0.15) 0.351, (0.87,1) 0.760, (0.09,1)
Note:
Note: Bold values indicate Bonferroni corrected statistical significance at alpha level = 0.05.
a Adjusted for sex of child in pooled sample, randomization status, and principal components.
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E.2 Pairwise differences in SNP-lipid associations across growth classes for other, non-
primary, lipid traits
Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Both Length HDL rs11604424 2.52 (-2.52, 7.56) 0.20 (-3.73, 4.13) 0.327, (0.96,1) 0.920, (0.01,1)
Both Length HDL rs1260326 -1.60 (-6.20, 2.99) 3.18 (-0.81, 7.18) 0.494, (0.47,1) 0.119, (2.44,1)
Both Length HDL rs12678919 -3.54 (-17.16, 10.08) -2.50 (-9.50, 4.51) 0.610, (0.26,1) 0.485, (0.49,1)
Both Length HDL rs12740374 3.63 (-1.49, 8.75) 0.22 (-3.92, 4.36) 0.165, (1.93,1) 0.918, (0.01,1)
Both Length HDL rs3135506 -4.26 (-13.80, 5.28) -2.49 (-8.28, 3.30) 0.382, (0.77,1) 0.400, (0.71,1)
Both Length HDL rs3741298 2.70 (-2.43, 7.83) 0.28 (-3.61, 4.17) 0.303, (1.06,1) 0.888, (0.02,1)
Both Length HDL rs7412 10.19 (-4.22, 24.59) 2.18 (-12.10, 16.46) 0.166, (1.92,1) 0.765, (0.09,1)
Both Length HDL rs964184 0.80 (-4.11, 5.71) -0.52 (-4.35, 3.32) 0.750, (0.10,1) 0.792, (0.07,1)
Both Length LDL rs11076175 6.65 (-9.84, 23.15) 6.43 (-5.43, 18.29) 0.429, (0.62,1) 0.288, (1.13,1)
Both Length LDL rs11604424 -3.34 (-14.38, 7.70) 3.05 (-5.97, 12.06) 0.553, (0.35,1) 0.508, (0.44,1)
Both Length LDL rs1260326 -0.47 (-11.02, 10.08) -2.33 (-11.60, 6.95) 0.930, (0.01,1) 0.623, (0.24,1)
Both Length LDL rs12678919 13.42 (-8.25, 35.10) -2.17 (-20.21, 15.87) 0.225, (1.47,1) 0.814, (0.06,1)
Both Length LDL rs247617 4.16 (-8.22, 16.54) 1.73 (-7.45, 10.91) 0.510, (0.43,1) 0.712, (0.14,1)
Both Length LDL rs3135506 17.66 (-2.11, 37.42) 14.49 (0.18, 28.80) 0.080, (3.06,1) 0.047, (3.94,1)
Both Length LDL rs3741298 -3.37 (-14.76, 8.03) 3.20 (-5.85, 12.25) 0.563, (0.34,1) 0.488, (0.48,1)
Both Length LDL rs964184 2.31 (-9.72, 14.33) 1.41 (-7.20, 10.02) 0.707, (0.14,1) 0.748, (0.10,1)
Both Length TG rs11076175 -0.00 (-0.06, 0.06) -0.01 (-0.05, 0.03) 0.890, (0.02,1) 0.578, (0.31,1)
Both Length TG rs11604424 -0.02 (-0.06, 0.02) -0.01 (-0.05, 0.02) 0.291, (1.11,1) 0.376, (0.78,1)
Both Length TG rs12678919 -0.03 (-0.13, 0.07) 0.05 (-0.01, 0.12) 0.580, (0.31,1) 0.122, (2.39,1)
Both Length TG rs12740374 -0.01 (-0.05, 0.04) 0.01 (-0.03, 0.05) 0.795, (0.07,1) 0.704, (0.14,1)
Both Length TG rs247617 0.04 (-0.01, 0.08) -0.03 (-0.06, 0.01) 0.123, (2.38,1) 0.151, (2.06,1)
Both Length TG rs3135506 0.02 (-0.06, 0.09) -0.01 (-0.07, 0.04) 0.619, (0.25,1) 0.571, (0.32,1)
Both Length TG rs3741298 -0.02 (-0.06, 0.02) -0.01 (-0.04, 0.02) 0.378, (0.78,1) 0.427, (0.63,1)
Both Length TG rs7412 -0.02 (-0.13, 0.09) -0.01 (-0.12, 0.11) 0.702, (0.15,1) 0.911, (0.01,1)
Both Weight HDL rs11604424 -2.02 (-8.65, 4.61) -1.05 (-7.35, 5.25) 0.550, (0.36,1) 0.744, (0.11,1)
Both Weight HDL rs1260326 -2.62 (-8.82, 3.57) -3.15 (-9.60, 3.30) 0.406, (0.69,1) 0.339, (0.91,1)
Both Weight HDL rs12678919 9.11 (-2.84, 21.05) 11.44 (2.10, 20.79) 0.135, (2.23,1) 0.016, (5.76,1)
Both Weight HDL rs12740374 1.31 (-8.63, 11.25) -0.90 (-10.19, 8.38) 0.796, (0.07,1) 0.849, (0.04,1)
Both Weight HDL rs3135506 -8.01 (-25.81, 9.80) -4.29 (-17.41, 8.84) 0.378, (0.78,1) 0.522, (0.41,1)
Both Weight HDL rs3741298 -1.76 (-8.68, 5.16) -0.78 (-7.27, 5.72) 0.618, (0.25,1) 0.815, (0.06,1)
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Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Both Weight HDL rs7412 -13.81 (-29.60, 1.98) -12.20 (-39.91, 15.51) 0.086, (2.94,1) 0.388, (0.74,1)
Both Weight HDL rs964184 -4.38 (-12.56, 3.81) -3.34 (-11.20, 4.53) 0.294, (1.10,1) 0.405, (0.69,1)
Both Weight LDL rs11076175 12.47 (-2.09, 27.02) 7.84 (-4.30, 19.97) 0.093, (2.82,1) 0.205, (1.60,1)
Both Weight LDL rs11604424 2.01 (-12.90, 16.93) 1.52 (-13.19, 16.23) 0.791, (0.07,1) 0.839, (0.04,1)
Both Weight LDL rs1260326 -5.07 (-19.48, 9.34) -2.66 (-15.61, 10.28) 0.490, (0.48,1) 0.687, (0.16,1)
Both Weight LDL rs12678919 -27.46 (-49.76, -5.17) -20.07 (-40.00, -0.13) 0.016, (5.83,1) 0.048, (3.89,1)
Both Weight LDL rs247617 5.57 (-8.27, 19.41) 8.02 (-4.77, 20.80) 0.430, (0.62,1) 0.219, (1.51,1)
Both Weight LDL rs3135506 23.24 (-8.38, 54.85) 26.41 (-3.53, 56.35) 0.150, (2.08,1) 0.084, (2.99,1)
Both Weight LDL rs3741298 4.58 (-10.59, 19.76) 3.81 (-11.15, 18.77) 0.554, (0.35,1) 0.618, (0.25,1)
Both Weight LDL rs964184 2.96 (-19.97, 25.89) 0.90 (-18.53, 20.32) 0.800, (0.06,1) 0.928, (0.01,1)
Both Weight TG rs11076175 -0.05 (-0.11, 0.02) -0.01 (-0.08, 0.06) 0.162, (1.96,1) 0.824, (0.05,1)
Both Weight TG rs11604424 0.02 (-0.03, 0.08) 0.04 (-0.02, 0.09) 0.392, (0.73,1) 0.176, (1.83,1)
Both Weight TG rs12678919 -0.00 (-0.10, 0.10) 0.02 (-0.07, 0.11) 0.959, (0.00,1) 0.637, (0.22,1)
Both Weight TG rs12740374 -0.05 (-0.13, 0.02) -0.07 (-0.16, 0.02) 0.169, (1.89,1) 0.132, (2.27,1)
Both Weight TG rs247617 -0.00 (-0.06, 0.05) 0.00 (-0.05, 0.05) 0.899, (0.02,1) 0.974, (0.00,1)
Both Weight TG rs3135506 -0.08 (-0.22, 0.05) -0.02 (-0.15, 0.11) 0.224, (1.48,1) 0.771, (0.08,1)
Both Weight TG rs3741298 0.02 (-0.04, 0.08) 0.03 (-0.02, 0.08) 0.482, (0.49,1) 0.229, (1.45,1)
Both Weight TG rs7412 0.08 (-0.09, 0.25) 0.10 (-0.13, 0.33) 0.339, (0.91,1) 0.376, (0.78,1)
Both WFL HDL rs11604424 -0.50 (-5.27, 4.28) 1.49 (-2.94, 5.92) 0.839, (0.04,1) 0.509, (0.43,1)
Both WFL HDL rs1260326 -0.61 (-6.00, 4.78) -0.73 (-5.88, 4.43) 0.825, (0.05,1) 0.782, (0.08,1)
Both WFL HDL rs12678919 2.06 (-6.51, 10.64) 2.99 (-4.90, 10.88) 0.637, (0.22,1) 0.458, (0.55,1)
Both WFL HDL rs12740374 -5.06 (-11.22, 1.10) -5.24 (-11.02, 0.54) 0.108, (2.59,1) 0.076, (3.16,1)
Both WFL HDL rs3135506 5.23 (-2.00, 12.45) 1.73 (-4.51, 7.98) 0.156, (2.01,1) 0.586, (0.30,1)
Both WFL HDL rs3741298 -0.31 (-5.07, 4.45) 1.73 (-2.70, 6.15) 0.899, (0.02,1) 0.445, (0.58,1)
Both WFL HDL rs7412 -17.39 (-31.98, -2.79) -11.72 (-24.35, 0.90) 0.020, (5.45,1) 0.069, (3.31,1)
Both WFL HDL rs964184 -2.22 (-7.45, 3.00) 0.29 (-4.83, 5.40) 0.404, (0.70,1) 0.912, (0.01,1)
Both WFL LDL rs11076175 10.15 (-1.07, 21.37) 10.26 (-0.71, 21.23) 0.076, (3.14,1) 0.067, (3.36,1)
Both WFL LDL rs11604424 0.64 (-10.17, 11.46) -0.67 (-10.98, 9.63) 0.907, (0.01,1) 0.898, (0.02,1)
Both WFL LDL rs1260326 -5.01 (-15.61, 5.59) -2.33 (-12.86, 8.19) 0.354, (0.86,1) 0.664, (0.19,1)
Both WFL LDL rs12678919 -2.08 (-20.54, 16.38) -4.09 (-22.55, 14.38) 0.825, (0.05,1) 0.664, (0.19,1)
Both WFL LDL rs247617 -1.36 (-12.58, 9.87) -3.75 (-15.14, 7.63) 0.813, (0.06,1) 0.518, (0.42,1)
Both WFL LDL rs3135506 4.45 (-15.52, 24.41) -0.68 (-20.51, 19.16) 0.662, (0.19,1) 0.947, (0.00,1)
Both WFL LDL rs3741298 1.31 (-9.50, 12.11) 0.09 (-10.16, 10.34) 0.812, (0.06,1) 0.987, (0.00,1)
Both WFL LDL rs964184 -1.14 (-13.69, 11.41) -2.15 (-14.38, 10.07) 0.859, (0.03,1) 0.730, (0.12,1)
Both WFL TG rs11076175 0.01 (-0.05, 0.06) 0.00 (-0.05, 0.05) 0.803, (0.06,1) 0.991, (0.00,1)
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Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Both WFL TG rs11604424 0.02 (-0.01, 0.06) 0.04 (-0.00, 0.07) 0.206, (1.60,1) 0.056, (3.65,1)
Both WFL TG rs12678919 0.02 (-0.05, 0.09) 0.02 (-0.04, 0.09) 0.649, (0.21,1) 0.488, (0.48,1)
Both WFL TG rs12740374 0.01 (-0.04, 0.06) -0.00 (-0.06, 0.05) 0.685, (0.16,1) 0.858, (0.03,1)
Both WFL TG rs247617 -0.01 (-0.06, 0.03) -0.00 (-0.05, 0.04) 0.592, (0.29,1) 0.824, (0.05,1)
Both WFL TG rs3135506 -0.02 (-0.10, 0.06) -0.04 (-0.12, 0.03) 0.655, (0.20,1) 0.237, (1.40,1)
Both WFL TG rs3741298 0.02 (-0.02, 0.06) 0.04 (-0.00, 0.07) 0.242, (1.37,1) 0.062, (3.49,1)
Both WFL TG rs7412 0.07 (-0.08, 0.21) 0.06 (-0.07, 0.20) 0.360, (0.84,1) 0.370, (0.80,1)
Female Length HDL rs11604424 -4.16 (-8.90, 0.58) -2.63 (-11.36, 6.09) 0.085, (2.96,1) 0.554, (0.35,1)
Female Length HDL rs1260326 -3.47 (-9.20, 2.25) 2.83 (-6.30, 11.97) 0.235, (1.41,1) 0.543, (0.37,1)
Female Length HDL rs12678919 -10.80 (-22.81, 1.21) 5.45 (-6.86, 17.76) 0.078, (3.11,1) 0.386, (0.75,1)
Female Length HDL rs12740374 -1.17 (-6.23, 3.89) -4.40 (-12.00, 3.20) 0.651, (0.20,1) 0.256, (1.29,1)
Female Length HDL rs3135506 -0.21 (-8.41, 7.98) -0.19 (-10.19, 9.81) 0.959, (0.00,1) 0.971, (0.00,1)
Female Length HDL rs3741298 -3.49 (-8.19, 1.22) -2.46 (-11.00, 6.08) 0.147, (2.11,1) 0.572, (0.32,1)
Female Length HDL rs7412 7.87 (-8.31, 24.04) – 0.341, (0.91,1) NA, ( NA,NA)
Female Length HDL rs964184 -3.46 (-8.43, 1.51) -4.08 (-12.41, 4.24) 0.173, (1.86,1) 0.336, (0.92,1)
Female Length LDL rs11076175 -7.35 (-23.97, 9.27) 11.85 (-6.85, 30.55) 0.386, (0.75,1) 0.214, (1.54,1)
Female Length LDL rs11604424 -2.09 (-12.75, 8.58) 2.95 (-14.30, 20.20) 0.701, (0.15,1) 0.737, (0.11,1)
Female Length LDL rs1260326 -4.24 (-16.48, 7.99) 7.17 (-12.64, 26.98) 0.497, (0.46,1) 0.478, (0.50,1)
Female Length LDL rs12678919 9.09 (-13.01, 31.18) -6.89 (-39.56, 25.79) 0.420, (0.65,1) 0.679, (0.17,1)
Female Length LDL rs247617 13.68 (-0.18, 27.53) 1.64 (-13.14, 16.42) 0.053, (3.74,1) 0.828, (0.05,1)
Female Length LDL rs3135506 21.57 (5.35, 37.78) 18.41 (-2.23, 39.06) 0.009, (6.79,1) 0.080, (3.06,1)
Female Length LDL rs3741298 -1.26 (-12.09, 9.57) 5.69 (-11.55, 22.93) 0.819, (0.05,1) 0.518, (0.42,1)
Female Length LDL rs964184 -0.47 (-11.06, 10.11) 1.25 (-15.45, 17.95) 0.930, (0.01,1) 0.883, (0.02,1)
Female Length TG rs11076175 -0.07 (-0.13, -0.01) -0.05 (-0.15, 0.05) 0.015, (5.89,1) 0.346, (0.89,1)
Female Length TG rs11604424 -0.03 (-0.08, 0.01) -0.05 (-0.12, 0.01) 0.171, (1.87,1) 0.109, (2.56,1)
Female Length TG rs12678919 -0.02 (-0.15, 0.12) 0.09 (-0.05, 0.23) 0.786, (0.07,1) 0.200, (1.64,1)
Female Length TG rs12740374 -0.00 (-0.06, 0.05) -0.01 (-0.09, 0.08) 0.923, (0.01,1) 0.860, (0.03,1)
Female Length TG rs247617 0.01 (-0.04, 0.06) -0.06 (-0.13, 0.01) 0.650, (0.20,1) 0.106, (2.61,1)
Female Length TG rs3135506 -0.01 (-0.08, 0.07) -0.02 (-0.12, 0.08) 0.862, (0.03,1) 0.746, (0.10,1)
Female Length TG rs3741298 -0.03 (-0.08, 0.02) -0.04 (-0.11, 0.02) 0.203, (1.62,1) 0.167, (1.91,1)
Female Length TG rs7412 -0.09 (-0.22, 0.05) – 0.215, (1.54,1) NA, ( NA,NA)
Female Weight HDL rs11604424 -1.62 (-8.65, 5.40) -4.65 (-13.85, 4.55) 0.650, (0.20,1) 0.322, (0.98,1)
Female Weight HDL rs1260326 -2.29 (-9.78, 5.20) 3.75 (-5.93, 13.42) 0.549, (0.36,1) 0.448, (0.58,1)
Female Weight HDL rs12678919 2.27 (-13.14, 17.67) -6.17 (-21.61, 9.27) 0.773, (0.08,1) 0.433, (0.61,1)
Female Weight HDL rs12740374 -1.19 (-7.32, 4.93) 0.92 (-10.14, 11.97) 0.702, (0.15,1) 0.871, (0.03,1)
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Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Female Weight HDL rs3135506 -3.61 (-18.09, 10.87) 6.07 (-3.29, 15.42) 0.625, (0.24,1) 0.204, (1.61,1)
Female Weight HDL rs3741298 -1.67 (-8.67, 5.34) -4.63 (-13.88, 4.62) 0.641, (0.22,1) 0.327, (0.96,1)
Female Weight HDL rs7412 1.39 (-15.36, 18.14) -36.29 (-190.45, 117.86) 0.871, (0.03,1) 0.644, (0.21,1)
Female Weight HDL rs964184 -1.12 (-9.14, 6.89) -5.91 (-14.17, 2.34) 0.783, (0.08,1) 0.160, (1.97,1)
Female Weight LDL rs11076175 -1.73 (-17.61, 14.15) 11.07 (-10.94, 33.08) 0.831, (0.05,1) 0.324, (0.97,1)
Female Weight LDL rs11604424 -0.43 (-11.65, 10.79) 3.74 (-17.67, 25.16) 0.940, (0.01,1) 0.732, (0.12,1)
Female Weight LDL rs1260326 -0.40 (-13.85, 13.05) -2.80 (-25.00, 19.39) 0.954, (0.00,1) 0.804, (0.06,1)
Female Weight LDL rs12678919 2.23 (-18.24, 22.71) 8.21 (-28.03, 44.46) 0.831, (0.05,1) 0.657, (0.20,1)
Female Weight LDL rs247617 22.42 (9.08, 35.76) -1.91 (-19.52, 15.70) 0.001, (10.85,1) 0.832, (0.04,1)
Female Weight LDL rs3135506 32.21 (5.44, 58.97) -4.26 (-37.53, 29.00) 0.018, (5.56,1) 0.802, (0.06,1)
Female Weight LDL rs3741298 0.26 (-11.03, 11.54) 4.75 (-16.79, 26.29) 0.964, (0.00,1) 0.665, (0.19,1)
Female Weight LDL rs964184 2.02 (-10.16, 14.19) 9.69 (-9.59, 28.96) 0.745, (0.11,1) 0.325, (0.97,1)
Female Weight TG rs11076175 -0.06 (-0.12, 0.01) -0.02 (-0.12, 0.08) 0.091, (2.85,1) 0.691, (0.16,1)
Female Weight TG rs11604424 -0.02 (-0.07, 0.04) 0.03 (-0.04, 0.10) 0.527, (0.40,1) 0.370, (0.80,1)
Female Weight TG rs12678919 0.02 (-0.10, 0.14) 0.03 (-0.10, 0.17) 0.769, (0.09,1) 0.643, (0.21,1)
Female Weight TG rs12740374 -0.03 (-0.09, 0.04) 0.04 (-0.05, 0.13) 0.420, (0.65,1) 0.423, (0.64,1)
Female Weight TG rs247617 0.04 (-0.02, 0.10) -0.03 (-0.09, 0.04) 0.167, (1.91,1) 0.410, (0.68,1)
Female Weight TG rs3135506 0.00 (-0.13, 0.14) -0.07 (-0.18, 0.05) 0.954, (0.00,1) 0.256, (1.29,1)
Female Weight TG rs3741298 -0.02 (-0.08, 0.04) 0.04 (-0.03, 0.10) 0.512, (0.43,1) 0.320, (0.99,1)
Female Weight TG rs7412 0.07 (-0.09, 0.22) -0.09 (-0.45, 0.27) 0.396, (0.72,1) 0.641, (0.22,1)
Female WFL HDL rs11604424 -2.56 (-10.86, 5.75) -3.20 (-18.55, 12.14) 0.546, (0.36,1) 0.682, (0.17,1)
Female WFL HDL rs1260326 -0.68 (-9.02, 7.66) 2.93 (-7.72, 13.58) 0.873, (0.03,1) 0.590, (0.29,1)
Female WFL HDL rs12678919 2.81 (-9.40, 15.01) -4.29 (-22.11, 13.52) 0.652, (0.20,1) 0.637, (0.22,1)
Female WFL HDL rs12740374 -7.33 (-14.28, -0.37) -9.96 (-28.11, 8.20) 0.039, (4.27,1) 0.282, (1.16,1)
Female WFL HDL rs3135506 9.45 (0.77, 18.13) 5.52 (-2.82, 13.87) 0.033, (4.55,1) 0.194, (1.68,1)
Female WFL HDL rs3741298 -2.59 (-10.87, 5.69) -3.14 (-18.59, 12.31) 0.540, (0.38,1) 0.690, (0.16,1)
Female WFL HDL rs7412 -0.09 (-16.95, 16.77) – 0.992, (0.00,1) NA, ( NA,NA)
Female WFL HDL rs964184 -5.51 (-13.33, 2.31) -4.36 (-14.19, 5.47) 0.167, (1.91,1) 0.385, (0.76,1)
Female WFL LDL rs11076175 0.80 (-14.56, 16.16) 0.73 (-21.35, 22.81) 0.918, (0.01,1) 0.949, (0.00,1)
Female WFL LDL rs11604424 1.80 (-10.99, 14.60) 9.04 (-18.75, 36.84) 0.782, (0.08,1) 0.524, (0.41,1)
Female WFL LDL rs1260326 -14.28 (-28.25, -0.30) -19.71 (-42.87, 3.45) 0.045, (4.01,1) 0.095, (2.78,1)
Female WFL LDL rs12678919 4.53 (-19.73, 28.78) 4.39 (-30.38, 39.16) 0.715, (0.13,1) 0.805, (0.06,1)
Female WFL LDL rs247617 19.29 (5.90, 32.69) 26.19 (-25.13, 77.51) 0.005, (7.97,1) 0.317, (1.00,1)
Female WFL LDL rs3135506 -4.58 (-35.59, 26.43) -14.30 (-44.12, 15.51) 0.772, (0.08,1) 0.347, (0.88,1)
Female WFL LDL rs3741298 2.40 (-10.43, 15.23) 10.12 (-18.00, 38.25) 0.714, (0.13,1) 0.480, (0.50,1)
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Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Female WFL LDL rs964184 2.54 (-11.99, 17.08) 7.03 (-11.77, 25.83) 0.731, (0.12,1) 0.464, (0.54,1)
Female WFL TG rs11076175 -0.05 (-0.12, 0.02) -0.02 (-0.10, 0.07) 0.170, (1.89,1) 0.680, (0.17,1)
Female WFL TG rs11604424 0.01 (-0.05, 0.07) 0.01 (-0.07, 0.09) 0.751, (0.10,1) 0.838, (0.04,1)
Female WFL TG rs12678919 0.01 (-0.10, 0.12) 0.04 (-0.10, 0.18) 0.824, (0.05,1) 0.569, (0.32,1)
Female WFL TG rs12740374 -0.04 (-0.10, 0.02) -0.01 (-0.15, 0.13) 0.229, (1.45,1) 0.852, (0.04,1)
Female WFL TG rs247617 0.01 (-0.06, 0.08) -0.06 (-0.16, 0.03) 0.764, (0.09,1) 0.171, (1.88,1)
Female WFL TG rs3135506 -0.07 (-0.20, 0.05) -0.05 (-0.17, 0.08) 0.260, (1.27,1) 0.474, (0.51,1)
Female WFL TG rs3741298 0.01 (-0.05, 0.07) 0.01 (-0.07, 0.09) 0.764, (0.09,1) 0.762, (0.09,1)
Female WFL TG rs7412 0.06 (-0.10, 0.22) – 0.442, (0.59,1) NA, ( NA,NA)
Male Length HDL rs11604424 16.25 (3.42, 29.08) -3.43 (-9.58, 2.72) 0.013, (6.17,1) 0.274, (1.20,1)
Male Length HDL rs1260326 -7.58 (-48.99, 33.83) -0.52 (-7.66, 6.62) 0.720, (0.13,1) 0.886, (0.02,1)
Male Length HDL rs12678919 -33.13 (-66.88, 0.61) -5.28 (-23.53, 12.96) 0.054, (3.71,1) 0.570, (0.32,1)
Male Length HDL rs12740374 -4.19 (-21.91, 13.52) 5.94 (-2.52, 14.40) 0.643, (0.21,1) 0.169, (1.89,1)
Male Length HDL rs3135506 -15.95 (-33.47, 1.57) -0.89 (-15.20, 13.43) 0.074, (3.18,1) 0.903, (0.01,1)
Male Length HDL rs3741298 16.23 (3.40, 29.05) -3.67 (-9.85, 2.52) 0.013, (6.15,1) 0.245, (1.35,1)
Male Length HDL rs7412 – -13.90 (-36.28, 8.47) NA, ( NA,NA) 0.223, (1.48,1)
Male Length HDL rs964184 9.26 (-0.51, 19.02) -2.53 (-9.07, 4.01) 0.063, (3.45,1) 0.448, (0.57,1)
Male Length LDL rs11076175 -10.89 (-32.92, 11.14) 36.48 (14.82, 58.14) 0.333, (0.94,1) 0.001, (10.90,1)
Male Length LDL rs11604424 -27.63 (-60.87, 5.61) 7.77 (-10.61, 26.14) 0.103, (2.65,1) 0.407, (0.69,1)
Male Length LDL rs1260326 69.25 (-25.85, 164.36) -18.99 (-36.49, -1.50) 0.153, (2.04,1) 0.033, (4.53,1)
Male Length LDL rs12678919 62.51 (-8.96, 133.98) -15.46 (-69.61, 38.69) 0.086, (2.94,1) 0.576, (0.31,1)
Male Length LDL rs247617 -16.58 (-43.70, 10.54) -4.12 (-22.20, 13.95) 0.231, (1.44,1) 0.655, (0.20,1)
Male Length LDL rs3135506 -4.88 (-61.88, 52.13) 1.35 (-31.18, 33.88) 0.867, (0.03,1) 0.935, (0.01,1)
Male Length LDL rs3741298 -28.02 (-61.28, 5.23) 8.02 (-10.23, 26.26) 0.099, (2.73,1) 0.389, (0.74,1)
Male Length LDL rs964184 1.65 (-29.77, 33.07) 8.68 (-8.57, 25.92) 0.918, (0.01,1) 0.324, (0.97,1)
Male Length TG rs11076175 0.01 (-0.06, 0.09) 0.01 (-0.08, 0.11) 0.714, (0.13,1) 0.788, (0.07,1)
Male Length TG rs11604424 -0.16 (-0.29, -0.02) 0.02 (-0.05, 0.08) 0.022, (5.26,1) 0.584, (0.30,1)
Male Length TG rs12678919 0.23 (0.05, 0.41) 0.05 (-0.08, 0.17) 0.010, (6.58,1) 0.453, (0.56,1)
Male Length TG rs12740374 -0.04 (-0.12, 0.05) 0.06 (-0.03, 0.14) 0.429, (0.62,1) 0.187, (1.74,1)
Male Length TG rs247617 0.00 (-0.09, 0.10) 0.06 (-0.02, 0.13) 0.959, (0.00,1) 0.127, (2.33,1)
Male Length TG rs3135506 0.18 (0.00, 0.36) -0.00 (-0.11, 0.10) 0.043, (4.08,1) 0.960, (0.00,1)
Male Length TG rs3741298 -0.16 (-0.29, -0.02) 0.02 (-0.05, 0.08) 0.022, (5.28,1) 0.589, (0.29,1)
Male Length TG rs7412 – 0.11 (-0.08, 0.31) NA, ( NA,NA) 0.270, (1.22,1)
Male Weight HDL rs11604424 -0.74 (-6.04, 4.55) 9.40 (0.55, 18.26) 0.783, (0.08,1) 0.037, (4.33,1)
Male Weight HDL rs1260326 -0.06 (-5.65, 5.54) 2.27 (-4.29, 8.83) 0.985, (0.00,1) 0.498, (0.46,1)
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Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Male Weight HDL rs12678919 3.33 (-6.15, 12.81) 4.25 (-13.03, 21.53) 0.491, (0.47,1) 0.630, (0.23,1)
Male Weight HDL rs12740374 -2.70 (-8.81, 3.40) -3.11 (-12.14, 5.91) 0.386, (0.75,1) 0.499, (0.46,1)
Male Weight HDL rs3135506 -4.46 (-12.22, 3.30) -5.36 (-18.11, 7.38) 0.260, (1.27,1) 0.410, (0.68,1)
Male Weight HDL rs3741298 -0.66 (-5.96, 4.64) 9.24 (0.83, 17.64) 0.807, (0.06,1) 0.031, (4.64,1)
Male Weight HDL rs7412 -10.19 (-37.06, 16.69) -3.92 (-17.80, 9.96) 0.458, (0.55,1) 0.580, (0.31,1)
Male Weight HDL rs964184 0.85 (-4.36, 6.07) 6.61 (-2.85, 16.07) 0.748, (0.10,1) 0.171, (1.88,1)
Male Weight LDL rs11076175 21.09 (6.60, 35.57) 34.74 (17.00, 52.48) 0.004, (8.14,1) 0.000, (14.73,1)
Male Weight LDL rs11604424 -1.89 (-14.69, 10.90) -7.09 (-28.78, 14.61) 0.772, (0.08,1) 0.522, (0.41,1)
Male Weight LDL rs1260326 -4.58 (-17.39, 8.23) -9.76 (-26.77, 7.25) 0.483, (0.49,1) 0.261, (1.26,1)
Male Weight LDL rs12678919 -7.38 (-30.72, 15.97) 9.63 (-29.18, 48.44) 0.536, (0.38,1) 0.627, (0.24,1)
Male Weight LDL rs247617 -0.65 (-12.76, 11.47) -4.51 (-21.61, 12.58) 0.917, (0.01,1) 0.605, (0.27,1)
Male Weight LDL rs3135506 0.60 (-21.47, 22.67) -13.81 (-45.02, 17.40) 0.957, (0.00,1) 0.386, (0.75,1)
Male Weight LDL rs3741298 -1.79 (-14.57, 10.99) -4.63 (-25.55, 16.30) 0.784, (0.07,1) 0.665, (0.19,1)
Male Weight LDL rs964184 -2.89 (-16.37, 10.59) -5.19 (-26.98, 16.60) 0.674, (0.18,1) 0.641, (0.22,1)
Male Weight TG rs11076175 0.02 (-0.04, 0.09) 0.08 (-0.02, 0.18) 0.472, (0.52,1) 0.117, (2.46,1)
Male Weight TG rs11604424 0.06 (0.01, 0.10) 0.03 (-0.05, 0.10) 0.011, (6.47,1) 0.452, (0.57,1)
Male Weight TG rs12678919 -0.04 (-0.12, 0.04) 0.01 (-0.11, 0.13) 0.291, (1.11,1) 0.842, (0.04,1)
Male Weight TG rs12740374 0.01 (-0.05, 0.08) -0.03 (-0.13, 0.06) 0.629, (0.23,1) 0.499, (0.46,1)
Male Weight TG rs247617 0.01 (-0.04, 0.06) -0.06 (-0.14, 0.03) 0.655, (0.20,1) 0.192, (1.70,1)
Male Weight TG rs3135506 0.00 (-0.08, 0.08) -0.05 (-0.15, 0.05) 0.974, (0.00,1) 0.350, (0.88,1)
Male Weight TG rs3741298 0.06 (0.01, 0.11) 0.03 (-0.04, 0.10) 0.010, (6.65,1) 0.425, (0.64,1)
Male Weight TG rs7412 -0.05 (-0.40, 0.31) -0.19 (-0.34, -0.04) 0.797, (0.07,1) 0.011, (6.45,1)
Male WFL HDL rs11604424 -2.56 (-7.82, 2.69) – 0.338, (0.92,1) NA, ( NA,NA)
Male WFL HDL rs1260326 1.18 (-4.19, 6.55) – 0.666, (0.19,1) NA, ( NA,NA)
Male WFL HDL rs12678919 8.68 (-0.17, 17.53) – 0.054, (3.70,1) NA, ( NA,NA)
Male WFL HDL rs12740374 -0.90 (-6.85, 5.06) – 0.768, (0.09,1) NA, ( NA,NA)
Male WFL HDL rs3135506 1.44 (-6.81, 9.68) – 0.732, (0.12,1) NA, ( NA,NA)
Male WFL HDL rs3741298 -2.47 (-7.71, 2.76) – 0.355, (0.86,1) NA, ( NA,NA)
Male WFL HDL rs7412 -110.94 (-2975.62, 2753.74) – 0.940, (0.01,1) NA, ( NA,NA)
Male WFL HDL rs964184 0.89 (-4.54, 6.33) – 0.747, (0.10,1) NA, ( NA,NA)
Male WFL LDL rs11076175 20.01 (5.98, 34.04) – 0.005, (7.81,1) NA, ( NA,NA)
Male WFL LDL rs11604424 3.49 (-9.21, 16.18) – 0.590, (0.29,1) NA, ( NA,NA)
Male WFL LDL rs1260326 -5.36 (-17.85, 7.14) – 0.401, (0.70,1) NA, ( NA,NA)
Male WFL LDL rs12678919 -9.63 (-32.50, 13.25) – 0.409, (0.68,1) NA, ( NA,NA)
Male WFL LDL rs247617 -5.38 (-17.27, 6.51) – 0.375, (0.79,1) NA, ( NA,NA)
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Table E.2: Latent growth class pairwise differences in coefficient of association between other, non-primary, distal lipid outcome
(mg/dL) and candidate SNPs (continued)
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid SNP Not adjusted Adjusteda Not adjusted Adjusteda
Male WFL LDL rs3135506 -10.14 (-31.48, 11.20) – 0.352, (0.87,1) NA, ( NA,NA)
Male WFL LDL rs3741298 3.60 (-9.03, 16.23) – 0.577, (0.31,1) NA, ( NA,NA)
Male WFL LDL rs964184 4.76 (-9.22, 18.75) – 0.504, (0.45,1) NA, ( NA,NA)
Male WFL TG rs11076175 0.03 (-0.03, 0.09) -0.00 (-0.11, 0.10) 0.307, (1.04,1) 0.926, (0.01,1)
Male WFL TG rs11604424 0.05 (0.01, 0.10) 0.03 (-0.07, 0.13) 0.023, (5.18,1) 0.553, (0.35,1)
Male WFL TG rs12678919 -0.06 (-0.13, 0.02) -0.01 (-0.13, 0.11) 0.170, (1.88,1) 0.886, (0.02,1)
Male WFL TG rs12740374 -0.01 (-0.07, 0.05) -0.07 (-0.16, 0.01) 0.765, (0.09,1) 0.091, (2.85,1)
Male WFL TG rs247617 -0.02 (-0.07, 0.03) 0.02 (-0.06, 0.10) 0.547, (0.36,1) 0.657, (0.20,1)
Male WFL TG rs3135506 -0.01 (-0.09, 0.07) -0.07 (-0.19, 0.05) 0.774, (0.08,1) 0.257, (1.29,1)
Male WFL TG rs3741298 0.05 (0.01, 0.10) 0.03 (-0.06, 0.12) 0.020, (5.38,1) 0.523, (0.41,1)
Male WFL TG rs7412 0.29 (-7.93, 8.50) -0.05 (-0.29, 0.19) 0.946, (0.00,1) 0.664, (0.19,1)
Note:
Note: Bold values indicate Bonferroni corrected statistical significance at alpha level = 0.05.
a Adjusted for sex of child in pooled sample, randomization status, and principal components.173
E.3 Pairwise differences in risk score-trait associations across growth classes
Table E.3: Latent growth class pairwise differences in coefficient of association between distal lipid outcome (mg/dL) and
lipid-specific risk scores
Categories Slower vs Faster Overall Wald test: p-value, (Chi-sq, df)
Sex of child Trajectory type Lipid Not adjusted Adjusteda Not adjusted Adjusteda
Both Length HDL 0.48 (-0.48, 1.45) -0.26 (-1.04, 0.52) 0.325, (0.97,1) 0.515, (0.42,1)
Both Length LDL 2.40 (-0.39, 5.20) 1.66 (-0.69, 4.02) 0.092, (2.85,1) 0.165, (1.93,1)
Both Length TG -0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 0.780, (0.08,1) 0.744, (0.11,1)
Both Weight HDL -1.01 (-2.86, 0.84) -1.20 (-2.54, 0.14) 0.283, (1.15,1) 0.079, (3.09,1)
Both Weight LDL -2.30 (-5.43, 0.82) -0.00 (-3.54, 3.54) 0.148, (2.09,1) 1.000, (0.00,1)
Both Weight TG -0.00 (-0.01, 0.01) -0.01 (-0.02, 0.01) 0.855, (0.03,1) 0.325, (0.97,1)
Both WFL HDL 0.04 (-1.10, 1.17) -0.21 (-1.30, 0.89) 0.952, (0.00,1) 0.710, (0.14,1)
Both WFL LDL -0.40 (-2.97, 2.18) -0.06 (-2.71, 2.59) 0.761, (0.09,1) 0.965, (0.00,1)
Both WFL TG -0.00 (-0.01, 0.01) -0.00 (-0.01, 0.01) 0.355, (0.85,1) 0.379, (0.78,1)
Female Length HDL 0.10 (-1.05, 1.26) 0.03 (-1.47, 1.53) 0.861, (0.03,1) 0.966, (0.00,1)
Female Length LDL 1.08 (-2.25, 4.42) -0.06 (-4.34, 4.22) 0.524, (0.41,1) 0.979, (0.00,1)
Female Length TG 0.00 (-0.01, 0.01) 0.01 (-0.01, 0.03) 0.762, (0.09,1) 0.340, (0.91,1)
Female Weight HDL -1.31 (-2.72, 0.11) -0.34 (-1.91, 1.24) 0.071, (3.27,1) 0.674, (0.18,1)
Female Weight LDL 0.45 (-2.85, 3.74) 1.57 (-2.30, 5.45) 0.791, (0.07,1) 0.426, (0.64,1)
Female Weight TG -0.00 (-0.01, 0.01) -0.01 (-0.03, 0.00) 0.833, (0.04,1) 0.155, (2.02,1)
Female WFL HDL -0.81 (-2.49, 0.86) -1.79 (-4.83, 1.25) 0.339, (0.92,1) 0.249, (1.33,1)
Female WFL LDL -0.25 (-3.38, 2.88) 2.83 (-1.79, 7.45) 0.876, (0.02,1) 0.230, (1.44,1)
Female WFL TG 0.00 (-0.01, 0.01) -0.00 (-0.02, 0.01) 0.991, (0.00,1) 0.732, (0.12,1)
Male Length HDL 3.61 (1.28, 5.94) 0.44 (-0.80, 1.68) 0.002, (9.24,1) 0.488, (0.48,1)
Male Length LDL 9.01 (-28.50, 46.53) 3.14 (-1.33, 7.62) 0.638, (0.22,1) 0.168, (1.90,1)
Male Length TG -0.04 (-0.06, -0.01) -0.01 (-0.02, 0.01) 0.013, (6.14,1) 0.401, (0.71,1)
Male Weight HDL 0.03 (-0.96, 1.03) 1.81 (0.31, 3.30) 0.947, (0.00,1) 0.018, (5.63,1)
Male Weight LDL 1.50 (-1.77, 4.77) 1.74 (-3.24, 6.72) 0.368, (0.81,1) 0.494, (0.47,1)
Male Weight TG -0.00 (-0.01, 0.01) -0.01 (-0.03, 0.00) 0.780, (0.08,1) 0.116, (2.47,1)
Male WFL HDL -0.16 (-1.16, 0.85) – 0.756, (0.10,1) NA, ( NA,NA)
Male WFL LDL 0.44 (-2.76, 3.63) – 0.788, (0.07,1) NA, ( NA,NA)
Male WFL TG 0.00 (-0.01, 0.01) -0.00 (-0.02, 0.02) 0.617, (0.25,1) 0.731, (0.12,1)
Note:
Note: Bold values indicate Bonferroni corrected statistical significance at alpha level = 0.05.
a Adjusted for sex of child in pooled sample, randomization status, and principal components.
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E.4 Selected SNP-lipid additive associations by growth class
Table E.4: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, selected SNP
and lipid outcome
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Both Length HDL rs11076175 -3.16 (-5.52, -0.81) -1.68 (-5.19, 1.84) 2.00 (-3.87, 7.86) -2.63 (-5.15, -0.10)
Both Length HDL rs247617 3.91 (1.97, 5.85) 2.73 (-0.12, 5.57) 1.07 (-4.30, 6.44) 3.35 (1.19, 5.51)
Both Length LDL rs12740374 -7.08 (-12.60, -1.56) -5.15 (-12.38, 2.08) 2.77 (-5.21, 10.74) -2.92 (-7.64, 1.80)
Both Length LDL rs7412 -11.96 (-30.35, 6.44) -36.61 (-57.75, -15.47) -8.37 (-21.73, 5.00) -8.72 (-19.03, 1.59)
Both Length TG rs1260326 -0.01 (-0.03, 0.01) -0.02 (-0.05, 0.01) -0.02 (-0.06, 0.01) -0.02 (-0.04, 0.00)
Both Length TG rs964184 -0.02 (-0.04, -0.00) -0.02 (-0.04, 0.01) -0.00 (-0.04, 0.03) -0.01 (-0.03, 0.00)
Both Weight HDL rs11076175 -1.84 (-4.18, 0.50) -1.45 (-3.88, 0.98) -3.53 (-9.52, 2.47) -4.88 (-10.54, 0.78)
Both Weight HDL rs247617 2.19 (0.20, 4.19) 1.20 (-0.81, 3.21) 6.57 (0.81, 12.32) 7.68 (3.14, 12.21)
Both Weight LDL rs12740374 -2.64 (-6.94, 1.66) -3.34 (-7.74, 1.06) -12.71 (-32.30, 6.87) -14.04 (-33.13, 5.05)
Both Weight LDL rs7412 -14.77 (-26.14, -3.40) -14.49 (-25.47, -3.51) -0.34 (-27.73, 27.05) 0.08 (-43.46, 43.61)
Both Weight TG rs1260326 -0.01 (-0.02, 0.01) -0.00 (-0.02, 0.01) -0.04 (-0.10, 0.01) -0.04 (-0.09, 0.01)
Both Weight TG rs964184 -0.01 (-0.03, 0.01) -0.01 (-0.02, 0.01) -0.08 (-0.15, -0.01) -0.07 (-0.13, -0.02)
Both WFL HDL rs11076175 -1.60 (-4.22, 1.01) -2.09 (-4.64, 0.46) -3.38 (-7.47, 0.71) -2.54 (-6.56, 1.48)
Both WFL HDL rs247617 2.77 (0.70, 4.84) 2.63 (0.48, 4.79) 3.92 (-0.37, 8.21) 3.94 (0.37, 7.52)
Both WFL LDL rs12740374 -3.42 (-8.25, 1.41) -4.23 (-9.38, 0.93) -4.07 (-12.79, 4.65) -4.94 (-13.95, 4.08)
Both WFL LDL rs7412 -14.73 (-25.97, -3.49) -11.85 (-25.05, 1.35) -2.75 (-26.20, 20.70) -14.85 (-33.49, 3.80)
Both WFL TG rs1260326 -0.01 (-0.03, 0.01) -0.01 (-0.03, 0.02) -0.04 (-0.07, 0.00) -0.04 (-0.07, -0.00)
Both WFL TG rs964184 -0.01 (-0.03, 0.01) -0.00 (-0.02, 0.01) -0.04 (-0.07, -0.00) -0.05 (-0.08, -0.01)
Female Length HDL rs11076175 -4.40 (-7.64, -1.16) 2.58 (-4.23, 9.39) -2.50 (-7.18, 2.17) -2.01 (-6.25, 2.23)
Female Length HDL rs247617 2.03 (-0.30, 4.36) -1.23 (-7.00, 4.55) 3.99 (-2.01, 10.00) 3.51 (0.10, 6.93)
Female Length LDL rs12740374 -7.47 (-14.87, -0.08) 1.70 (-10.45, 13.85) -4.31 (-11.50, 2.89) -11.14 (-19.37, -2.91)
Female Length LDL rs7412 -15.95 (-37.29, 5.40) NA ( NA, NA) 1.11 (-11.60, 13.82) NA ( NA, NA)
Female Length TG rs1260326 -0.01 (-0.04, 0.01) -0.06 (-0.12, 0.00) -0.03 (-0.06, 0.00) -0.03 (-0.07, 0.01)
Female Length TG rs964184 -0.02 (-0.05, -0.00) -0.05 (-0.10, -0.00) 0.01 (-0.03, 0.05) 0.00 (-0.04, 0.04)
Female Weight HDL rs11076175 -1.43 (-5.60, 2.74) -0.20 (-3.41, 3.00) -7.50 (-12.12, -2.88) -0.59 (-9.98, 8.80)
Female Weight HDL rs247617 1.56 (-1.01, 4.13) 2.47 (-0.61, 5.56) 5.68 (-0.17, 11.53) -0.53 (-7.34, 6.29)
Female Weight LDL rs12740374 -7.02 (-15.04, 0.99) -7.22 (-14.46, 0.02) -2.97 (-10.57, 4.63) -10.26 (-27.97, 7.46)
Female Weight LDL rs7412 -11.44 (-37.96, 15.07) 94.04 (-339.28, 527.35) -6.11 (-24.97, 12.75) -15.17 (-50.45, 20.11)
Female Weight TG rs1260326 -0.01 (-0.04, 0.02) -0.01 (-0.05, 0.04) -0.05 (-0.09, -0.00) -0.08 (-0.13, -0.04)
Female Weight TG rs964184 -0.02 (-0.04, 0.01) 0.01 (-0.03, 0.05) -0.01 (-0.06, 0.04) -0.07 (-0.12, -0.03)
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Table E.4: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, selected SNP
and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Female WFL HDL rs11076175 -3.26 (-6.50, -0.03) 1.76 (-2.38, 5.90) -5.63 (-11.49, 0.22) -4.82 (-12.93, 3.28)
Female WFL HDL rs247617 2.61 (0.11, 5.11) 1.18 (-1.95, 4.32) 2.84 (-4.61, 10.28) 5.21 (-4.85, 15.28)
Female WFL LDL rs12740374 -3.87 (-9.91, 2.18) -8.46 (-15.53, -1.38) -13.18 (-23.97, -2.40) -11.41 (-38.71, 15.90)
Female WFL LDL rs7412 -10.26 (-37.97, 17.45) NA ( NA, NA) -7.09 (-25.34, 11.16) NA ( NA, NA)
Female WFL TG rs1260326 -0.01 (-0.04, 0.01) -0.02 (-0.06, 0.02) -0.05 (-0.10, -0.00) -0.07 (-0.12, -0.03)
Female WFL TG rs964184 -0.00 (-0.02, 0.02) -0.00 (-0.04, 0.03) -0.06 (-0.11, -0.01) -0.06 (-0.11, -0.02)
Male Length HDL rs11076175 1.36 (-8.73, 11.45) -4.75 (-8.69, -0.81) -1.06 (-3.96, 1.83) 1.16 (-4.28, 6.60)
Male Length HDL rs247617 11.94 (1.18, 22.69) 0.77 (-4.72, 6.26) 3.19 (0.71, 5.66) 6.17 (2.42, 9.92)
Male Length LDL rs12740374 -4.59 (-29.38, 20.21) 0.57 (-15.43, 16.56) -0.93 (-6.82, 4.96) -0.76 (-11.03, 9.50)
Male Length LDL rs7412 2514.03 ( NA, NA) 16.77 (-36.42, 69.96) 73.39 ( NA, NA) -32.26 (-50.40, -14.11)
Male Length TG rs1260326 0.21 (-0.05, 0.48) -0.01 (-0.06, 0.04) -0.02 (-0.04, -0.00) -0.02 (-0.06, 0.03)
Male Length TG rs964184 -0.08 (-0.16, -0.00) -0.02 (-0.07, 0.02) -0.01 (-0.03, 0.01) -0.04 (-0.07, 0.00)
Male Weight HDL rs11076175 -2.52 (-6.51, 1.48) -7.32 (-13.45, -1.20) 0.82 (-3.22, 4.86) 2.80 (-1.60, 7.20)
Male Weight HDL rs247617 3.01 (-0.47, 6.49) 5.93 (-0.83, 12.68) 4.49 (0.82, 8.15) 2.54 (-0.78, 5.85)
Male Weight LDL rs12740374 -2.20 (-10.10, 5.70) -3.39 (-20.01, 13.23) -2.63 (-13.18, 7.91) 0.10 (-13.00, 13.20)
Male Weight LDL rs7412 -13.70 (-27.00, -0.41) -16.88 (-36.51, 2.75) -35.19 (-103.48, 33.10) -36.94 (-58.10, -15.77)
Male Weight TG rs1260326 -0.01 (-0.04, 0.02) -0.03 (-0.08, 0.02) -0.02 (-0.06, 0.02) -0.02 (-0.06, 0.02)
Male Weight TG rs964184 0.00 (-0.02, 0.03) -0.00 (-0.07, 0.07) -0.05 (-0.08, -0.01) -0.03 (-0.07, -0.00)
Male WFL HDL rs11076175 -2.24 (-6.04, 1.56) -6.25 ( NA, NA) 0.72 (-3.43, 4.86) 0.57 ( NA, NA)
Male WFL HDL rs247617 2.91 (-0.53, 6.35) 1.97 ( NA, NA) 4.58 (0.90, 8.26) 4.82 ( NA, NA)
Male WFL LDL rs12740374 -2.91 (-10.84, 5.02) -7.38 ( NA, NA) -1.45 (-11.78, 8.88) 4.99 ( NA, NA)
Male WFL LDL rs7412 -13.99 (-26.14, -1.84) -20.83 ( NA, NA) -288.58 (-7558.23, 6981.06) -30.96 ( NA, NA)
Male WFL TG rs1260326 -0.02 (-0.05, 0.01) 0.00 (-0.05, 0.06) 0.00 (-0.04, 0.04) -0.03 (-0.07, 0.01)
Male WFL TG rs964184 -0.01 (-0.03, 0.02) -0.00 (-0.12, 0.11) -0.03 (-0.07, 0.00) -0.02 (-0.06, 0.01)
Note:
Note: Adjusted estimates include sex of child (for pooled analyses), randomization status and principal components.
a Bold values indicate statistical significance at Bonferroni corrected alpha level of 0.05.
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E.5 SNP-lipid additive associations for other lipid traits by growth class
Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Both Length HDL rs11604424 0.76 (-1.14, 2.66) 0.61 (-2.37, 3.60) -1.76 (-5.72, 2.20) 0.41 (-1.43, 2.26)
Both Length HDL rs1260326 0.51 (-2.00, 3.01) 2.42 (-0.33, 5.16) 2.11 (-0.87, 5.09) -0.77 (-3.00, 1.46)
Both Length HDL rs12678919 -1.30 (-4.61, 2.02) -2.32 (-7.32, 2.68) 2.24 (-9.73, 14.21) 0.17 (-3.53, 3.87)
Both Length HDL rs12740374 0.31 (-2.14, 2.77) -0.59 (-3.70, 2.53) -3.32 (-6.91, 0.27) -0.80 (-2.76, 1.15)
Both Length HDL rs3135506 -1.33 (-4.29, 1.62) -2.33 (-6.46, 1.80) 2.93 (-5.09, 10.94) 0.16 (-2.85, 3.17)
Both Length HDL rs3741298 0.76 (-1.11, 2.63) 0.60 (-2.32, 3.53) -1.94 (-6.02, 2.14) 0.32 (-1.53, 2.18)
Both Length HDL rs7412 6.95 (-2.16, 16.05) 3.70 (-8.27, 15.67) -3.24 (-11.31, 4.83) 1.52 (-3.61, 6.66)
Both Length HDL rs964184 1.14 (-0.84, 3.12) 1.05 (-1.75, 3.86) 0.34 (-3.45, 4.13) 1.57 (-0.35, 3.49)
Both Length LDL rs11076175 2.21 (-3.24, 7.65) 5.45 (-3.56, 14.46) -4.45 (-18.10, 9.21) -0.98 (-6.25, 4.29)
Both Length LDL rs11604424 -0.88 (-5.20, 3.44) 1.26 (-5.43, 7.95) 2.46 (-6.10, 11.03) -1.78 (-6.13, 2.56)
Both Length LDL rs1260326 1.16 (-4.18, 6.49) -0.26 (-6.85, 6.34) 1.62 (-5.64, 8.89) 2.07 (-2.92, 7.07)
Both Length LDL rs12678919 1.35 (-6.22, 8.93) -2.70 (-16.77, 11.38) -12.07 (-29.91, 5.77) -0.53 (-8.10, 7.04)
Both Length LDL rs247617 -1.21 (-5.53, 3.11) -1.27 (-8.19, 5.65) -5.37 (-15.43, 4.69) -3.00 (-7.37, 1.38)
Both Length LDL rs3135506 3.91 (-3.27, 11.09) 8.74 (-0.77, 18.24) -13.74 (-29.90, 2.42) -5.75 (-13.80, 2.30)
Both Length LDL rs3741298 -0.53 (-4.81, 3.75) 1.73 (-4.93, 8.39) 2.83 (-6.14, 11.81) -1.47 (-5.89, 2.95)
Both Length LDL rs964184 -0.12 (-4.35, 4.10) -0.36 (-6.43, 5.72) -2.43 (-12.11, 7.25) -1.77 (-6.36, 2.82)
Both Length TG rs11076175 -0.01 (-0.03, 0.01) -0.02 (-0.04, 0.01) -0.00 (-0.05, 0.04) -0.00 (-0.03, 0.02)
Both Length TG rs11604424 -0.02 (-0.03, -0.00) -0.02 (-0.04, 0.00) 0.00 (-0.03, 0.04) -0.01 (-0.02, 0.01)
Both Length TG rs12678919 -0.00 (-0.03, 0.03) 0.04 (-0.01, 0.09) 0.02 (-0.06, 0.11) -0.01 (-0.04, 0.02)
Both Length TG rs12740374 0.00 (-0.02, 0.02) 0.01 (-0.02, 0.04) 0.01 (-0.02, 0.04) 0.00 (-0.02, 0.02)
Both Length TG rs247617 0.01 (-0.00, 0.03) -0.01 (-0.04, 0.01) -0.02 (-0.06, 0.01) 0.01 (-0.01, 0.03)
Both Length TG rs3135506 -0.00 (-0.03, 0.03) -0.01 (-0.05, 0.02) -0.02 (-0.08, 0.04) 0.00 (-0.03, 0.03)
Both Length TG rs3741298 -0.02 (-0.03, -0.00) -0.02 (-0.04, 0.00) 0.00 (-0.03, 0.04) -0.01 (-0.02, 0.01)
Both Length TG rs7412 -0.02 (-0.08, 0.04) -0.01 (-0.11, 0.08) 0.00 (-0.06, 0.07) -0.01 (-0.05, 0.04)
Both Weight HDL rs11604424 -0.23 (-1.98, 1.52) -0.01 (-1.74, 1.71) 1.79 (-3.86, 7.44) 1.04 (-4.39, 6.46)
Both Weight HDL rs1260326 0.67 (-1.32, 2.67) 0.38 (-1.71, 2.47) 3.29 (-1.83, 8.42) 3.52 (-1.78, 8.83)
Both Weight HDL rs12678919 0.91 (-2.64, 4.45) 1.75 (-1.95, 5.44) -8.20 (-18.33, 1.93) -9.69 (-17.18, -2.21)
Both Weight HDL rs12740374 -0.91 (-2.80, 0.98) -0.95 (-2.78, 0.89) -2.22 (-11.20, 6.76) -0.04 (-8.47, 8.38)
Both Weight HDL rs3135506 -1.28 (-3.93, 1.38) -1.02 (-3.66, 1.62) 6.72 (-9.92, 23.37) 3.27 (-8.72, 15.26)
Both Weight HDL rs3741298 -0.17 (-1.91, 1.56) 0.02 (-1.68, 1.73) 1.59 (-4.38, 7.55) 0.80 (-4.84, 6.44)
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Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Both Weight HDL rs7412 -0.74 (-6.79, 5.31) 0.74 (-4.52, 6.01) 13.07 (-0.05, 26.20) 12.95 (-12.94, 38.83)
Both Weight HDL rs964184 0.47 (-1.20, 2.15) 0.52 (-1.16, 2.20) 4.85 (-2.51, 12.22) 3.86 (-3.19, 10.91)
Both Weight LDL rs11076175 3.92 (-1.67, 9.50) 3.27 (-2.55, 9.09) -8.55 (-20.54, 3.44) -4.57 (-13.36, 4.22)
Both Weight LDL rs11604424 0.28 (-3.68, 4.25) 0.47 (-3.49, 4.43) -1.73 (-14.54, 11.08) -1.06 (-13.63, 11.51)
Both Weight LDL rs1260326 -0.01 (-4.33, 4.31) -0.73 (-5.48, 4.03) 5.06 (-7.21, 17.33) 1.93 (-8.39, 12.25)
Both Weight LDL rs12678919 -5.44 (-13.27, 2.39) -4.93 (-13.69, 3.84) 22.03 (3.51, 40.54) 15.14 (0.12, 30.16)
Both Weight LDL rs247617 -0.86 (-5.09, 3.36) -0.04 (-4.41, 4.33) -6.43 (-17.98, 5.11) -8.06 (-18.49, 2.37)
Both Weight LDL rs3135506 2.03 (-4.32, 8.37) 2.49 (-4.25, 9.23) -21.21 (-50.53, 8.12) -23.92 (-51.42, 3.58)
Both Weight LDL rs3741298 1.10 (-2.87, 5.06) 1.30 (-2.67, 5.27) -3.48 (-16.61, 9.64) -2.51 (-15.37, 10.35)
Both Weight LDL rs964184 -0.28 (-3.99, 3.43) -0.17 (-3.97, 3.64) -3.24 (-24.40, 17.92) -1.06 (-18.47, 16.35)
Both Weight TG rs11076175 -0.02 (-0.04, 0.00) -0.01 (-0.03, 0.01) 0.03 (-0.03, 0.09) -0.00 (-0.06, 0.06)
Both Weight TG rs11604424 -0.01 (-0.02, 0.01) -0.01 (-0.02, 0.01) -0.03 (-0.08, 0.02) -0.04 (-0.08, 0.00)
Both Weight TG rs12678919 -0.00 (-0.03, 0.03) 0.00 (-0.03, 0.03) 0.00 (-0.08, 0.09) -0.02 (-0.09, 0.05)
Both Weight TG rs12740374 0.00 (-0.02, 0.02) 0.00 (-0.02, 0.02) 0.05 (-0.01, 0.12) 0.07 (-0.01, 0.15)
Both Weight TG rs247617 0.00 (-0.01, 0.02) 0.00 (-0.01, 0.02) 0.01 (-0.04, 0.05) 0.00 (-0.04, 0.05)
Both Weight TG rs3135506 -0.01 (-0.04, 0.01) -0.00 (-0.03, 0.02) 0.07 (-0.05, 0.20) 0.01 (-0.10, 0.13)
Both Weight TG rs3741298 -0.01 (-0.03, 0.01) -0.01 (-0.02, 0.01) -0.03 (-0.08, 0.02) -0.04 (-0.08, 0.01)
Both Weight TG rs7412 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.05) -0.07 (-0.22, 0.07) -0.09 (-0.30, 0.12)
Both WFL HDL rs11604424 0.02 (-1.85, 1.88) 0.98 (-0.91, 2.87) 0.51 (-3.21, 4.24) -0.51 (-3.87, 2.84)
Both WFL HDL rs1260326 0.87 (-1.30, 3.04) 0.47 (-1.78, 2.71) 1.47 (-2.66, 5.61) 1.20 (-2.61, 5.00)
Both WFL HDL rs12678919 -0.05 (-4.23, 4.14) 0.08 (-3.95, 4.11) -2.11 (-8.17, 3.94) -2.91 (-8.37, 2.55)
Both WFL HDL rs12740374 -2.43 (-4.48, -0.38) -2.34 (-4.47, -0.21) 2.63 (-2.46, 7.72) 2.90 (-1.75, 7.56)
Both WFL HDL rs3135506 0.69 (-2.34, 3.71) -0.70 (-3.68, 2.27) -4.54 (-10.22, 1.14) -2.44 (-6.93, 2.06)
Both WFL HDL rs3741298 0.06 (-1.81, 1.93) 1.03 (-0.86, 2.91) 0.37 (-3.33, 4.07) -0.70 (-4.04, 2.65)
Both WFL HDL rs7412 -1.51 (-7.28, 4.27) -1.09 (-7.72, 5.53) 15.88 (3.50, 28.26) 10.63 (1.60, 19.67)
Both WFL HDL rs964184 0.44 (-1.40, 2.28) 1.46 (-0.35, 3.26) 2.67 (-1.55, 6.89) 1.17 (-2.94, 5.28)
Both WFL LDL rs11076175 4.57 (-1.71, 10.85) 4.49 (-1.71, 10.69) -5.58 (-13.00, 1.84) -5.77 (-12.87, 1.34)
Both WFL LDL rs11604424 -0.23 (-4.43, 3.98) -0.90 (-5.21, 3.40) -0.87 (-9.32, 7.59) -0.23 (-8.04, 7.57)
Both WFL LDL rs1260326 -0.49 (-5.32, 4.33) -0.38 (-5.41, 4.66) 4.52 (-3.24, 12.27) 1.96 (-5.52, 9.43)
Both WFL LDL rs12678919 -0.38 (-9.15, 8.39) -1.36 (-10.54, 7.82) 1.70 (-11.41, 14.82) 2.73 (-10.11, 15.56)
Both WFL LDL rs247617 -2.64 (-7.09, 1.80) -3.34 (-8.00, 1.32) -1.29 (-10.07, 7.49) 0.41 (-8.34, 9.17)
Both WFL LDL rs3135506 0.78 (-6.41, 7.96) -0.45 (-7.88, 6.98) -3.67 (-20.01, 12.67) 0.22 (-15.71, 16.15)
Both WFL LDL rs3741298 0.26 (-3.98, 4.51) -0.31 (-4.67, 4.04) -1.04 (-9.46, 7.38) -0.40 (-8.10, 7.30)
178
Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Both WFL LDL rs964184 -1.22 (-5.28, 2.84) -1.68 (-5.81, 2.46) -0.08 (-10.44, 10.28) 0.48 (-9.48, 10.43)
Both WFL TG rs11076175 -0.01 (-0.03, 0.02) -0.01 (-0.03, 0.01) -0.01 (-0.06, 0.03) -0.01 (-0.05, 0.03)
Both WFL TG rs11604424 -0.00 (-0.02, 0.01) 0.00 (-0.02, 0.02) -0.03 (-0.06, 0.00) -0.04 (-0.06, -0.01)
Both WFL TG rs12678919 0.00 (-0.03, 0.04) 0.01 (-0.03, 0.04) -0.01 (-0.06, 0.04) -0.02 (-0.06, 0.03)
Both WFL TG rs12740374 0.01 (-0.01, 0.03) 0.00 (-0.02, 0.02) -0.00 (-0.04, 0.04) 0.01 (-0.03, 0.05)
Both WFL TG rs247617 0.00 (-0.02, 0.02) 0.00 (-0.02, 0.02) 0.01 (-0.02, 0.05) 0.00 (-0.03, 0.04)
Both WFL TG rs3135506 -0.01 (-0.04, 0.02) -0.01 (-0.04, 0.02) 0.01 (-0.05, 0.07) 0.03 (-0.03, 0.09)
Both WFL TG rs3741298 -0.00 (-0.02, 0.01) -0.00 (-0.02, 0.02) -0.03 (-0.06, 0.00) -0.04 (-0.06, -0.01)
Both WFL TG rs7412 0.01 (-0.03, 0.05) 0.01 (-0.03, 0.06) -0.06 (-0.19, 0.07) -0.05 (-0.15, 0.06)
Female Length HDL rs11604424 -0.54 (-3.00, 1.93) -1.75 (-7.95, 4.46) 3.62 (0.05, 7.19) 0.89 (-3.36, 5.13)
Female Length HDL rs1260326 -0.17 (-3.87, 3.52) 1.81 (-4.76, 8.39) 3.30 (-0.29, 6.88) -1.02 (-5.62, 3.58)
Female Length HDL rs12678919 -0.91 (-5.39, 3.56) 3.25 (-4.20, 10.70) 9.89 (-0.45, 20.23) -2.19 (-10.43, 6.04)
Female Length HDL rs12740374 -0.07 (-3.47, 3.33) -3.18 (-8.87, 2.51) 1.10 (-1.94, 4.14) 1.22 (-2.41, 4.85)
Female Length HDL rs3135506 0.67 (-2.96, 4.29) 0.36 (-6.80, 7.51) 0.88 (-5.64, 7.41) 0.55 (-4.35, 5.44)
Female Length HDL rs3741298 -0.35 (-2.79, 2.08) -1.57 (-7.43, 4.29) 3.13 (-0.42, 6.68) 0.89 (-3.42, 5.21)
Female Length HDL rs7412 10.30 (2.56, 18.05) NA ( NA, NA) 2.44 (-10.15, 15.04) NA ( NA, NA)
Female Length HDL rs964184 -0.04 (-2.93, 2.85) -1.18 (-6.41, 4.04) 3.42 (-0.06, 6.90) 2.90 (-2.12, 7.92)
Female Length LDL rs11076175 -0.57 (-7.52, 6.38) 9.64 (-4.90, 24.17) 6.78 (-6.85, 20.41) -2.21 (-10.43, 6.01)
Female Length LDL rs11604424 -0.54 (-5.75, 4.66) 4.68 (-7.71, 17.06) 1.54 (-6.75, 9.83) 1.73 (-7.34, 10.79)
Female Length LDL rs1260326 -4.72 (-11.90, 2.46) 2.05 (-11.67, 15.77) -0.48 (-9.02, 8.07) -5.12 (-15.56, 5.33)
Female Length LDL rs12678919 -6.03 (-15.58, 3.51) -10.06 (-31.52, 11.40) -15.12 (-33.06, 2.82) -3.17 (-20.16, 13.82)
Female Length LDL rs247617 0.31 (-5.41, 6.03) 0.38 (-9.96, 10.73) -13.37 (-24.92, -1.82) -1.26 (-9.39, 6.88)
Female Length LDL rs3135506 4.58 (-5.76, 14.91) 9.72 (-4.08, 23.53) -16.99 (-27.83, -6.16) -8.69 (-20.28, 2.90)
Female Length LDL rs3741298 0.24 (-5.00, 5.48) 6.97 (-5.06, 19.00) 1.50 (-6.94, 9.94) 1.28 (-8.05, 10.62)
Female Length LDL rs964184 -0.34 (-5.99, 5.32) 3.75 (-6.39, 13.90) 0.14 (-7.71, 7.98) 2.50 (-8.32, 13.33)
Female Length TG rs11076175 -0.01 (-0.04, 0.01) -0.02 (-0.10, 0.07) 0.06 (0.01, 0.11) 0.03 (-0.01, 0.08)
Female Length TG rs11604424 -0.02 (-0.04, -0.00) -0.06 (-0.11, -0.01) 0.01 (-0.03, 0.05) -0.01 (-0.04, 0.03)
Female Length TG rs12678919 0.01 (-0.03, 0.05) 0.05 (-0.04, 0.15) 0.02 (-0.09, 0.14) -0.04 (-0.11, 0.03)
Female Length TG rs12740374 0.01 (-0.02, 0.04) 0.00 (-0.06, 0.07) 0.01 (-0.03, 0.05) 0.01 (-0.02, 0.04)
Female Length TG rs247617 0.01 (-0.01, 0.04) -0.04 (-0.09, 0.02) 0.00 (-0.04, 0.04) 0.02 (-0.01, 0.05)
Female Length TG rs3135506 0.00 (-0.04, 0.04) 0.00 (-0.08, 0.09) 0.01 (-0.04, 0.06) 0.02 (-0.02, 0.07)
Female Length TG rs3741298 -0.02 (-0.04, -0.00) -0.05 (-0.10, -0.01) 0.01 (-0.03, 0.05) -0.01 (-0.04, 0.02)
Female Length TG rs7412 -0.04 (-0.11, 0.03) 0.87 ( NA, NA) 0.04 (-0.06, 0.15) 2.12 ( NA, NA)
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Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Female Weight HDL rs11604424 0.12 (-2.03, 2.28) -0.63 (-3.59, 2.33) 1.75 (-4.22, 7.72) 4.02 (-3.98, 12.02)
Female Weight HDL rs1260326 0.36 (-3.10, 3.82) 1.97 (-2.77, 6.71) 2.65 (-2.92, 8.22) -1.78 (-8.78, 5.23)
Female Weight HDL rs12678919 1.55 (-3.05, 6.15) -3.98 (-11.34, 3.38) -0.71 (-13.92, 12.50) 2.19 (-8.95, 13.33)
Female Weight HDL rs12740374 -0.25 (-3.74, 3.25) 0.50 (-2.42, 3.43) 0.95 (-3.04, 4.94) -0.41 (-10.29, 9.46)
Female Weight HDL rs3135506 0.63 (-2.85, 4.10) 1.16 (-3.29, 5.61) 4.24 (-8.80, 17.28) -4.91 (-12.32, 2.50)
Female Weight HDL rs3741298 0.08 (-2.07, 2.23) -0.58 (-3.46, 2.30) 1.75 (-4.20, 7.70) 4.04 (-4.03, 12.12)
Female Weight HDL rs7412 7.91 (-3.71, 19.54) -21.98 (-165.13, 121.16) 6.52 (-2.32, 15.37) 14.31 (0.95, 27.67)
Female Weight HDL rs964184 0.36 (-2.07, 2.80) -1.21 (-4.64, 2.22) 1.49 (-5.37, 8.34) 4.70 (-1.87, 11.27)
Female Weight LDL rs11076175 1.82 (-8.16, 11.81) 3.92 (-6.00, 13.85) 3.56 (-5.70, 12.81) -7.15 (-23.91, 9.62)
Female Weight LDL rs11604424 1.16 (-4.16, 6.47) 4.40 (-2.40, 11.21) 1.59 (-6.62, 9.79) 0.66 (-17.96, 19.28)
Female Weight LDL rs1260326 -3.11 (-10.43, 4.21) -4.87 (-15.06, 5.31) -2.71 (-11.85, 6.43) -2.07 (-17.92, 13.77)
Female Weight LDL rs12678919 -5.64 (-16.51, 5.23) -0.61 (-16.66, 15.44) -7.88 (-21.71, 5.95) -8.82 (-36.30, 18.66)
Female Weight LDL rs247617 3.41 (-3.10, 9.93) -1.53 (-10.21, 7.16) -19.01 (-29.15, -8.86) 0.38 (-12.64, 13.41)
Female Weight LDL rs3135506 0.78 (-8.32, 9.89) -7.00 (-17.76, 3.76) -31.43 (-54.86, -7.99) -2.74 (-30.60, 25.11)
Female Weight LDL rs3741298 1.70 (-3.74, 7.14) 5.28 (-1.57, 12.13) 1.45 (-6.72, 9.61) 0.52 (-18.23, 19.28)
Female Weight LDL rs964184 2.41 (-3.24, 8.05) 8.84 (0.14, 17.54) 0.39 (-8.72, 9.50) -0.84 (-15.88, 14.19)
Female Weight TG rs11076175 -0.02 (-0.06, 0.02) 0.00 (-0.04, 0.04) 0.03 (-0.01, 0.08) 0.02 (-0.06, 0.10)
Female Weight TG rs11604424 -0.02 (-0.04, 0.00) -0.02 (-0.05, 0.01) 0.00 (-0.05, 0.05) -0.05 (-0.11, 0.00)
Female Weight TG rs12678919 0.02 (-0.03, 0.06) 0.03 (-0.04, 0.11) -0.00 (-0.10, 0.10) 0.00 (-0.10, 0.10)
Female Weight TG rs12740374 -0.00 (-0.04, 0.03) 0.01 (-0.03, 0.04) 0.02 (-0.02, 0.07) -0.03 (-0.11, 0.05)
Female Weight TG rs247617 0.02 (-0.00, 0.05) 0.00 (-0.04, 0.04) -0.02 (-0.06, 0.03) 0.03 (-0.02, 0.08)
Female Weight TG rs3135506 0.01 (-0.03, 0.05) 0.02 (-0.03, 0.06) 0.01 (-0.11, 0.12) 0.08 (-0.01, 0.18)
Female Weight TG rs3741298 -0.02 (-0.04, 0.00) -0.02 (-0.05, 0.01) 0.00 (-0.05, 0.05) -0.05 (-0.11, 0.00)
Female Weight TG rs7412 0.02 (-0.07, 0.11) -0.11 (-0.41, 0.20) -0.05 (-0.15, 0.05) -0.02 (-0.11, 0.07)
Female WFL HDL rs11604424 0.06 (-1.93, 2.06) 0.21 (-2.65, 3.08) 2.62 (-4.83, 10.07) 3.42 (-10.78, 17.61)
Female WFL HDL rs1260326 0.92 (-2.23, 4.06) 2.08 (-2.53, 6.69) 1.59 (-5.23, 8.42) -0.85 (-8.57, 6.87)
Female WFL HDL rs12678919 1.40 (-3.44, 6.25) -5.16 (-12.87, 2.56) -1.40 (-11.26, 8.46) -0.86 (-14.32, 12.59)
Female WFL HDL rs12740374 -1.14 (-3.83, 1.54) -0.81 (-4.10, 2.47) 6.18 (0.38, 11.99) 9.14 (-7.78, 26.06)
Female WFL HDL rs3135506 2.82 (-0.79, 6.42) 1.84 (-2.83, 6.52) -6.63 (-13.97, 0.70) -3.68 (-9.27, 1.91)
Female WFL HDL rs3741298 0.03 (-1.96, 2.02) 0.23 (-2.54, 3.00) 2.62 (-4.81, 10.04) 3.37 (-10.95, 17.69)
Female WFL HDL rs7412 7.36 (-4.80, 19.52) NA ( NA, NA) 7.45 (-1.28, 16.17) 33054.81 ( NA, NA)
Female WFL HDL rs964184 -0.44 (-2.77, 1.88) -0.88 (-4.27, 2.51) 5.07 (-1.72, 11.86) 3.48 (-4.31, 11.27)
Female WFL LDL rs11076175 2.38 (-5.74, 10.49) 3.90 (-10.72, 18.52) 1.57 (-9.26, 12.40) 3.18 (-10.28, 16.63)
Female WFL LDL rs11604424 1.60 (-3.19, 6.39) 2.90 (-3.86, 9.66) -0.20 (-10.80, 10.39) -6.14 (-30.98, 18.70)
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Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Female WFL LDL rs1260326 -6.81 (-13.25, -0.37) -11.25 (-24.34, 1.85) 7.46 (-3.37, 18.29) 8.46 (-4.19, 21.11)
Female WFL LDL rs12678919 -3.93 (-14.03, 6.16) 2.31 (-15.96, 20.58) -8.46 (-27.81, 10.89) -2.08 (-27.41, 23.26)
Female WFL LDL rs247617 0.52 (-5.33, 6.38) 3.47 (-11.39, 18.32) -18.77 (-29.39, -8.15) -22.72 (-63.04, 17.60)
Female WFL LDL rs3135506 -5.61 (-14.38, 3.16) -10.06 (-21.72, 1.60) -1.03 (-28.28, 26.22) 4.24 (-18.71, 27.19)
Female WFL LDL rs3741298 2.07 (-2.82, 6.96) 3.72 (-3.04, 10.47) -0.32 (-10.89, 10.24) -6.41 (-31.61, 18.80)
Female WFL LDL rs964184 2.20 (-2.92, 7.33) 7.33 (-1.12, 15.79) -0.34 (-12.62, 11.94) 0.30 (-13.75, 14.36)
Female WFL TG rs11076175 -0.01 (-0.04, 0.02) 0.01 (-0.05, 0.06) 0.04 (-0.02, 0.10) 0.03 (-0.03, 0.08)
Female WFL TG rs11604424 -0.01 (-0.03, 0.01) -0.03 (-0.06, -0.00) -0.02 (-0.07, 0.03) -0.04 (-0.11, 0.03)
Female WFL TG rs12678919 0.01 (-0.03, 0.06) 0.04 (-0.04, 0.13) 0.00 (-0.09, 0.09) 0.00 (-0.09, 0.10)
Female WFL TG rs12740374 0.00 (-0.03, 0.03) -0.00 (-0.03, 0.03) 0.04 (-0.01, 0.09) 0.01 (-0.11, 0.14)
Female WFL TG rs247617 0.01 (-0.01, 0.04) -0.01 (-0.05, 0.03) 0.00 (-0.06, 0.07) 0.06 (-0.02, 0.13)
Female WFL TG rs3135506 -0.01 (-0.04, 0.03) 0.01 (-0.04, 0.06) 0.07 (-0.05, 0.18) 0.06 (-0.04, 0.16)
Female WFL TG rs3741298 -0.01 (-0.03, 0.01) -0.03 (-0.06, -0.00) -0.02 (-0.07, 0.03) -0.04 (-0.11, 0.02)
Female WFL TG rs7412 0.01 (-0.08, 0.11) 88220.94 ( NA, NA) -0.05 (-0.15, 0.05) 3744.96 ( NA, NA)
Male Length HDL rs11604424 15.26 (2.69, 27.82) -0.64 (-5.11, 3.82) -1.00 (-3.23, 1.23) 2.79 (-0.53, 6.11)
Male Length HDL rs1260326 -7.11 (-47.82, 33.60) 0.53 (-3.46, 4.53) 0.47 (-1.54, 2.48) 1.05 (-3.39, 5.50)
Male Length HDL rs12678919 -34.31 (-68.70, 0.08) -8.58 (-23.79, 6.63) -1.17 (-4.83, 2.48) -3.30 (-9.08, 2.48)
Male Length HDL rs12740374 -6.05 (-22.58, 10.49) 1.77 (-3.88, 7.43) -1.85 (-4.18, 0.47) -4.17 (-8.41, 0.08)
Male Length HDL rs3135506 -17.15 (-33.31, -0.98) -2.06 (-13.81, 9.70) -1.20 (-4.68, 2.29) -1.17 (-5.71, 3.37)
Male Length HDL rs3741298 15.25 (2.69, 27.81) -0.67 (-5.13, 3.79) -0.98 (-3.20, 1.25) 3.00 (-0.38, 6.37)
Male Length HDL rs7412 NA ( NA, NA) -11.34 (-32.00, 9.32) NA ( NA, NA) 2.56 (-2.91, 8.04)
Male Length HDL rs964184 9.67 (0.88, 18.47) -0.10 (-4.85, 4.65) 0.42 (-1.86, 2.70) 2.43 (-1.05, 5.91)
Male Length LDL rs11076175 -8.90 (-27.65, 9.84) 25.43 (11.97, 38.90) 1.99 (-4.79, 8.76) -11.05 (-23.73, 1.64)
Male Length LDL rs11604424 -26.92 (-57.83, 3.98) -0.93 (-14.98, 13.12) 0.70 (-4.72, 6.13) -8.70 (-17.63, 0.24)
Male Length LDL rs1260326 71.40 (-23.12, 165.91) -8.77 (-18.66, 1.12) 2.14 (-2.81, 7.10) 10.22 (-1.92, 22.36)
Male Length LDL rs12678919 64.09 (-8.89, 137.06) -13.62 (-59.50, 32.27) 1.57 (-7.40, 10.55) 1.85 (-13.15, 16.85)
Male Length LDL rs247617 -17.42 (-43.00, 8.15) -7.63 (-21.37, 6.11) -0.84 (-5.82, 4.14) -3.51 (-11.52, 4.50)
Male Length LDL rs3135506 -0.34 (-52.19, 51.51) 10.08 (-15.43, 35.60) 4.54 (-4.97, 14.04) 8.73 (-5.33, 22.80)
Male Length LDL rs3741298 -27.01 (-57.94, 3.92) -0.90 (-14.86, 13.05) 1.02 (-4.41, 6.44) -8.92 (-17.70, -0.13)
Male Length LDL rs964184 -1.28 (-29.56, 26.99) 0.21 (-11.71, 12.12) -2.93 (-8.64, 2.77) -8.47 (-18.13, 1.19)
Male Length TG rs11076175 -0.01 (-0.07, 0.06) -0.01 (-0.07, 0.04) -0.02 (-0.05, 0.00) -0.03 (-0.09, 0.04)
Male Length TG rs11604424 -0.16 (-0.29, -0.02) -0.01 (-0.06, 0.03) -0.00 (-0.02, 0.02) -0.03 (-0.06, -0.00)
Male Length TG rs12678919 0.21 (0.03, 0.38) 0.02 (-0.08, 0.12) -0.02 (-0.05, 0.01) -0.03 (-0.08, 0.02)
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Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Male Length TG rs12740374 -0.03 (-0.12, 0.05) 0.05 (-0.01, 0.11) 0.00 (-0.02, 0.03) -0.00 (-0.05, 0.04)
Male Length TG rs247617 -0.00 (-0.09, 0.08) 0.04 (-0.02, 0.09) -0.00 (-0.03, 0.02) -0.02 (-0.06, 0.02)
Male Length TG rs3135506 0.14 (-0.01, 0.30) -0.03 (-0.11, 0.04) -0.04 (-0.07, -0.00) -0.03 (-0.08, 0.03)
Male Length TG rs3741298 -0.16 (-0.30, -0.02) -0.01 (-0.06, 0.03) 0.00 (-0.02, 0.02) -0.03 (-0.06, 0.00)
Male Length TG rs7412 -2915.95 ( NA, NA) 0.09 (-0.05, 0.23) -62.77 ( NA, NA) -0.02 (-0.12, 0.08)
Male Weight HDL rs11604424 -0.23 (-3.59, 3.13) 8.09 (0.12, 16.06) 0.52 (-2.56, 3.60) -1.31 (-3.65, 1.02)
Male Weight HDL rs1260326 0.12 (-2.69, 2.93) 3.23 (-2.18, 8.64) 0.17 (-3.82, 4.17) 0.96 (-2.08, 4.00)
Male Weight HDL rs12678919 -1.45 (-6.64, 3.74) -2.93 (-13.83, 7.98) -4.78 (-11.16, 1.59) -7.18 (-15.85, 1.49)
Male Weight HDL rs12740374 -3.25 (-6.30, -0.19) -4.09 (-10.81, 2.63) -0.54 (-4.99, 3.91) -0.98 (-4.88, 2.92)
Male Weight HDL rs3135506 -4.84 (-10.60, 0.92) -5.88 (-16.48, 4.71) -0.38 (-3.75, 2.99) -0.52 (-4.59, 3.54)
Male Weight HDL rs3741298 -0.15 (-3.46, 3.15) 7.75 (0.33, 15.16) 0.51 (-2.64, 3.65) -1.49 (-3.94, 0.96)
Male Weight HDL rs7412 -3.21 (-8.48, 2.06) -1.89 (-8.62, 4.84) 6.97 (-18.12, 32.06) 2.03 (-8.60, 12.66)
Male Weight HDL rs964184 1.87 (-1.03, 4.76) 5.94 (-2.35, 14.23) 1.01 (-2.43, 4.46) -0.68 (-3.23, 1.88)
Male Weight LDL rs11076175 11.02 (0.86, 21.18) 21.07 (8.98, 33.16) -10.06 (-17.92, -2.21) -13.67 (-25.05, -2.29)
Male Weight LDL rs11604424 -2.27 (-9.92, 5.37) -9.12 (-25.45, 7.21) -0.38 (-8.41, 7.65) -2.04 (-11.33, 7.26)
Male Weight LDL rs1260326 2.41 (-5.10, 9.91) -3.62 (-14.70, 7.47) 6.99 (-1.02, 15.00) 6.14 (-3.65, 15.93)
Male Weight LDL rs12678919 1.40 (-11.17, 13.97) 6.78 (-15.99, 29.56) 8.78 (-7.23, 24.78) -2.85 (-24.88, 19.18)
Male Weight LDL rs247617 -2.56 (-9.47, 4.35) -6.93 (-17.59, 3.73) -1.92 (-9.84, 6.01) -2.42 (-12.83, 7.99)
Male Weight LDL rs3135506 4.04 (-8.68, 16.77) 0.71 (-21.45, 22.88) 3.44 (-10.90, 17.78) 14.52 (-0.26, 29.31)
Male Weight LDL rs3741298 -2.01 (-9.51, 5.50) -7.15 (-22.76, 8.45) -0.21 (-8.35, 7.92) -2.52 (-11.70, 6.65)
Male Weight LDL rs964184 -3.65 (-10.35, 3.05) -6.69 (-21.66, 8.29) -0.76 (-10.49, 8.97) -1.50 (-12.19, 9.20)
Male Weight TG rs11076175 -0.01 (-0.04, 0.03) 0.01 (-0.05, 0.07) -0.03 (-0.07, 0.01) -0.07 (-0.13, -0.00)
Male Weight TG rs11604424 0.02 (-0.01, 0.04) -0.00 (-0.06, 0.05) -0.04 (-0.07, -0.01) -0.03 (-0.06, 0.00)
Male Weight TG rs12678919 -0.02 (-0.07, 0.02) 0.00 (-0.06, 0.06) 0.02 (-0.04, 0.08) -0.01 (-0.09, 0.07)
Male Weight TG rs12740374 0.01 (-0.02, 0.04) -0.01 (-0.08, 0.06) -0.01 (-0.05, 0.04) 0.02 (-0.03, 0.07)
Male Weight TG rs247617 0.01 (-0.02, 0.04) -0.02 (-0.07, 0.03) -0.01 (-0.04, 0.03) 0.03 (-0.02, 0.09)
Male Weight TG rs3135506 -0.02 (-0.07, 0.03) -0.06 (-0.13, 0.01) -0.02 (-0.07, 0.03) -0.01 (-0.07, 0.04)
Male Weight TG rs3741298 0.02 (-0.01, 0.04) 0.00 (-0.05, 0.05) -0.04 (-0.07, -0.01) -0.03 (-0.06, 0.00)
Male Weight TG rs7412 -0.00 (-0.05, 0.04) -0.07 (-0.19, 0.04) 0.05 (-0.30, 0.39) 0.12 (0.02, 0.22)
Male WFL HDL rs11604424 -1.15 (-4.50, 2.21) 6.97 ( NA, NA) 1.42 (-1.68, 4.52) 0.73 ( NA, NA)
Male WFL HDL rs1260326 0.71 (-2.15, 3.56) 4.32 ( NA, NA) -0.48 (-4.21, 3.25) 0.99 ( NA, NA)
Male WFL HDL rs12678919 1.01 (-4.77, 6.80) NA ( NA, NA) -7.67 (-12.94, -2.39) NA ( NA, NA)
Male WFL HDL rs12740374 -2.70 (-5.70, 0.29) -4.31 ( NA, NA) -1.81 (-6.14, 2.52) -1.38 ( NA, NA)
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Table E.5: Additive association between SNP and distal outcome by growth class, sex of child, adjusted status, other,
non-primary, SNP and lipid outcome (continued)
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid SNP Not adjusted Adjusted Not adjusted Adjusted
Male WFL HDL rs3135506 -2.06 (-7.88, 3.76) 0.53 ( NA, NA) -3.50 (-7.78, 0.78) -2.65 ( NA, NA)
Male WFL HDL rs3741298 -1.05 (-4.34, 2.23) 6.54 ( NA, NA) 1.42 (-1.74, 4.58) 0.70 ( NA, NA)
Male WFL HDL rs7412 -3.43 (-8.25, 1.40) -3.60 ( NA, NA) 107.51 (-2757.33, 2972.35) 2.95 ( NA, NA)
Male WFL HDL rs964184 1.87 (-0.83, 4.57) 5.50 ( NA, NA) 0.98 (-2.96, 4.92) 1.07 ( NA, NA)
Male WFL LDL rs11076175 9.83 (0.15, 19.51) 30.93 ( NA, NA) -10.18 (-17.90, -2.46) -13.49 ( NA, NA)
Male WFL LDL rs11604424 0.47 (-7.40, 8.33) -1.38 ( NA, NA) -3.02 (-10.84, 4.80) -5.16 ( NA, NA)
Male WFL LDL rs1260326 1.88 (-5.96, 9.72) -5.91 ( NA, NA) 7.24 (-0.18, 14.65) 7.43 ( NA, NA)
Male WFL LDL rs12678919 0.31 (-12.41, 13.03) 9.43 ( NA, NA) 9.94 (-5.64, 25.51) -6.15 ( NA, NA)
Male WFL LDL rs247617 -5.00 (-11.79, 1.79) -16.71 ( NA, NA) 0.38 (-7.46, 8.22) -1.91 ( NA, NA)
Male WFL LDL rs3135506 -1.14 (-14.74, 12.45) -19.25 ( NA, NA) 8.99 (-3.60, 21.59) 16.93 ( NA, NA)
Male WFL LDL rs3741298 0.69 (-7.00, 8.39) 0.76 ( NA, NA) -2.90 (-10.79, 4.99) -6.05 ( NA, NA)
Male WFL LDL rs964184 -0.27 (-6.75, 6.20) -0.75 ( NA, NA) -5.04 (-15.65, 5.58) -5.00 ( NA, NA)
Male WFL TG rs11076175 -0.00 (-0.04, 0.03) -0.04 (-0.10, 0.03) -0.04 (-0.08, 0.01) -0.03 (-0.09, 0.03)
Male WFL TG rs11604424 0.02 (-0.01, 0.04) 0.01 (-0.08, 0.09) -0.04 (-0.06, -0.01) -0.02 (-0.05, 0.01)
Male WFL TG rs12678919 -0.03 (-0.08, 0.02) -0.00 (-0.08, 0.07) 0.02 (-0.03, 0.08) 0.00 (-0.07, 0.07)
Male WFL TG rs12740374 -0.00 (-0.03, 0.02) -0.03 (-0.08, 0.03) 0.00 (-0.04, 0.05) 0.04 (-0.00, 0.09)
Male WFL TG rs247617 -0.01 (-0.04, 0.02) 0.01 (-0.04, 0.07) 0.01 (-0.03, 0.04) -0.00 (-0.05, 0.04)
Male WFL TG rs3135506 -0.03 (-0.08, 0.03) -0.09 (-0.19, 0.00) -0.01 (-0.06, 0.03) -0.02 (-0.07, 0.02)
Male WFL TG rs3741298 0.02 (-0.01, 0.04) 0.01 (-0.07, 0.09) -0.04 (-0.06, -0.01) -0.02 (-0.05, 0.01)
Male WFL TG rs7412 -0.00 (-0.05, 0.04) -0.02 (-0.13, 0.09) -0.29 (-8.50, 7.92) 0.03 (-0.15, 0.21)
Note:
Note: Adjusted estimates include sex of child (for pooled analyses), randomization status and principal components.
a Bold values indicate statistical significance at Bonferroni corrected alpha level of 0.05.
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E.6 Additive associations between risk scores and lipid traits
Table E.6: Additive association between risk scores and distal lipid traits by growth class, sex of child, adjusted status, risk
scores and lipid outcome
Categories Latent Growth Classa
Slower Growth Faster Growth
Sex of child Trajectory type Lipid Not adjusted Adjusted Not adjusted Adjusted
Both Length HDL 0.69 (0.28, 1.10) 0.24 (-0.35, 0.82) 0.21 (-0.50, 0.92) 0.50 (0.12, 0.88)
Both Length LDL 1.58 (0.36, 2.81) 1.92 (0.16, 3.68) -0.82 (-2.86, 1.23) 0.26 (-0.88, 1.39)
Both Length TG 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01)
Both Weight HDL 0.38 (0.05, 0.71) 0.22 (-0.12, 0.56) 1.39 (-0.30, 3.08) 1.42 (0.25, 2.59)
Both Weight LDL 0.32 (-0.80, 1.44) 0.92 (-0.19, 2.02) 2.63 (0.08, 5.17) 0.92 (-2.06, 3.89)
Both Weight TG 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.02)
Both WFL HDL 0.50 (0.14, 0.85) 0.36 (0.01, 0.71) 0.46 (-0.50, 1.42) 0.57 (-0.35, 1.49)
Both WFL LDL 0.62 (-0.66, 1.90) 0.80 (-0.48, 2.09) 1.02 (-0.79, 2.83) 0.86 (-1.01, 2.74)
Both WFL TG 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01) 0.01 (-0.00, 0.01) 0.01 (0.00, 0.01)
Female Length HDL 0.34 (-0.20, 0.88) -0.19 (-1.19, 0.81) 0.24 (-0.66, 1.15) -0.22 (-1.05, 0.60)
Female Length LDL 1.69 (0.20, 3.17) 2.02 (-1.28, 5.32) 0.60 (-2.08, 3.29) 2.08 (-0.10, 4.26)
Female Length TG 0.00 (-0.00, 0.01) 0.01 (-0.00, 0.03) 0.00 (-0.00, 0.01) 0.00 (-0.00, 0.01)
Female Weight HDL -0.08 (-0.66, 0.50) -0.53 (-1.36, 0.31) 1.23 (0.09, 2.37) -0.19 (-1.36, 0.98)
Female Weight LDL 1.74 (0.03, 3.45) 2.90 (0.75, 5.04) 1.29 (-1.03, 3.62) 1.32 (-1.35, 4.00)
Female Weight TG 0.00 (-0.00, 0.01) -0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 0.01 (0.00, 0.02)
Female WFL HDL 0.14 (-0.36, 0.65) -0.50 (-1.21, 0.20) 0.96 (-0.51, 2.43) 1.28 (-1.57, 4.14)
Female WFL LDL 1.53 (-0.03, 3.08) 3.33 (0.97, 5.69) 1.78 (-0.55, 4.11) 0.50 (-2.69, 3.69)
Female WFL TG 0.00 (-0.00, 0.01) 0.00 (-0.01, 0.01) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.02)
Male Length HDL 3.89 (1.53, 6.25) 1.13 (0.15, 2.11) 0.28 (-0.15, 0.71) 0.69 (0.12, 1.26)
Male Length LDL 9.13 (-27.95, 46.22) 3.24 (0.08, 6.39) 0.12 (-1.14, 1.39) 0.09 (-2.32, 2.50)
Male Length TG -0.03 (-0.06, -0.00) 0.00 (-0.01, 0.01) 0.00 (0.00, 0.01) 0.01 (-0.00, 0.02)
Male Weight HDL 0.59 (-0.04, 1.22) 2.13 (0.77, 3.50) 0.56 (-0.02, 1.14) 0.33 (-0.14, 0.80)
Male Weight LDL 0.85 (-1.17, 2.88) 2.17 (-1.22, 5.57) -0.65 (-2.63, 1.33) 0.43 (-2.34, 3.21)
Male Weight TG 0.00 (-0.00, 0.01) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.02) 0.01 (0.00, 0.02)
Male WFL HDL 0.51 (-0.05, 1.08) NA ( NA, NA) 0.67 (0.00, 1.34) 0.75 ( NA, NA)
Male WFL LDL 0.39 (-1.68, 2.46) 1.75 ( NA, NA) -0.05 (-1.91, 1.81) 0.25 ( NA, NA)
Male WFL TG 0.00 (-0.00, 0.01) 0.00 (-0.01, 0.02) 0.00 (-0.01, 0.01) 0.01 (-0.00, 0.02)
Note:
Adjusted estimates include sex of child (for pooled analyses), randomization status and principal components.
a Bold values indicate statistical significance at Bonferroni corrected alpha level of 0.05.
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E.7 SITAR GXE interaction analyses for risk scores and lipid traits
Table E.7: Gene-environment coefficients for models including lipid outcomes with risk scores and SITAR growth parameters
as the genetic and environment covariates, respectively.
Regression parameters (SE)
Outcome Trajectory type SITAR growth parameter Intercept Growth parameter Risk scorea Product term
Length tempo 40.34 (0.48) -1.89 (1.25) 0.51 (0.14) 0.14 (0.36)
Length velocity 40.36 (0.48) 13.40 (4.63) 0.48 (0.14) 1.37 (1.33)
Weight size 40.41 (0.48) -7.37 (4.84) 0.50 (0.14) 2.63 (1.43)
Weight tempo 40.33 (0.48) -2.05 (1.18) 0.53 (0.15) 0.44 (0.36)
Weight velocity 40.40 (0.48) -0.77 (2.01) 0.49 (0.14) 0.12 (0.62)
WFL tempo 40.45 (0.48) -9.73 (4.98) 0.49 (0.14) 3.04 (1.66)
HDL-C
WFL velocity 40.35 (0.48) -2.18 (1.05) 0.52 (0.15) 0.41 (0.35)
Length tempo 94.18 (1.04) 7.49 (2.70) 0.79 (0.44) 2.38 (1.09)
Length velocity 94.16 (1.04) -23.17 (10.05) 0.73 (0.43) -11.89 (4.20)
Weight size 94.11 (1.06) -9.25 (10.67) 0.77 (0.44) 0.46 (4.67)
Weight tempo 94.20 (1.05) 0.89 (2.58) 0.85 (0.44) 1.52 (1.04)
Weight velocity 94.26 (1.05) -8.07 (4.36) 0.86 (0.44) -2.14 (1.76)
WFL tempo 94.03 (1.05) -20.37 (10.89) 0.74 (0.44) -2.12 (4.43)
LDL-C
WFL velocity 94.07 (1.05) -3.17 (2.29) 0.80 (0.44) 0.28 (0.89)
Length tempo 4.35 (0.02) -0.02 (0.05) 0.02 (0.01) 0.00 (0.02)
Length velocity 4.35 (0.02) 0.02 (0.19) 0.02 (0.01) -0.01 (0.07)
Weight size 4.35 (0.02) 0.26 (0.19) 0.02 (0.01) -0.06 (0.07)
Weight tempo 4.35 (0.02) -0.02 (0.05) 0.02 (0.01) -0.00 (0.02)
Weight velocity 4.35 (0.02) 0.01 (0.08) 0.02 (0.01) 0.03 (0.03)
WFL tempo 4.35 (0.02) 0.30 (0.20) 0.02 (0.01) 0.04 (0.07)
TG
WFL velocity 4.35 (0.02) 0.00 (0.04) 0.02 (0.01) 0.01 (0.01)
Note:
No product term coefficients were significant after multiple comparison correction.
a The genetic risk score was centered around 0 to aid in coefficient interpretation.
185
APPENDIX F: BACKGROUND FOR POWER CALCULATIONS
To determine which single variants to select for a linear additive model we considered
conditions under which we could achieve power = 0.8 in testing the association between
a variant and a continuous outcome/trait (in unrelated individuals). We assume that
we pool both males and females in the analysis (n=600) and adjust for sex of child. We
assume power would be lower and more conservative in the circumstances provided below
absent any adjustment.
The linear model would be:
Y = β0 + β1X + 
To test the effect of β1 under H0 : β1 = 0 versus Ha : β1 6= 0, we assume the following
%(copied from http://faculty.washington.edu//tathornt//SISG2014//2014_SISG_10_5.pdf):
T = βˆ1√
var(βˆ1)
∼ tN−2 ≈ N(0, 1) for large N
T 2 = βˆ
2
1
var(βˆ1)
∼ F1,N−2 ≈ χ21 for large N
and
var(βˆ1) =
σ2
SXX
where SXX is the corrected sum of squares for the X ′is. In this context we assume
V ar(X) = 2p(1− p) where p = MAF.
The non-centrality parameter (NCP) for this model is: %
λ = N × β
2V ar(X)
σ2
Next, we used the NCP, λ, in a 1 df chi-square test for equality of means. We made the plots
below to examine power across different levels of MAF, standard deviation of the trait and
varying β1 values all based on the SNPs listed in Appendix D of my dissertation proposal.
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APPENDIX G: SCRIPTS FOR ANALYSES
This dissertation was written in R markdown, and the scripts for both this document and
the analyses herein are available at https://avonholle.github.io/diss/final-doc/.
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